ANNUAL REPORT
2021-22

NATH SEEDS®

Nath Bio-Genes (I) Ltd.

हर बीज खरा, शक्ति भरा®

29th Annual Report 2021-22

Corporate Information

Directors
Mr. Satish Kagliwal - Managing Director
Mrs. Jeevanlata Kagliwal
Mrs. Sweta Kagliwal
Mr. Hitesh Purohit
Mr. Vadla Nagabhushanam
Mr. Madhukar Deshpande
Ms. Ashu Jain

Chief Financial Officer
Mr. Devinder Khurana

Company Secretary
Mr. Dhiraj Rathi

Statutory Auditors
Ashok R Majethia
Chartered Accountants
Utsav Complex office No-7
Bazar Peth, Dist Raigad
Khopoli-410 203

Bankers
1. Axis Bank Ltd.
2. IDBI Bank Ltd.
3. HDFC Bank Ltd.
4. Janakalyan Sahakari Bank Ltd.

Registered Office
Nath House, Nath Road, Aurangabad-431005
0240-6645555

Corporate Office
1, Chateau Windsor
86, Veer Nariman Road
Churchgate, Mumbai – 400 020

Registrar & Transfer Agents
Big Share Service Private Limited,
1st floor, Bharat Tin Works Building,
Opp. Vasant Oasis, Makwana Road,
Moral, Andheri - (East), Mumbai-400059
Tel.: 022-62638200.

Contents

Notice	04
Managing Director's Statement	17
Director's Report	19
Management Discussion & Analysis Report	49
Business Responsibility Report	59
Corporate Governance Report	74
Auditor's Report	94
Balance Sheet	105
Profit & Loss Account	106
Cash Flow Statement	108
Notes to Account	110

NOTICE OF ANNUAL GENERAL MEETING

==========

Notice is hereby given that the Twenty Nineth ANNUAL GENERAL MEETING of NATH BIO-GENES (INDIA) LIMITED will be held on 30th June 2022 at 11.00 A.M. IST through Video Conferencing (VC)/ other Audio Visual Means (OAVM) to transact the following Business:

ORDINARY BUSINESS.

1. **ADOPTION OF FINANCIAL STATEMENTS.**

   To receive, consider and adopt Audited Balance Sheet of the Company as at March 31, 2022 and Statement of Profit & Loss for the year ended as on that date together with the Reports of Directors and Auditors thereon.

2. **DECLARATION OF DIVIDEND.**

   To declare a final Dividend of ₹ 2 per equity shares of face value of ₹ 10 each for financial year ended 31st March 2022.

3. **APPOINTMENT OF STATUTORY AUDITORS.**

   To appoint M/s Gautam N Associates, Chartered Accountants as statutory auditors of the Company and to fix their remuneration.

   To consider and if thought fit, to pass the following resolution, with or without modification(s), as an Ordinary Resolution:

   "RESOLVED THAT pursuant to Section 139, 142 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof) and pursuant to the recommendations of the Audit Committee and the Board of Directors of the Company, M/s Gautam N Associates, Chartered Accountants, having Membership No. 032742/103117W be and are hereby appointed as the Statutory Auditors of the Company for term of five consecutive years, who shall hold office from the conclusion of this 29th Annual General Meeting till the conclusion of the 34th Annual General Meeting to be held in the year 2027 on such remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors of the Company."

NATH BIO-GENES (INDIA) LIMITED

4. RE-APPOINTMENT OF DIRECTOR

To appoint Mrs. Sweta Kagliwal (DIN-02052811) as Director of the Company, who retires by rotation and being eligible, offer herself for re-appointment.

SPECIAL BUSINESS

5. APPOINTMENT OF INDEPENDENT DIRECTOR.

To consider the appointment of Mr. Hitesh Rajnikant Purohit (DIN:02340858) as an Independent Director of the Company as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 149, 150, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (the Act) and the Companies (Appointment and Qualifications of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), on the recommendation of the Nomination & Remuneration Committee and approval of the Board of Directors for appointment of Hitesh Rajnikant Purohit (DIN:02340858) as an Additional Director in the capacity of an Independent Director of the Company w.e.f. March 30, 2022, who has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations and is eligible for appointment, and in respect of whom the Company has received a notice in writing in terms of Section 160(1) of the Act and who holds office as such up to the date of ensuing Annual General Meeting, be and is hereby, appointed as a Non-Executive Independent Director of the Company not liable to retire by rotation, to hold office for a period effective from March 30, 2022 till March 29, 2027.

NATH BIO-GENES (INDIA) LIMITED

By order of the Board of Directors

Date: 30.05.2022
Registered Office: Nath House
Nath Road,
Aurangabad-431005
CIN: L01110MH1993PLC072842

Satish Kagliwal
Managing Director
DIN: 00119601

==========

NOTES:

1. In view of the massive outbreak of the COVID-19 pandemic, social distancing is a norm to be followed and pursuant to the Circular No. 14/2020 dated April 08, 2020, Circular No.17/2020 dated April 13, 2020 issued by the Ministry of Corporate Affairs followed by Circular No. 20/2020 dated May 05, 2020 and Circular No. 02/2021 dated January 13, 2021 and all other relevant circulars issued from time to time, physical attendance of the Members to the AGM venue is not required and general meeting be held through video conferencing (VC) or other audio visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM.

2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate thereat and cast their votes through e-voting.

3. The Members can join the EGM/AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM/AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM/AGM without restriction on account of first come first served basis.

4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system as well as venue voting on the date of the AGM will be provided by NSDL.

6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.nathbiogenes.com The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

NATH BIO-GENES (INDIA) LIMITED

7. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 08, 2020 and MCA Circular No. 17/2020 dated April 13, 2020, MCA Circular No. 20/2022 dated May 05, 2020, MCA Circular No. 02/2021 dated January 13, 2021 and MCA Circular No. 19/2021 dated December 12, 2021

8. As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from, April 1, 2019, except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents, Bigshare Services Private Limited for assistance in this regard.

9. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with Bigshare Services Private Limited in case the shares are held by them in physical form.

10. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their DPs in case the shares are held by them in electronic form and to RTA Bigshare Services Private Limited in case the shares are held by them in physical form.

11. In compliance with the aforesaid MCA Circulars and SEBI Circular dated May 12, 2020, Notice of the AGM along with the Annual Report 2021-22 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. Members may note that the Notice and Annual Report 2021-22 will also be available on the Company's website www.nathbiogenes.com websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

12. The Business set out in the Notice will be transacted through electronic voting system and the Company is providing facility for voting by electronic means. Instructions and other information relating to e-voting are given in this Notice.

13. Pursuant to Section 91 of the Companies Act, 2013, The Register of Members and Share Transfer Books of the Company will be closed from 25th June 2022 to 30th June 2022 both days inclusive. And record date is 24th June 2022. For the purpose of payment of dividend.

14. The Board of Directors, at its meeting held on 30th May 2022, has recommended dividend of ₹ 2 per equity share of the face value of ₹ 10 each for FY2022 for the approval of members at the 28th e-AGM.

NATH BIO-GENES (INDIA) LIMITED

15. Subject to the provisions of section 126 of the Act, dividend on equity shares, if declared, at the AGM, will be credited/dispatched on/after Wednesday, 06th July 2022 and within thirty days from the date of declaration of dividend to:

    (a) to all those members holding shares in dematerialized form, as per the details provided by the share transfer agent of the Company, i.e., Bigshare Services as on closing hours on Friday, 24th June 2022; and

    (b) to all those members holding shares in physical form, as per the details provided by the share transfer agent of the Company, i.e., Bigshare Services as on closing hours on Friday, 24th June 2022.

16. As per SEBI Listing Regulations and pursuant to SEBI circular dated 20 April 2018, a listed entity shall use any electronic mode of payment approved by the Reserve Bank of India for making payment to the members. Accordingly, dividend, if declared will be paid through electronic mode, where the bank account details of the members are available. Where dividend is paid through electronic mode, intimation regarding such remittance will be sent separately to the members. In case where the dividend could not be paid through electronic mode, payment will be made through physical instrument such as banker's cheque or demand draft incorporating bank account details of such members.

17. Pursuant to Finance Act 2020, dividend income will be taxable in the hands of shareholders w.e.f. April 1, 2020 and the Company is required to deduct tax at source from dividend paid to shareholders at the prescribed rates. For the prescribed rates for various categories, the shareholders are requested to refer to the Finance Act, 2020 and amendments thereof. The shareholders are requested to update their PAN with the Company/ RTA Bigshare Services Private Limited (in case of shares held in physical mode) and Depositories (in case of shares held in demat mode).

18. The relative Explanatory Statements pursuant to Section 102(1) of the Companies Act, 2013, relating to the special business to be transacted at the meeting is annexed hereto.

19. The Securities & Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in the securities market. Members holding shares in the Electronic form are therefore requested to submit their PAN to their depository Participants with whom they are maintaining their demat accounts. Members holding Physical shares can submit their PAN to the Company/ Bigshare Services.

20. The Company has appoint M/s Neha P Agrawal, Practicing Company Secretaries Membership No. 7350, to scrutinize the Voting at the meeting and remote e voting process in a fare and transparent manner.

21. Since AGM will be held through VC/OAVM, the Route Map is not annexed in the Notice.

22. Instruction for E-Voting and joining AGM are as follows:

MATH BIO-GENES (INDIA) LIMITED

EVOTING INSTRUCTIONS

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER:-

The remote e-voting period begins on Monday, 27th June 2022 at 09:00 A.M. and ends on Wednesday 29th June 2022 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. 24th June 2022, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 24th June 2022.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

In terms of SEBI circular dated December 9, 2022 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the e-Voting website of NSDL. Open web browser by

NATH BIO-GENES (INDIA) LIMITED

	typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 4. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. **NSDL Mobile App is available on** App Store Google Play
Individual Shareholders holding securities in demat mode with CDSL	1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. 2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of **e-Voting service provider i.e. NSDL.** Click on **NSDL** to cast your vote. 3. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful

NATH BIO-GENES (INDIA) LIMITED

	authentication, user will be provided links for the respective ESP i.e. **NSDL** where the e-Voting is in progress.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43

NATH BIO-GENES (INDIA) LIMITED

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12********** then your user ID is 12**********
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the

NATH BIO-GENES (INDIA) LIMITED

.pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

(ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

6. If you are unable to retrieve or have not received the " Initial password" or have forgotten your password:
   a) Click on "**Forgot User Details/Password**?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) **Physical User Reset Password**?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

MATH BIO-GENES (INDIA) LIMITED

General Guidelines for shareholders

1 Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to nath.scrutinizer@gmail.com with a copy marked to evoting@nsdl.co.in.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800-222-990 or send a request at evoting@nsdl.co.in.

NATH BIO-GENES (INDIA) LIMITED

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical register details:
https://www.bigshareonline.com//InvestorRegistration.aspx

OR

2. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to (investor@nathbiogenes.com)

In case shares are held in demat mode:

1. Please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to (investor@nathbiogenes.com). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**.

2. Alternatively shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

3. In terms of SEBI circular dated December 9, 2021 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access the same at https://www.evoting.nsdl.com under shareholders/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVEN of Company will be displayed. Members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush. Further members can also use the OTP based login for logging into the e-Voting system of NSDL.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at investor@nathbiogenes.com. The same will be replied by the company suitably.

NATH BIO-GENES (INDIA) LIMITED

6. Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered email address mentioning their name, DP ID and Client ID/folio number, PAN, mobile number, mail ID and questions or a topic they would like to speak at AGM at investor@nathbiogenes.com from June 24, 2022 (9:00 a.m. IST) to June 26, 2022 (5:00 p.m. IST). Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

Dividend Related Information

Pursuant to the changes in the Income-tax Act, 1961 ('the Act'), as amended by the Finance Act, 2020, dividends paid or distributed by the Company on or after 1st April, 2020 shall be taxable in the hands of the shareholders. The Company shall therefore be required to deduct tax at source ('TDS') (at the applicable rates) at the time of payment of the dividend. The withholding tax rate would vary depending on the residential status of the shareholder(s) and subject to verification of documents, sent by the shareholder(s)

NATH BIO-GENES (INDIA) LIMITED

Resident Shareholders:
Tax shall be deducted at source under section 194 of the Income Tax Act, 1961 (the 'IT Act') @ 10% on the amount of dividend declared and paid by the Company during financial year 2022-22, subject to the following:

Sr No	Particulars	Rate of TDS	Section under IT Act
1	PAN is not available/Invalid PAN	20%	206AA
2	Non-filing of return of income tax for any of the last two financial years (i.e. FY 2018-19 and FY 2019-20); and TDS as well as TCS deduction in each of these years in case of the shareholder is ₹ 50000 or more (Refer Note 1)	20%	206AA

Note 1: Provisions of section 206AB of the IT Act are applicable with effect from 1 July 2021

No tax shall be deducted at source on the dividend payable to a resident individual if the total dividend to be received by the said resident individual from the Company during a financial year does not exceed ₹ 5000; or if an eligible resident shareholder provides a valid declaration in Form 15G/Form 15H or other documents as may be applicable to different categories of shareholders.

Further, if a shareholder has obtained a lower or Nil withholding tax certificate from the tax authorities and provides a copy of the same to the Company, tax shall be deducted on the dividend payable to such shareholder at the rate specified in the said certificate.

Non-resident Shareholders:
Tax is required to be deducted at source in the case of non-resident shareholders in accordance with the provisions of section 195 of the IT Act at the rates in force. As per the relevant

provisions of the IT Act, the TDS on dividend shall be @ 20% or applicable rate plus applicable surcharge and health & education cess on the amount of dividend payable to the non-resident shareholders. For FII/FPI shareholders, section 196D provides for TDS @ 20% or applicable rate plus applicable surcharge and health & education cess.

However, as per section 90 of the IT Act, non-resident shareholders have the option to be governed by the provisions of the Double Tax Avoidance Agreement (DTAA) read with applicable Multilateral Instrument (MLI) provisions, if they are more beneficial to them.

A list of documents/declarations required to be provided by the resident shareholders and list of documents/ declarations required to claim the benefit of DTAA by the non-resident shareholders are available on the Company's website https:/www.nathbiogenes.com.

Kindly note that the documents should be send to Bigshare Services Private Limited., the registrar and share transfer agent at tds@bigshareonline.com.

No communication on the tax determination/deduction shall be entertained after 20th June 2022.

The above referred documents submitted by you will be verified by us and we will consider the same while deducting the appropriate taxes, if any, provided that these documents are in accordance with the provisions of the IT Act. In addition to the above, please note the following:

- In case you hold shares under multiple accounts under different status/category but under a single PAN, the highest rate of tax as applicable to the status in which shares held under the said PAN will be considered on the entire holding in different accounts.

- In case of joint shareholding, the withholding tax rates shall be considered basis the status of the primary beneficial shareholder

- For deduction of tax at source, the Company would be relying on the above data shared by Bigshare Services Private Limited as updated up to the record date.

May be further noted that in case tax on dividend is deducted at a higher rate in the absence of receipt of any of the aforementioned details/documents from the shareholders, and such shareholders may consider filing their return of income and claiming an appropriate refund, as may be eligible. No claim shall lie against the Company for such taxes deducted.

The Company shall arrange to email the soft copy of the TDS certificate to shareholders at the registered email ID within the prescribed time, post payment of the said dividend, if declared in the AGM. The said certificate can also be viewed in Form 26AS at TRACES https://www.tdscpc.gov.in/app/login.xhtml or the website of the Income Tax department of India https://www.incometax.gov.in/home.

In the event of any income-tax demand (including interest, penalty, etc.) arising from any misrepresentation, inaccuracy or omission of information provided by the shareholder/s, such shareholder/s will be responsible to indemnify the Company, and also provide the Company with all information/documents and co-operation in any assessment/appellate proceedings before the Tax/Government authorities.
For further details and formats of declaration, please refer to FAQs on Dividend Distribution available on the Company's website https://www.nathbiogenes.com.

NATH BIO-GENES (INDIA) LIMITED

Explanatory Statement
(Pursuant to Section 102 of the Companies Act, 2013)

As required by Section 102 of the Companies Act, 2013 ("Act"), the following explanatory statement sets out all material facts relating to the business mentioned in the accompanying Notice:

None of the Directors or Key Managerial Personnel (KMP) or relatives of directors and KMP is concerned or interested in the Resolution at Item No. 4 of the accompanying Notice

Item No. 3:

TO APPOINT M/S GAUTAM N ASSOCIATES, CHARTERED ACCOUNTANTS AS STATUTORY AUDITORS OF THE COMPANY AND TO FIX THEIR REMUNERATION.

M/s Gautam N Associates, Chartered Accountants, have given their consent for their re-appointment as Statutory Auditors of the Company and has issued certificate confirming that their appointment, if made, will be within the limits prescribed under the provisions of Section 139 of the Companies Act, 2013 ('the Act') and the rules made thereunder. M/s Gautam N Associates, have confirmed that they are eligible for the proposed appointment under the Act, the Chartered Accountants Act, 1949 and the rules or regulations made thereunder. As confirmed to Audit Committee and stated in their report on financial statements, the Auditors have reported their independence from the Company and its subsidiary according to the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') and the ethical requirements relevant to audit. Based on the recommendations of the Audit Committee and the Board of Directors, it is hereby proposed to appoint M/s Gautam N Associates, Chartered Accountants, having registration No. 032742/103117W, as the Statutory Auditors of the Company for the term of five consecutive years, who shall hold office from the conclusion of this 29th AGM till the conclusion of the 34th AGM of the Company. The Board of Directors of the Company will decide the remuneration of Auditors for conducting the audit for the financial year 2022-23, excluding applicable taxes and reimbursement of out-of-pocket expenses on actuals. The remuneration proposed to be paid to the Statutory Auditors during their second and final term would be in line with the existing remuneration and shall be commensurate with the services to be rendered by them during the said tenure. The Board of Directors in consultation with the Audit Committee may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the Statutory Auditors.

NATH BIO-GENES (INDIA) LIMITED

Item No-4.

DETAILS OF DIRECTORS RETIRING BY ROTATION AND SEEKING RE-APPOINTMENT.

NAME OF DIRECTOR	Mrs. Sweta Kagliwal
Date of Birth	04.02.1982
Qualification	Diploma in Business Management
Expertise in specific Functional areas	Wide Business experience across variety of industries
Director in other Public Companies	1. Agri-Tech (India) Ltd 2. Techindia Nirman Ltd 3. Nath Royal Limited

	4. Nath Bio-Technologies Limited 5. Nath Royal Seeds Limited 6. Tapovan Paper and Board Mills Limited 7. Global Transgenes Limited
Chairman/ Member of Committees of other Companies	NIL
No of shares held in the Company	NIL

Item No -5

APPOINTMENT OF MR. HITESH RAJNIKANT PUROHIT (DIN-02340858) AS INDEPENDENT DIRECTOR.

The Company received a notice from a Member under Section 160 of the Companies Act, 2013, signifying his intention to propose the candidature of Mr. Hitesh Rajnikant Purohit (DIN: 02340858) for the office of Independent Director of the Company. Mr. Hitesh Rajnikant Purohit, is a Commerce Graduate, and he has have over 30 years of rich experience in the field of, Management and finance with various industries.

Mr. Hitesh Rajnikant Purohit is not related to any Director of the Company. In terms of proviso to sub-section (5) of Section 152, the Board of Directors is of the opinion that Mr. Hitesh Rajnikant Purohit fulfils the conditions specified in the Act for their appointment as an Independent Director. After taking into consideration the recommendation of the Nomination & Remuneration Committee, the Board is of the opinion that Mr. Hitesh Rajnikant Purohit's vast knowledge and varied experience will be of great value to the Company and has recommended the Resolution at Item No.04 of this Notice relating to the appointment of Mr. Hitesh Rajnikant Purohit as an "Independent Director", not liable to retire by rotation for a period of five consecutive years w.e.f. March 30, 2022 till March 29, 2027, for the your approval. Mr. Hitesh Rajnikant Purohit has given a declaration to the Board that he meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and Regulation 16 of the SEBI Listing Regulations. The Company has also received:- (i) the consent in writing to act as Director and (ii) intimation that he is not disqualified under section 164(2) of the Companies Act, 2013. (iii) a declaration to the effect that he is not debarred from holding the office of Director pursuant to any Order issued by the Securities and Exchange Board of India (SEBI).

By order of the Board of Directors

Date: 30th May 2022
Registered Office: Nath House
Nath Road,
Aurangabad-431005
CIN: L01110MH1993PLC072842

Satish Kagliwal
Managing Director
DIN: 00119601

NATH BIO-GENES (INDIA) LIMITED

MANAGING DIRECTORS STATEMENT

==========

Dear Shareholders,

FY22 has been a challenging year for us as an organisation. At start of the year, we saw the deadly second wave of covid hitting us right at the beginning of the crucial Kharif season. We also saw massive headwinds on account of illegal BT cotton in the country. Despite a challenging macro environment, we have been able maintain our performance on various parameters.

Our strategy to de-risk and diversify our product portfolio is showing satisfactory results. The combined revenue contribution from Paddy and Cotton is declining and for FY22 it reduced to 59%. Similarly, our efforts to reduce and rationalise working capital is also yielding satisfactory results. Despite a challenging operating environment, we have been able to reduce our working capital cycle and rationalize our receivable days. Overall inventory has decreased, and we expect the inventory levels to normalize further over the next two seasons.

This year, we have clocked reduced sales and profit, pursuant to the reduction in paddy sales due to change in product mix. As a matter of prudent accounting policy, we have created provisions against the advances which had been given to the farmers. We have been working with over fifty thousand contract farmers over the last three to four years and have had a natural cycle of production. However, the situation had been on a decline over the last two-three years primarily on an account of COVID. Our farming community has been facing undue stress either on an account of climate vagaries or due to loss of lives of the key family member on account of COVID. While we are working on an amicable solution with the farmers and growers to recover our advances, as a matter of abundant precaution, we have made a provision for the potential bad advances to the farmers. The company would continue to make all the necessary efforts to recover these payments through recovery or through future production. However, we would ensure that our farmers are not aggrieved, and all viable option are worked out with them.

We are confident of a good FY23, and the outlook looks good. The entire farm sector and farming community is buoyant with unprecedented farm produce prices currently hovering in the country. The news of bountiful monsoon has also added the cheer. With all these aspects, we expect a good Kharif season this year.

The seed industry has been pursuing with the government for approval of the much-awaited HTBT technology. We will continue to harness genomics and modern technology to develop superior seeds. We plan to launch several products in different crops and segments. Our focus as we go forward will be with the field crops like Maize, Bajra, Mustard and Wheat.

NATH BIO-GENES (INDIA) LIMITED

Along with this we are also working on current portfolio of Cotton and Paddy. We expect to register a rapid growth in vegetable and Plant Nutrient verticals given that our team building efforts in these segments are now complete. Things are also looking bright for exports. We will expand our presence offshore and are excited about introducing our products in many countries, once all the approvals come through.

We are confident of overcoming all the short-term challenges and delivering a strong operational and financial performance next year. Our teams on the ground are quite excited about the new products that we are planning.

DIRECTORS' REPORT

==========

The Directors of the Company pleased to present the Annual Report together with the Audited Accounts of your Company for the financial year ended 31st March 2022.

1. FINANCIAL RESULTS

(Rs in Lacs)

Sr. No	PARTICULARS	YEAR ENDED	
		31.03.2022	31.03.2021
1.	Sales	27836.23	30756.11
2.	Profit before Interest & Depreciation	3909.05	6838.64
3.	Interest	1061.10	881.94.60
4.	Depreciation	308.41	281.59
5.	Profit Before Tax & Exceptional items	2539.55	5675.11
6.	Tax Provision (Net of Deferred Tax)	395.15	108.95
7.	Profit After Tax	2144.39	5566.16
8.	Exceptional Items	8878.19	0.00
9.	Profit available for Appropriation	-6733.80	5566.16
10	Balance carried to Balance Sheet	-6733.80	5566.16

NATH BIO-GENES (INDIA) LIMITED

2. COMPANY'S PERFORMANCE AND OPERATION.

Income from operations during the financial year ended 31st March 2022 was at Rs.27836.23Lacs as against Rs.30756.11Lacs representing a marginal decrease of 9.50 % over the previous year. Profit after Tax for the year under review amounted to Rs 2144.39 Lacs as against profit of Rs 5566.16 Lacs in the previous year. The decrease in profit during the year under review was on account of reduced sales and enhanced credit passed to the trade to maintain market presence. The Company also made a provision of Rs. 8878.19 Lacs against the advances made to the farmers and growers taking up production of seeds on behalf of the Company. The recoverability is being pursued and all efforts are being made to that end. However, keeping in view the prolonged period, as a matter of prudent policy, your company made a provision of the said advances.

3. DIVIDEND.

In view of the proposed growth plan, the Directors have recommended dividend for financial year 2021-22 of Rs. 2/-(i.e., 20%) per equity shares of the nominal value of Rs. 10.00 per share fully paid up, subject to approval of shareholders in upcoming Annual General Meeting of the Company.

4. DEPOSITS.

The company has not accepted any fixed deposits during the year under review.

5. SHARE CAPITAL.

The paid-up equity share capital as on 31st March2022 was Rs.190040000/- divided into 19004000 equityshares of face value of 10/- each. There was no public issue, rights issue, bonus issue or preferential issue, etc. during the has not issued shares with differential voting rights, sweat equity shares, nor has initiated any stock options.

6. FINANCIAL STATEMENT.

Full version of the Annual Report 2021-22 containing complete Balance Sheet, Statement of Profit & Loss, other statements and notes thereto, prepared as per the requirements of Schedule III to the Companies Act, 2013, Directors' Report (including Management Discussion and Analysis, Corporate Governance Report) are being sent via email to all shareholders who have provided their email address(es). Full version of Annual Report 2021-22 is also available for inspection at the registered office of the Company during working hours upto the date of ensuing Annual General Meeting (AGM). It is also available at the Company`s website at www.nathbiogenes.com.

7. TRANSFER TO RESERVES.

The entire retained earnings closing balance of the retained earnings of the Company for FY 2022, after all appropriation and adjustments was Rs. 52296.54 Lakhs and the same has been retained as such.

8. COVID-19 IMPACT.

The outbreak of the deadly COVID-19 virus and the ensuing lockdown imposed across the country affected business operations. The health of the employees and workers became a priority; stoppage of operations for an uncertain period resulted in a large financial burden on the one hand and workforce idling on the other. COVID 19 was an unprecedented challenge. The lockdown gave India time to make a concerted effort to flatten the outbreak curve. Now, with the COVID having been dealt with and controlled, the globe can witness a renewed economic condition. We are also planning to be a part of this.

9. STATUTORY AUDITORS AND AUDITORS REPORT.

At the Annual General Meeting held on Authorized signatory 24th August 2017, M/s Ashok R Majethia, Chartered Accountants, were appointed as the Statutory Auditors of the Company to hold office till the conclusion of Annual General Meeting to be held in year 2022.

The statutory auditors report is annexed to this annual report. There are no adverse remarks on disclosure by the statutory auditors in their report. They have not reported any incident of fraud to the Audit Committee of the Company during the year under review. Pursuant to Section 139(2) of the Companies Act, 2013, read with Companies (Audit and Auditors) Rules, 2014, the Company at its Annual General Meeting (AGM) held on 24th August 2017, had appointed M/s Ashok R Majethia, Chartered Accountants as Statutory Auditors to hold office from the conclusion of Annual General Meeting to be held in year 2022, subject to

NATH BIO-GENES (INDIA) LIMITED

ratification by shareholders every year, as may be applicable. However, the Ministry of Corporate Affairs (MCA) vide its notification dated 7th May 2018 has omitted the requirement under first proviso to section 139 of the Companies Act, 2013 and rule 3(7) of the Companies (Audit and Auditors) Rules, 2014, regarding ratification of appointment of statutory auditors by shareholders at every subsequent AGM.

10. AUDITORS' REPORT.

The Notes on financial statement referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation, or adverse remark.

11. INTERNAL AUDITORS.

The Board of Directors of the Company has appointed M/s M.K. Ghatiya and Associates, Company Secretaries Internal Auditors to conduct Internal Audit of the Company for the financial year ended 31st March 2022. The Internal Audit reports are being reviewed by the Audit Committee of the Company.

12. SECRETARIAL AUDIT REPORT.

Pursuant to the provisions of Section 204 of the Companies Act,2013 and the Companies (Appointment and Remuneration of Managerial Personnel) rules, 2014, the Board of Directors have appointed M/s. Neha P Agrawal Company Secretaries in Practice (C.P.No.8048) as Secretarial Auditors to conduct Secretarial Audit of the Company for the financial year ended 31st March 2022. The Secretarial Audit Report issued by M/s. Neha P Agrawal Practicing Company Secretaries in Form MR-3 is annexed to this Board's Report as **Annexure – VI**.

13. SUBSIDIARIES.

The Company does not have any subsidiary within the meaning of the Companies Act, 2013.

14. ADEQUACY OFINTERNAL FINANCIAL CONTROL SYSTEM.

According to Section 134(5)(e) of the Companies Act, 2013,the term Internal Financial Control (IFC) means the policies and procedures adopted by the company for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information. Rule 8(5)(viii) of Companies (Accounts) Rules, 2014 requires the information regarding adequacy of Internal Financial Controls with reference to the financial statements to be disclosed in the Board`s report. The Company has a well-placed, proper, and adequate IFC system which ensures that all assets are safeguarded and protected and that the transactions are authorised, recorded, and reported correctly. The Internal Auditors are an integral part of the internal control system of the Company. Maintain its objective and independence, the Internal Auditors report to the Audit Committee of the Board. The

NATH BIO-GENES (INDIA) LIMITED

Internal Auditors monitor and evaluate the efficacy and adequacy of internal control systems in the Company.

15. DIRECTORS' RESPONSIBILITY STATEMENT.

Pursuant to the provisions of Section 134 (3) (c) of the Companies Act, 2013, the Board of Directors hereby confirms that,

i. In the preparation of the annual accounts, the applicable accounting standards have been followed and that there are no material departures.
ii. It has in the selection of the accounting policies, consulted the Statutory Auditors, and has applied them consistently and made judgments and estimates that are reasonable and prudent, to give a true and fair view of the state of affairs of the company as of 31st March2022 and of the profits of the company for that period.
iii. It has taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities, to the best of its knowledge and ability. There are, however, inherent limitations, which should be recognized while relying on any system of internal control and records.
iv. It has prepared the annual accounts on a going concern basis.
v. The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operation efficiently.
vi. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

16. DIRECTORS& KEY MANAGERIAL PERSON

Director Retires by rotation

- Ms Sweta Kagliwal (holding DIN 02052811) retires by rotation under Section 152 of the Companies Act, 2013 and being eligible, offers herself for re-appointment.

Appointment of Directors.

- Mr. Hitesh Purohit (DIN-02340858) appointed as Additional Director (Independent) of the Company from 30th March2022.

Cessation of Director

- Resignation of Mr. Shrirang Shrikishan Agrawal (DIN-00119681)as Independent Director of the Company with effect from 15th February2022 due to attaining age 75.

The Key Managerial Personnel (KMP) of the Company as per Section 2(51) and 203 of the Companies Act, 2013 are as follows:

Mr. Satish Kagliwal-Managing Director
Mr. Devinder Khurana- Chief Financial Officer
Mr. Dhiraj Rathi- Company Secretary

NATH BIO-GENES (INDIA) LIMITED

NATH BIO-GENES (INDIA) LIMITED

17. DECLARATION OF INDEPENDENT DIRECTOR.

The Independent Directors have submitted the declaration of independence, as required pursuant to section 149 (7) of the Companies Act, 2013 stating that they meet the criteria of Independence as provided in sub section (6) of Section 149.

18. FAMILIARIZATION PROGRAMME OF INDEPENDENT DIRECTOR.

The details of the familiarization program for the Independent Directors are reported in the Report on Corporate Governance.

19. NUMBER OF MEETINGS OF THE BOARD.

Five meeting of the Board were held during the year. The dates on which the Board meetings were held are 24thJune 2021, 10th August 2021, 01stNovember 2021, and 11thFebruary2022.And 30th March 2022 The details of attendance of Board meetings and Committee meetings held during the Financial Year 2021-22 forms part of the Corporate Governance Report.

20. PERFORMANCE EVALUATION OF THE BOARD, ITS COMMITTEE, AND INDIVIDUAL DIRECTORS.

Pursuant to applicable provisions of the Companies Act, 2013 and the Listing Regulations 2015, the Board, in consultation with its Nomination & Remuneration Committee, has formulated a framework containing, inter-alia, the criteria for performance evaluation of the

entire Board of the Company, its Committees and Individual Directors, including Independent Directors. The detailed information in this regard has been given in the Corporate Governance Report.

21. MANAGEMENT DISCUSSION & ANALYSIS.

The Management Discussion and Analysis has been given separately in the Annual report.

22. PARTICULARS OF CONTRACT OR ARRANGEMENTS PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES.

All transactions entered with Related Parties for the year under review were on arm's length basis and in the ordinary course of business. There are no material related party transactions during the year under review with the Promoters, Directors, or Key Managerial Personnel. The Company has developed a Related Party Transactions framework through standard operation procedures for the purpose of identification and monitoring of such transactions. All Related Party Transactions are placed before the Audit Committee as also to be Board for approval. The particulars of contracts or arrangements entered by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 disclosed in **Form No. AOC – 2** and is set out as **Annexure –II** and forms part of this report.

23. PARTICULARS OF LOANS, AGURANTEES OR INVESTMENTS UNDER SECTION 186 OF THECOMPANIES ACT, 2013.

The loan given or guarantee provided, or investment made by the Company during the financial year 2021-22as per Section 186 of the Companies Act, 2013have been given in the Balance Sheet and Audit Report.

24. CORPORATE SOCIAL RESPONSIBILITY (CSR).

The brief outline of the Corporate Social Responsibility (CSR) policy of the Company and the initiatives under taken by the Company on CSR activities during the year under review are set out in **Annexure IV** of this report in the format prescribed in the Companies (Corporate Social Responsibility Policy) Rules, 2014. For other details regarding the CSR Committee, please refer to the Corporate Governance Report, which is a part of this report.

25. DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the board has approved and adopted the Dividend Distribution Policy and the same in available at Companies website and provided as Annexure-VII to the Annual Report.

26. INSIDER TRADING CODE.

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ('the PIT Regulations') on prevention of insider trading, the Company have its Code of Conduct for regulating, monitoring, and reporting of trading by

NATH BIO-GENES (INDIA) LIMITED

Designated Persons in line with the recent amendments brought by SEBI in the PIT Regulations. The said Code lays down guidelines, which advise Designated Persons on the procedures to be followed and disclosures to be made in dealing with the shares of the Company and cautions them on consequences of non-compliances. the Company has also updated its Code of practices and procedures of fair disclosures of unpublished price sensitive information by including a policy for determination of legitimate purposes.

27. MATERIAL CHANGES AND COMMITMENTS.

There are no material changes and commitments in the business operations of the Company from the financial year ended March 31, 2022, to the date of signing of the Director's Report.

28. RISK ASSESMENT AND MANAGEMENT.

The Company is exposed to various business risks. These risks are driven through external factors like economic environment, competition, regulations etc. The Company has laid down a well-defined risk management mechanism covering the risk mapping and trend analysis, risk exposure, potential impact, and risk mitigation process. A detailed exercise is being conducted to identify, evaluate, manage, and monitor business and non-business risks. The Audit Committee and Board periodically review the risks and suggest steps to be taken to manage/mitigate the same through a properly defined framework. During the year, a risk analysis and assessment was conducted, and no major risks were noticed, which may threaten the existence of the Company.

NATH BIO-GENES (INDIA) LIMITED

29. POLICY AGAINST SEXUAL HARRASMENT AT WORKPLACE.

Pursuant to the provisions of Section 4(1) of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has in place an Internal Complaints' Committee. The following is a summary of sexual harassment complaints received and disposed of during the year

No. of complaints received: Nil
No. of complaints disposed of: Nil

30. ENVIRONMENTAL SAFETY.

The Company is conscious of the importance of environmentally clean and safe operations. The Company's policy requires conduct of operations in such a manner, to ensure safety of all concerned, compliances environmental regulations and preservation of natural resources.

31. COMMITTEE OF THE BOARD

Currently the Board has Four Committees:
1. Audit Committee.
2. Stakeholders' Relationship Committee,
3. Nomination & Remuneration committee.
4. Corporate Social Responsibility Committee
5. Risk Management Committee

A detailed note on the Board and its committees, composition, and compliances, as per the applicable provisions of the Act and Rules is provided under the Corporate Governance Report.

32. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO.

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under the Act, are provided in Annexure -III to this Report.

33. EXTRACT OF ANNUAL RETURN.

As per the requirements of Section 92(3) of the Act and Rules framed there under, the extract of the annual return for FY 2022 is given in **Annexure-V** in the prescribed Form No. MGT-9, which is a part of this report.

34. INSURANCE

All the insurable interest of the company, including Inventories, Buildings, Machinery etc., is adequately insured.

35. INDUSTRIAL RELATION.

The Company enjoyed cordial relations with its employees at all levels. Your directors record their appreciation of the support and co-operation of all employees and counts on them for the accelerated growth of the Company.

36. ACKNOWLEDGEMENTS.

The Directors place on record their sincere appreciation for the dedication, hard work and commitment of the employees at all levels and their significant contribution to your Company's growth. Your Company is grateful to the Distributors, Dealers, and Customers for their support and encouragement. Your directors thank the Banks, Financial Institutions, Government Departments and Shareholders and look forward to having the same support in all our future endeavors.

For and on behalf of the Board of Directors

30th May2022
Registered Office:
Nath House,
Nath Road
Aurangabad-431005

Managing Director	Director
Satish Kagliwal	Jeevanlata Kagliwal
DIN: 00119601	DIN: 02057459

NATH BIO-GENES (INDIA) LIMITED

ANNEXURE-1

PARTICULARS OF EMPLOYEES PURSUANT TO SECTION 134(3) (q) AND SECTION 197(12) OF THE COMPANIES ACT, 2013 READ WITH RULE 5(1) OF THE COMPANIES

(APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

1. **The Ratio of the remuneration of each Director to the median remuneration to the employee of the Company for the financial year 2021-22:-**

   Satish Kagliwal: Managing Director 14.09

   Note

   i. Independent Directors have been paid sitting fees for attending meeting of the Board or its Committees as disclosed in the Corporate Governance Report. The sitting fees paid have not been included in the details mentioned above.

   ii. For Calculation of median remuneration, the employee count taken is 462 which comprises of employees who have served for whole of the Financial Year 2021-22.

2. **Percentage increase in remuneration of each Director, Chief financial officer, Company Secretary in Financial Year 2021-22:**

Directors/CFO/CS Name	Designation	% Increase /decrease in remuneration of 2021-22
Satish Kagliwal	Managing Director	0.00 %
Devinder Khurana	Chief Financial Officer	8.35 %
Dhiraj Rathi	Company Secretary	9.07%

3. **Percentage increase in the median remuneration of employees in the financial year 2021-22:7.29%**

4. **Number of the Permanent employees on the rolls of the company as on 31.03.2022: 462**

5. **Average percentile increases in salaries of Employees other than Managerial personnel in the last financial year and its comparison with the percentile increase in the Managerial Remuneration and justification thereof and any exceptional circumstances for increase in the Managerial Remuneration (if any):**

   The percentage increase in the salaries of employees other than the managerial personnel in the last financial year is 7.56%. The increment given to each individual employee is based on the employees' potential, experience as well as their performance and contribution to the Company's progress over a period.

6. **Affirmation of remuneration is as per the remuneration policy of the company.**

NATH BIO-GENES (INDIA) LIMITED

It is affirmed that the remuneration paid is as per the Nomination and Remuneration Policy adopted by the Company.

7. **Top ten Employees in terms of remuneration drawn during the year 2021-22**

TOP TEN EMPLOYEES-2021-22						
Sr. No.	**Name**	**Designation**	**Remuneration (INR in Lakhs)**	**Qualification**	**Joining Date**	**Age**
1	Devinder Khurana	CFO	₹ 65.20	CFA, CFE, CAIIB	01/08/1996	64
2	K Ravinder Reddy	VICE PRESIDENT-	₹ 64.67	MSc (Agri.),	05/05/2020	62
3	Ram Kumar Pandey	ASSOCIATE VICE PRESIDENT	₹ 58.19	BSc (Agri.),Diploma in Marketing Management,	01/08/2020	50
4	Harish Pandey	ASSOCIATE VICE PRESIDENT	₹ 53.66	BSc (Agri.)	28/08/2020	48
5	Satish Kagliwal	MANAGING DIRECTOR	₹48.00	MMS	01/11/1990	65
6	Syed Sajid Hassan	VICE PRESIDENT-	₹ 44.22	BSc. (Agri.),MBA	02/07/2019	58
7	Abhinay Jadhav	CHIEF PEOPLE OFFICER	₹ 35.91	BCom.,MBA (HR)	01/06/2021	50
8	Venkatesh Kulkarni	VICE PRESIDENT	₹ 33.00	PhD.,MSc. (Agri.)	21/05/2018	57
9	Santosh Joshi	VICE PRESIDENT	₹ 27.47	MCom.,DBM.	01/01/2008	52
10	Satyadev Pathak	GENERAL MANAGER	₹ 26.30	MSc. (Bot.),BSc (Agri.)	14/10/2016	56

Notes:

1. The employees have adequate experience to discharge responsibilities assigned to them
2. None of the employees are relatives of the Directors of the Company

MATH BIO-GENES (INDIA) LIMITED

Annexure – II

Form No- AOC 2

Particulars of contracts / arrangement entered into by the Company with Related Parties	
Pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules 2014.	
Form for Disclosure of particulars of contracts / arrangements entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act 2013 including certain arm's length transaction under third proviso thereto)	
1. **Details of contract or arrangement or transactions not at arm's length basis:**	All contracts / arrangements entered in to by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act 2013 are at arm's length basis.
2. **Details of contract or arrangement or transactions at arm's length basis:**	S. No / Particulars / Details a) / Name of the Related Party / Global Transgenes

		Limited
b)	Nature of transaction	Operational
c)	Duration of transaction	NA
d)	Salient features of transaction including the value if any	Research & Development

S. No	Particulars	Details
a)	Name of the Related Party	Agri-Tech (India) Limited
b)	Nature of transaction	Operational
c)	Duration of transaction	NA
d)	Salient features of transaction including the value if any	Land Purchase

S. No	Particulars	Details
a)	Name of the Related Party	Paithan Mega Food Park Limited
b)	Nature of transaction	Operational
c)	Duration of transaction	NA
d)	Salient features of transaction including the value if any	Warehouse Renting

NATH BIO-GENES (INDIA) LIMITED

ANNEXURE III

Particulars of Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo required under the Companies (Accounts) Rules, 2014.

Conservation of Energy:

Energy conservation dictates how efficiently a company can conduct its operations. Your Company recognizes the importance of energy conservation in decreasing the detrimental effects of global warming and climate changes. Being in the field of Agriculture, we are constantly endeavoring to improve upon the agro-climatic conditions. As a contentious effort, we have taken necessary measure to achieve economy in consumption of energy.

Technology Absorption & Research and Development:

The company is in the field of Technology Absorption and Research & Development since inception. Our state-of-the-art R & D facility, at Aurangabad is constantly in the process of developing new seeds to enhance the yield to the farming community without jeopardizing the environment. We have employed state-of-the-art technology, wherever applicable.

Expenditure on R & D	**888.52 Lacs**
Foreign Exchange Earning and Outgo:	
Earnings	192.30 Lacs
Outgo	59.80 Lacs

ANNEXURE IV

Annual Report on Corporate Social Responsibility (CSR) activities for the financial year 2021-22

1. A brief outline of the Company's CSR Policy including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR Policy and projects or programs and the composition of CSR Committee	Refer Sections: (a) Corporate Social Responsibility and (b) Disclosures: CSR&G Committee in this Report
2. Average net profit of the Company for last three financial years `	INR 4875.14 Lacs
3. Prescribed CSR expenditure (two percent of the amount mentioned in item 2 above)	INR 97.50 Lacs
4. Details of CSR spent during the financial year: • **Total amount spent for the financial year** • **Amount unspent if any** • **Manner in which the amount spent during the financial year**	 99.45 Lacs Not Applicable Details given below

DETAILS OF AMOUNT SPENT ON CSR ACTIVITIES DURING THE FINANCIAL YEAR 2021-22

Sr. No.	CSR project or Activity Identified Sector in which the project is covered (Clause no. of Schedule VII to the Companies Act, 2013, as amended)	Project of Program (1) Local Area or Other (2) Specify the State and district where projects or programs was undertaken	Amount Outlay (Budget) Project or Program wise (in lacs)	Amount spent on the Projects or Programs Sub Heads: (1) Direct Expenditure on Projects or Programs (2) Overheads (in lacs)	Cumulative Expenditure Up to the reporting period i.e. FY 2019-2022 (in lacs)	Amount Spent Direct or through Implementing Agency
1	(i)	PAN India	Rural Transformation		INR 99.45	Self through Company Staff
Total					INR 99.45	

NATH BIOGENES (INDIA) LIMITED

CORPORATE SOCIAL RESPONSIBILITY AT NATH BIO-GENES (INDIA) LIMITED

At NBIL, Corporate Social Responsibility (CSR) is being embedded in the long-term business strategy of the Company. For NBIL, business priorities and social commitments are meant to co-exist in harmony for the development of people and communities at large. The Company's CSR initiatives in rural development would help elevate the quality of life of millions of farmers. We further plan to venture into healthcare, education, and rural employment over a period.

Your Company has been making systematic efforts at educating the farming community on the best agriculture cultivation practices to aim at rural development. We combine a judicious mix of technology, material, and information with specific focus on agriculture. We are continuously working on enhancing opportunities by disseminating information relevant to improving livelihood options among rural communities. We deploy locally relevant solutions to promote agriculture and other farm-based activities. We focus on building the capacity of farming communities from the time that we engage them by ensuring their participation in the resource mapping and planning exercise. Need-based training programs are conducted to further enhance the skills and knowledge of small and marginal farmers. Trainings on sustainable agricultural practices, soil and water conservation, pest management, use of fertilizers, are imparted.

NATH BIO-GENES (INDIA) LIMITED

ANNEXURE V

Form No. MGT-9

EXTRACT OF ANNUAL RETURN

As on the financial year ended on March 31, 2022

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS	
i) CIN	L01110MH1993PLC072842
ii) Registration Date	14-07-1993
iii) Name of the Company	Nath Bio-Genes (India) Limited
iv) Category / Sub-Category of the Company	Public Company / Limited by shares
v) Address of the Registered office and contact details	Nath House, Nath Road, Aurangabad-431005
vi) Whether listed company	Yes
vii) Name, Address and Contact details of Registrar and Transfer Agent,	Big Share Services Pvt. Ltd, 1st Floor, Bharat Tin Works Building, Opp Vasant oasis, Makwana Road, Marol, Andheri East, Mumbai-400 059.
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY	
All the business activities contributing 10% or more of the total turnover ofthe company	GM and Hybrid Seeds
Horticulture Business	100%
III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES	
Holding Company	NIL
Subsidiary Company	
Associate Companies	As per Attachment A
IV. SHARE HOLDING PATTERN (EQUITY SHARE CAPITAL BREAKUP AS PERCENTAGE OF TOTAL EQUITY)	
i) Category-wise Share Holding **ii) Shareholding of Promoters** **iii) Change in Promoters' Shareholding** **iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs)** **v) Shareholding of Directors and Key Managerial Personnel**	As per Attachment B As per Attachment C As per Attachment C As per Attachment D As per Attachment E
V. INDEBTEDNESS	
Indebtedness of the Company including interest outstanding/accrued but not due for payment	As per Attachment F
VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL	
A. Remuneration to Managing Director, Whole-time Directors and/or Manager **B. Remuneration to other directors** **C. Remuneration to Key Managerial Personnel other than MD/MANAGER/WTD**	As per Attachment G As per Attachment G As per Attachment G
VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES	NIL

NATH BIO-GENES (INDIA) LIMITED

Attachment A

Particulars of Associate Companies

Sr No	Name of the Company	Address of Company	CIN	% Of shares held	Applicable Section

Not Applicable

Attachment B

SHARE HOLDING PATTERN as on 31st March 2022

Category wise shareholding

	Category of Shareholders	No. of shares at the beginning of the year (As on 01.04.2021)				No. of shares at the end of the year (As on 31.03.2022)				% Of change during the year
		Demat	**Physical**	**Total**	**% Of total shares**	**Demat**	**Physical**	**Total**	**% Of total shares**	
(A)	**Promoter**									
1	**Indian**									
(a)	Individuals/ HUF	439	0	439	0.00	439	0	439	0.00	0.00
(b)	Central Govt.	0	0	0	0	0	0	0	0	0.00
(c)	Bodies Corporate	7764310	0	7764310	40.85	7801344	0	7801344	41.05	0.20
(d)	FI/ Banks	0	0	0	0	0	0	0	0	0.00
(e)	Any Others	0	0	0	0	0	0	0	0	0.00
	Sub Total(A)(1)	**7764749**	0	**7764749**	**40.85**	**7801783**	0	**7801783**	**41.05**	0.20
2	**Foreign**									
A	Individuals (NRI)	0	0	0	0	0	0	0	0	0.00
B	Bodies Corporate	0	0	0	0	0	0	0	0	0.00
C	Institutions	0	0	0	0	0	0	0	0	0.00
D	QFI	0	0	0	0	0	0	0	0	0.00
E	Any Others	0	0	0	0	0	0	0	0	0.00
	Sub Total(A)(2)	0	0	0	0	0	0	0	0	0.00
	Total Shareholding of Promoters (A) = (A)(1) + (A)(2)	**7764749**	**0**	**7764749**	**40.85**	**7801783**	**0**	**7801783**	**41.05**	0.20
(B)	**Public shareholding**									
1	**Institutions**									
(a)	Mutual Funds / UTI	1623123	1694	1624817	8.54	919645	1694	921339	4.84	-3.70
(b)	FI / Banks	0	22	22	0.00	0	22	22	0.00	0.00
(c)	Alternative Investment									

NATH BIO-GENES (INDIA) LIMITED

	Fund	439560	0	439560	2.32	0	0	0	0.00	2.32
(d)	Venture Capital Funds	0	0	0	0	0	0	0	0.00	0.00
(e)	Insurance Companies	0	0	0	0	0	0	0	0.00	0.00
(f)	FII's	0	0	0	0	0	0	0	0.00	0.00
(g)	Foreign Venture Capital Investors	0	0	0	0	0	0	0	0.00	0
(h)	Foreign Portfolio Investor	34192	0	34192	0.17	13989	0	13989	0.73	0.56
(i)	Any Other	0	550	550	0.01	0	550	550	0.01	0.00
(i-ii)	Overseas Bodies Corporate	880	0	880	0.01	880	0	880	0.01	0.00
	Sub-Total (B)(1)	**2097755**	**2266**	**2100021**	**11.05**	**934514**	**2266**	**936780**	**4.92**	**-6.13**
B 2	**Non-institutions**									
(a)	Bodies Corporate	4179858	42857	4222715	22.22	3734038	10297	3744335	19.70	-2.52
(b)	Individuals									
I	Individual shareholders holding share capital up to Rs 2 lakh	2517690	267308	2784998	14.65	4027990	264888	4292878	22.58	7.98
II	Individual shareholders holding share capital in excess of Rs. 2 lakhs.	1318819	0	1318819	6.93	1381566	0	1381566	7.26	0.33
(c)	NBFC	945	0	945	0.02	0	0	0	0	0.02
(d)	Any Other	207847	0	207847	1.09	216542	0	216542	1.13	0.04
(d-i)	NRI	497533	15268	512801	2.69	503848	14668	518516	2.72	-0.03
(d-ii)	Clearing Member	167736	0	167736	0.88	111600	0	111600	0.58	-0.30
	Sub-Total (B)(2)	**8814237**	**324993**	**9139230**	**48.09**	**9975584**	**289853**	**10265437**	**54.01**	**5.92**
(B)	**Total Public Shareholding (B) = (B)(1) + (B)(2)**	**10911992**	**327259**	**11239251**	**59.14**	**10910098**	**292119**	**11202217**	**58.94**	**-0.20**
	TOTAL (A)+(B)	**8676741**	**327259**	**19004000**	**100.00**	**18711881**	**292119**	**19004000**	**100.00**	**0.00**
(C)	**Shares held by Custodians for ADRs and GDRs**									
1	Promoter and Promoter Group	**0**	**0**	**0**	0.00	**0**	**0**	**0**	0.00	0.00
2	Public	0	0	0	0.00	0	0	0	0.00	0.00

NATH BIO-GENES (INDIA) LIMITED

	Sub-Total (C)	0	0	0	0.00	0	0	0	0.00	0.00
	GRAND TOTAL (A)+(B)+(C)	**18676741**	**327259**	**19004000**	**100.00**	**18711881**	**292119**	**19004000**	**100**	**0.00**

Attachment C

Shareholding of Promoters& Change in Promoter Holding

Sr. No	Shareholders Name	No. of shares at the beginning of the year (As on 01.04.2021)			No. of shares at the end of the year (As on 31.03.2022)			% Of change during the year
		No. of Shares	% Of total Shares of the company	% Of Shares Pledged / encumbered to total shares *	No. of Shares	% Of total Shares of the company	% Of Shares Pledged / encumbered to total shares *	
1	Akash Farms LLP	2042452	10.75	66.10	1510452	7.95	0.00	-2.80
2	Ashu Farms LLP	2088449	10.99	55.26	2088449	10.99	24.13	0.00
3	Agri-Tech India Ltd	1317538	6.94	40.23	1322012	6.96	0.00	0.20
4	Tingli Finvest Pvt. Ltd	562360	2.96	0.00	562360	2.96	0.00	0.00
5	Nath Royal Ltd.	462132	2.43	0.00	494692	2.60	0.00	0.00
6	Barkha Farms Pvt. Ltd	354030	1.86	0.00	354030	1.86	0.00	0.00
7	Ferry fax farms Pvt. ltd.	307644	1.62	0.00	307644	1.62	48.76	0.00
8	Pithambar Farms Pvt. Ltd.	250000	1.32	0.00	250000	1.32	0.00	0.00
9	Arati Farms Pvt. Ltd.	202641	1.07	0.00	202641	1.07	0.00	0.00
10	Nath Biotechnologies Ltd.	101200	0.53	0.00	101200	0.53	0.00	0.00
11	Prabha Farms Pvt. Ltd	75271	0.40	0.00	75271	0.40	0.00	0.00
12	Paresh Farms Pvt. Ltd.	374	0.00	0.00	374	0.01	0.00	0.00
13	Jeevan Investment and Finance Pvt. Ltd	219	0.00	0.00	219	0.01	0.00	0.00
14	Nath Industries Limited	0	0	0	532000	2.80	0.00	2.80
15	Jeevanlata Kagliwal	293	0.00	0.00	293	0.01	0.00	0.00
16	Nandkishor Kagliwal	146	0.00	0.00	146	0.01	0.00	0.00
	TOTAL	**7764749**	**40.86**	41..01	**7801783**	**41.05**	8.38	0.20

NATH BIO-GENES (INDIA) LIMITED

Attachment D

Shareholding Pattern of top ten Shareholders (Other than Directors, Promoters and Holders of GDRs and ADRs)

Sr. No.	Name	No of shares	% Of Total Shares of the Company
1	Authum Investment and Infrastructure Limited	2623178	13.80
2	Aditya Birla Sun Life Trustee Private Limited	919139	4.83
3	Satpal Khattar	400000	2.10
4	Meghal Bakulesh Shah	308000	1.62
5	Girish Kulkarni	150000	0.78
6	Dishant Milanbhai Parikh	150000	0.78

7	Arun Kumar	115409	0.60
8	C Mackertich Private Limited	112676	0.59
9	Jaideep Sampat	100000	0.52
10	Girish Nilkanth Kulkarni	96000	0.50

Attachment E

Shareholding of Directors and Key Managerial Personnel

Sr. No	Name	No of shares	% Of Total Capital of the company	Date	Increase of Decrease in Shareholding
A	**Directors**				
1	Mr. Satish Kagliwal	0	0	01/04/2021	0
	Managing Director			31/03/2022	
2	Mrs. Jeevanlata Kagliwal	293	0.001	01/04/2021	0
	Director			31/03/2022	
3	Mrs. Sweta Kagliwal	0	0	01/04/2021	0
	Director			31/03/2022	
4	Mr. Shrirang Agrawal	0	0	01/04/2021	0
	Independent Director			31/03/2022	
	(Resign on 15/02/2022)				
5	Ms. Ashu Jain			01/04/2021	0
	Independent Director	0	0	31/03/2022	0
6	Mr. Vadla Nagabhushanam	0		01/04/2021	0
	Independent Director	0	0	31/03/2022	0
7	Mr. Hitesh Purohit	0		30/03/2022	0
	(Independent Director) Additional	0	0	31/03/2022	0
	(Appointed on30/03/2022)				
B	**Key Managerial Person**				
8	Mr. Devinder Khurana	0	0	01/04/2021	0
	Chief Financial Officer			31/03/2022	
9	Mr. Dhiraj Rathi	0	0	01/04/2021	0
	Company Secretary			31/03/2022	

NATH BIO-GENES (INDIA) LIMITED

Attachment F

Indebtedness of the Company including interest outstanding/accrued but not due for payment

Indebtedness at the beginning of the financialyear (01.04.2021)	Secured Loans excluding Deposits	Unsecured Loans	Deposits from Dealers	Total Indebtedness
i) Principal Amount	8863.16	200.97	592.53	9656.66
ii) Interest due but not paid	0.00	0.00	0.00	0.00
iii) Interest accrued but not due	0.00	0.00	0.00	0.00
Total i + ii + III	8863.16	200.97	592.53	9656.66
Change in Indebtedness during the financial year				
Addition	244.31		43.91	288.22
Reduction		12.58		12.58
Exchange Difference				
Net Change	244.31	(12.58)	43.91	275.64
Indebtedness at the end of the financial year (31.03.2022)				
i) Principal Amount	9107.47	188.39	636.44	9932.30
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total i + ii + III	9107.47	188.39	636.44	9932.30

NATH BIO-GENES (INDIA) LIMITED

Attachment G

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

(Rs in Lacs)

Sr. No	Particulars of Remuneration	Satish Kagliwal	Total
1	Salary as perprovisionscontained insection 17(1) ofthe Income-taxAct, 1961	48.00	48.00
2	Value ofperquisites u/s17(2) of theIncome-tax Act,1961	Nil	Nil
3	Profits in lieuof salary undersection 17(3) of the Income tax Act, 1961	Nil	Nil
4	Commission	Nil	Nil
	Total	48.00	48.00

B. Remuneration to other directors

(INR)

Sr. No	Particulars of Remuneration	Jeevanlata Kagliwal	Shrirang Agrawal	Sweta Kagliwal	Vadla Nagabhushanam	Madhukar Deshpande	Ashu Jain	Hitesh Purohit
1	Independent Directors	Nil	Nil	Nil	Nil	Nil	Nil	Nil
2	Fee for Attending Board Meetings	18000	18000	18000	21890	21600	18000	0
3	Commission	Nil	Nil	Nil	Nil	Nil	Nil	Nil
4	Others	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	Total	18000	18000	18000	21890	21600	18000	Nil

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

(Rs in lacs).

Sr. No	Particulars of Remuneration	Devinder Khurana Chief Financial Officer	Dhiraj Rathi Company Secretary	Total
1	Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	65.20	5.53	70.73
2	Value of perquisites u/s 17(2) of the Income-tax Act,1961	0.00	0.00	0.00
3	Others	0.00	0.00	0.00
	Total	65.20	5.53	70.73

NATH BIO-GENES (INDIA) LIMITED

Annexure-VI

FORM NO. MR -3
SECRETARIAL AUDIT REPORT
For the financial year ended 31st March 2022
[Pursuant to section 204(1) of The Companies Act, 2013 and the Rule no. 9 of the Companies (Appointment and Remuneration Personnel Rules, 2014) and Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended]

To,
The Members,
Nath Bio-Genes (India) Limited
Nath house, Nath Road, Aurangabad
CIN L01110MH1993PLC072842

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by NATHBIO-GENES (INDIA) LIMITED bearing CIN L01110MH1993PLC072842, ('the Company'). The secretarial audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on March 31, 2022 (Audit Period) generally complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent and in the manner reported hereinafter:

I have examined the books, papers, minute books, forms, and returns filed and other records maintained by the Company for the financial year ended on March 31, 2022, according to the provisions of –

1. The Companies Act, 2013 (the Act) and the rules made there under including any re-enactment thereof.
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made under that Act.
3. The Depositories Act, 1996 and the Regulations and Byelaws framed under that Act.
4. The Foreign Exchange Management Act, 1999 (FEMA) and the Rules and Regulations made under that Act to the extent applicable to Overseas Direct Investment (ODI), Foreign Direct Investment (FDI) and External Commercial Borrowings (ECB).

NATH BIO-GENES (INDIA) LIMITED

5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

    a. Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

    b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 & 2015

    c. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

    d. TheSecuritiesandExchangeBoardofIndia(IssueofCapitalandDisclosureRequirements)Regulations,2009; -

    e. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014

    f. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; - **Not applicable as the company has not granted any options to its employees during the financial year under review**

    g. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; - **Not applicable as the company has not issued any debt securities during the financial year under review**

    h. TheSecuritiesandExchangeBoardofIndia(DelistingofEquityShares)Regulations,2009;**Not applicable as the company has not delisted its equity shares from any stock exchange during the financial year under review**

    i. TheSecuritiesandExchangeBoardofIndia(BuybackofSecurities)Regulations, 1998; - **Not applicable as the company has not bought back any of its securities during the financial year under review**

    j. The Company has complied with the provisions of the SEBI (Depositories and Participants) Regulations, 1996 including submitting of Reconciliation of Share Capital Audit Reports

    k. The Securities and Exchange Board of India (Registrars to an Issue and share Transfer Agents) Regulations, 1993 regarding the companies Act and dealing with client; and

    l. The Memorandum and Articles of Association.

I have also examined compliance with the applicable clauses of the following: -

a) Secretarial Standards with regard to Meeting of Board of Directors (SS-1) and

NATH BIO-GENES (INDIA) LIMITED

General Meetings (SS-2) issued by The Institute of Company Secretaries of India.

b) The listing Agreement entered into by the company with BSE Limited and National Stock Exchange of India Limited.

The company has identified the following all laws as specifically applicable to the During the period under review and the company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

The company has identified the following laws as specifically applicable to the company.

a. The Seeds Act 1966
b. Employees' Provident Funds and Miscellaneous Provisions Act, 1952
c. Factories Act 1948
d. Minimum Wages Act 1923
e. Contract Labor (Regulations & Abolition) Act 1970
f. The Income Tax Act 1961

I further report that:

1. The board of directors of the company is duly constituted with proper balance of Executive directors, non-executive directors, independent directors, and women director.

2. Adequate notice is given to all directors to schedule the Board/ Committee Meetings, agenda and detailed notes on agenda were sent seven days in advance.

3. A system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

4. The status of the company during the financial year under review has been that of Listed Public Company.

5. The company has not been a holding or subsidiary of another company. The company has not been a government company or a financial company.

6. The Directors have complied with the requirements as to disclosure of interests and concerns in contracts and arrangements, shareholdings / ~~debenture holdings~~ and directorships in other companies and interests in other entities.

7. Majority decision is carried through while the dissenting member's views are captured and recorded as part of the Minutes of Meeting.

8. The Directors have complied with the disclosure requirements in respect of their eligibility of appointment, their being independent and compliance with

NATH BIO-GENES (INDIA) LIMITED

the Code of Business Conduct & Ethics for Directors and Management Personnel.

9. As Per the SEBI Guidelines, The Registry and Share Transfer Activity is being managed by M/s Big Share Services Private Limited.

10. The company has proper board process.

11. The Company has obtained all necessary approvals under the various provisions of the Act; and

12. There was no prosecution initiated and no fines or penalties Ire imposed during the year under review under the Act, SEBI Act, SCRA, Depositories Act, Listing Agreement and Rules, Regulations and Guidelines framed under these Acts against / on the Company, its directors, and Officers.

I further report that compliance of applicable financial laws including Direct and Indirect tax laws by the company has not been reviewed in this Audit since the same has been subject to review by the Statutory auditor and other designated professionals.

I further report that based on the information received and records maintained there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations, and guidelines.

NATH BIO-GENES (INDIA) LIMITED

Neha P Agrawal
Practicing Company Secretary
FCS No 7350 & CP No 8048
Peer review Certificate No.1304/2021

Date: - 30th May 2022
Place: - Aurangabad
UDIN: - F007350D000448648

Note: - This report is to be read with my letter of even date which is annexed as "ANNEXURE A" and forms an integral part of this report.

"ANNEXURE A"

To,
The Members,
Nath Bio-Genes (India) Limited
Nath house, Nath Road, Aurangabad
CIN L01110MH1993PLC072842

My Secretarial audit report of even date is to be read along with this letter:

Management's responsibility: -

1. It is the responsibility of management of the company to maintain Secretarial records, devise proper systems to ensure compliance with the provisions of applicable laws and regulations and to ensure that the systems are adequate and operate effectively. My responsibility is to express an opinion on these secretarial records based on my audit.
2. The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to verification of procedures on test basis

Auditor's responsibility: -

1. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
2. I have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
3. I believe that audit evidence and information obtained from the company's management is adequate and appropriate for me to provide a basis for my opinion.
4. Wherever required, I have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.

Disclaimer: -

5. The secretarial audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Neha P Agrawal
Practicing Company Secretary
FCS No 7350 & CP No 8048
Peer review Certificate No.1304/2021

Date: - 30th May 2022
Place: - Aurangabad
UDIN: - F007350D000448648

NATH BIO-GENES (INDIA) LIMITED

Compliance Certificate under Regulation 17 (8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015.

The Members,
Nath Bio-Genes (India) Limited
Nath house, Nath Road
Aurangabad-431005

Sub: Compliance Certificate under regulation 17(8) read with Part B of schedule II to the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

We hereby certify that:

a. We have reviewed financial statements and the cash flow statement for the Financial Year ended 31st March 2022 and that to the best of our knowledge and belief:

i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
ii. These statements together present a true and fair view of the company's affairs and are in compliance with Indian Accounting Standards (IND AS), applicable laws and regulations.

b. There are, to the best of our knowledge and belief, no transactions are entered into by the company during the year which are fraudulent, illegal, or violative of the Company's code of conduct.

c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

d. We have indicated to the auditors and the Audit Committee that there are no:

i. Significant changes in internal control over financial reporting during the year.
ii. Significant changes in accounting policies during the year and that the same have been disclosing in the notes to the financial statements; and
iii. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having significant role in the company's internal control system over financial reporting.

For Nath Bio-Genes (India) Limited

Satish Kagliwal	Devinder Khurana
Managing Director	Chief Financial Officer
DIN-00119601	

NATH BIO-GENES (INDIA) LIMITED

Annexure-VII

Dividend Distribution Policy

NATH BIO-GENES (INDIA) LIMITED DIVIDEND DISTRIBUTION POLICY

1. PREAMBLE

As per Regulation 43A of SEBI (LODR) Regulations (Amended), 2015, the top (1000) listed entities on market capitalization (calculated as on March 31 of every financial year) shall formulate dividend distribution policy which shall be disclosed in their annual Reports and on their Annual Reports and on their websites. Nath Bio-Genes (India) Limited being one of the top 1000 listed companies as per the market capitalization, frames this policy to comply With the SEBI (LODR) Regulations, 2015.

2. OBJECTIVE

The objective of the policy is to broadly specify the external and internal factors including financial parameters that shall be considered while declaring dividend and the circumstances under which the shareholders of the Company may or may not expect Dividend

3. PHILOSOPHY.

The Company is deeply committed to driving superior value creation for all its shareholders. The Company believes that driving growth creates maximum shareholder value and thus it would first like to deploy its profits to fund its working capitalrequirements, capital expenditure requirements, reducing debt, allocate reserves for inorganic growth opportunities and thereafter distribute the surplus profits in the form of dividend to the shareholders.

4. DEFINIATION

Company- Means Nath Bio-Genes (India) Limited.

'Board' or 'Board of Directors' means Board of Directors of the Company.

'Dividend' means Dividend as defined under Companies Act, 2013.

'Policy or this Policy' means the Dividend Distribution Policy.

'SEBI (LODR) Regulations' means the Securities and Exchange Board of India (ListingObligations and Disclosure Requirements) Regulations, 2015 together with the circulars issuedthereunder, inc luding any statutory modification(s) or reenactment(s) thereof for the timebeing in force.

NATH BIO-GENES (INDIA) LIMITED

5. PARAMETERS FOR DECLARATION OF DIVIDEND

Internal Factors / Financial Parameters - The Board of Directors of the Company would consider the following financial parameters before declaring or recommending dividend to Shareholders.

- Investment Opportunities, for expansion and diversification into new project, acquisitions and other potential strategic action that may help grow Company.
- Liquidity position of the Company.
- Growth in earnings of the Company.
- Restrictions in debt agreements executed with lenders in relation to the Payment of dividends.
- The Board of Directors of the Company would consider its working capital requirements, R&D expenditure, and capital expenditure requirements for future growth before declaring the dividend.
- The dividend declaration would also depend upon the liquidity position of the Company, Outstanding borrowings and the cash flow required to meet contingencies.
- The Board of Directors of the Company shall also consider past dividend trends of the Company.
- Contingencies Requirements.
- State of Economy and Nature of Industry.
- Macro-economic and business Condition in General.
- Any other factors before declaring the dividend.

External Factors- The Board of Directors of the Company would consider the following external parameters before declaring or recommending dividend to Shareholders.

- Dividend declared would be in compliance with prevailing legal requirements, regulatory conditions or restrictions laid down under the Applicable Laws including tax laws.
- The Board of Directors of the Company would consider dividend pay-out ratios of Companies in the same industry.
- Prevailing legal requirements, tax rules, Government policies and statutory conditions or restrictions as may be provided under applicable laws.
- The declaration of dividends and its quantum may have a positive impact on the market prices.
- The Company may also consider the rate of inflation when declaration of dividend.

NATH BIO-GENES (INDIA) LIMITED

6. CIRCUMSTANCES UNDER WHICH SHAREHOLDERS MAY OR MAY NOT EXPECT DIVIDEND.

The Company shall not recommend dividend if it is of the opinion that it is financially not prudent to do so. The shareholders of the Company may not expect Dividend under the following circumstances.

- In case the Company is undertaking significant expansion which would require higher allocation of resources.
- If the Company requires significant amount of working capital to fund its future growth.
- In case the Company proposes to use surplus cash for buy-back of securities.
- In the event of inadequacy of profits or whenever the Company has incurred losses

The Company may declare dividend out of the profits of the Company for the year or outo f the profits for any previous year or years or out of the free reserves available for distribution of Dividend, after having due parameters laid down in this Policy.

7. UTILISATION OF RETAINED EARNING.

The Company maintains enough retained earnings to address the financing of working capital, capital expenditure, corporate actions, inter alia, buyback and reduction of capital, and unanticipated and emergency expenditures.

The Company may also use the retained earnings for such purposes as are within the Provisions the Act, Rules, Listing Regulations, and any other applicable law.

8. AMENDMENTS

The Board may, subject to applicable law, amend, suspend, or rescind this Policy at any time. Any difficulties or ambiguities in this Policy will be resolved by the Board and/ or administrative committee of the Board, in line with the broad intent of this Policy, as and when required.

9. DISCLAIMER

This Policy shall not be construed as a solicitation for investments in the Company's Securities and shall neither act as an assurance of guaranteed returns (in any form), On investments in the Company's securities.

10. CHANGE IN LAW.

In case of any subsequent changes in the provisions of the Act or further rules and regulations / guidelines from the Securities and Exchange Board of India including the Listing Regulations or any other regulations which makes any of the provisions of this Policy inconsistent, then the provisions of the Act or such other regulations would prevail over this Policy and the relevant provisions contained in the Policy would be modified accordingly in due course to make it consistent with applicable laws.

NATH BIO-GENES (INDIA) LIMITED

NATH BIO-GENES (INDIA) LIMITED

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

==========

INDIAN ECONOMY

Indian economy grew 4.1% in January-March the slowest in full year marred by the third wave of Covid-19, high commodity prices and supply disruptions. In FY22 GDP grew 8.7% which has made India to become one of fastest growing major economy. Full year GDP growth was less than forecasted 8.9%was higher by 1.5% than pre pandemic levels. It is expected to grow by 7% in FY23 as it continues to face multiple challenges.

Coming to the global macros, The Russian invasion of Ukraine and lower exports of Russian crude oil have kept crude oil prices elevated for a protracted period and led to meaningful upside risks to inflation and downside risks to corporate profits through increased pressure on margins and volumes both. Increased risks of global crude prices staying elevated in the next 2-3 quarters due to imbalances in the global crude oil markets.

In a bid to control inflationwhich has increased to 7.8% YoY in Apr'22, the finance minister announced few measures such as- reduced excise duty on petrol/diesel by INR8/INR6 per liter, taking the excise duty to INR20/INR15.8 from INR28/INR21.8 per liter. Global fertilizer prices rose 119% YoY in Apr'22, with a growth ~115% YoY on an average in the past eight months. To lessen the burden of higher international prices on farmers, the government will allocate an additional fertilizer subsidy to the tune of INR1.1t, over and above the already allocated INR1.05t in Union Budget FY23.Government will provide householdswith an additional subsidy worth INR200/gas cylinder. The government is likely to incur INR61b on account of this measure.

GST collections were up by 18.5% YoY in April'22. Exports grew by 24.2% YoY, led by petroleum exports whereas non-petroleum exports were up by 12.3% YoY. Imports grew by 26.5% YoY with non-oil, non-gold imports up by 27.7% YoY indicating relatively robust domestic demand.

Overall, the Indian economy is poised to grow at the quickest pace among the league of large nations on the back of various initiatives taken by the government

MATH BIO GENES (INDIA) LIMITED

AGRICUTURAL SECTOR IN INDIA

India has the largest arable land resource in the world. Agriculture is the livelihood of 58% of India's population. India is the largest producer of spices, pulses, milk, tea, cashew, and jute, and the second largest producer of wheat, rice, fruits and vegetables, sugarcane, cotton, and oilseeds. Further, India is second in the global production of fruits and vegetables and is the largest producer of mango and banana.

The Indian food industry is poised for huge growth, increasing its contribution to world food trade every year due to its immense potential for value addition, particularly within the food processing industry. Indian food and grocery market is the world's sixth largest, with retail contributing 70% of the sales with expected CAGR of 37.1% from FY2021 to FY2028.

India is among the 15 leading exporters of agricultural products in the world. India's agricultural products export rose by 20% at $50bn for FY22. The highest exports have been achieved for staples like rice (% 9.7bn), wheat ($2.2bn), sugar ($4.6bn), and other cereals ($1.1bn). Wheat has

recorded an extraordinary growth of more than 273%from $568mnin 2020-21 to touch to $2.12bn in 2021-22.The organic food segment in India is expected to grow at a CAGR of 10% during 2015-25 and is estimated to reach Rs. 75,000cr ($10.73 billion) by 2025.

India is expected to achieve the ambitious goal of doubling farm income by 2022. The agriculture sector in India is expected to generate better momentum in the next few years due to increased investment in agricultural infrastructure such as irrigation facilities, warehousing, and cold storage. Furthermore, the growing use of genetically modified crops will likely improve the yield for Indian farmers. India is expected to be self-sufficient in pulses in the coming few years due to concerted effort of scientists to get early maturing varieties of pulses and the increase in minimum support price.

Agriculture, which continues to see a constant increase in net sown area and cropdiversification, will strengthen food buffers while benefiting farmers through generousvolumes of procurement at remunerative minimum support prices and income transfers through PM KISAN scheme.

LIST OF MEASURES ANNOUNCED BY THE GOVERNMENT – BUDGETARY AND POLICY SUPPORT

The government in benefit of agriculture industry announced some measures and policies. The FY2022-23budget has reserved₹2.37 lakhCrores as direct payments as MSP to 163 lakh wheat and paddy farmers. Wheat procurement in Rabi 2021-22 and the estimated paddy procurement in Kharif 2021-22 will cover 1208 lakh metric tons of the two crops.

Government announced support for post-harvest value addition of millets to enhance domestic consumption, along with support for branding millet products nationally and internationally.India is one of the largest global producers of millets.Nearly two-thirds of country's oilseed needs depend on imports.

This Budget proposal is in line with the vision for Atam Nirbhar Bharat, thereby ensuring the edible oil security of the nation. The focus will be on farmlands in 5-km-wide corridors along the river Ganga. Also, the Government intends to launch a scheme in the PPP (public-private partnership) model to deliver digital and hi-tech services to farmers, which will bring together public sector research and extension institutions, private Agri-tech players, and stakeholders in the Agri-value chain. It has raised the budget allocation for the Ministry of Fisheries, Animal Husbandry and Dairying by 44% to ₹6,407cr.It has reduced the alternate minimum tax for the former, from 18.5% to 15%. In addition, the surcharge on cooperative societies generating a total income ranging from 1Cr to up to 10 Cr will be reduced from 12% to 7% to help enhance the earnings of the societies and their members who are primarily from rural and farming communities.Budget had an allocation of ₹10,433 Cr under Rastriya Krishi Vikas Yojana this scheme for 2022-23—nearly triple the budgeted estimate of ₹3,712.44 Cr in the current fiscal.

SEED SECTOR IN INDIA

Indian seed industry size is around US$4bn has been growing at 20% CAGR in last 8-10years. The Indian seed market is projected to record a CAGR of 6.8% during the period 2022-2027.Global seed market is US$60-70bn and growing at 6-7% and likely to touch US$90-100bn by FY25-26. India despite the 2nd largest population is just 4% of the global seed market. At the same time, India's share of global export market is a mere 1%.COVID-19 affected the seed industry, with the availability of quality seeds being the greatest challenge for farmers.

NATH BIO-GENES (INDIA) LIMITED

Sharp improvement happened in productivity of cotton farming due to use of Genetically modified seeds. Similar scope is there for other crops too. It seems like a secular growth story and seed companies can grow their revenues more than 10-15% consistently in the foreseeable future.

The adoption of hybrid seeds has significantly increased in the country during and after the Green Revolution, due to the increasing pressure for high crop production for food security. The hybrid seed sector witnessed a growth of 15-20% per year, over the past decade. The major boost has come from the increased adoption of Bt cotton hybrids, single-cross corn hybrids, and hybrid vegetables. This increased demand for hybrid seeds has boosted the market for commercial seeds. The aggressive promotion measures are undertaken for the use of hybrid seeds resulted in the increased demand for, and production of, hybrid seeds in the country. Farmers are adopting and using more hybrid seeds, considering the disease- and pest-resistant properties of these seeds, and reducing the losses and cost of production.

Under the row crop segment of the market studied, cotton holds the maximum revenue share. This is primarily due to the large-scale adoption of BT cotton seeds in India. The cottonseed segment in India has witnessed the highest CAGR during the forecast period. Cotton is an important part of the Indian economy, as this crop forms the backbone of the Indian textile industry.

Cotton has been a stellar example of the role of seeds in improving the productivity of the crop. Indian yields are a far cry from global averages and those seen in the developed world. Apart from fraction land holdings and limited irrigation facility, quality of seeds plays an important role. Looking at the Seed ReplacementRatio (SRR), the ratio of cultivation done by new seeds, there is huge scope in increasing seed sales of Paddy, Maize, and Vegetables. Many factors are driving the demand for high quality seeds

1. Increasing Disposal Income
2. Increasing Seed Replacement Ratio
3. Government Policy Support
4. Increasing adoption of hybrid seeds
5. Patent Protection systems & intellectual rights over plant varieties
6. Increased investment from public as well as private sector

NATH BIO-GENES (INDIA) LIMITED

Nath Bio Genes (India) Limited

Nath Bio-Genes (India) Limited is one of the seasoned seed companies in the country with around 20 years of experience in manufacturing & distributing seeds to Indian farmers. Relying upon its strong R&D background, Your Company has produced several highly ranked cotton seeds in the country which have done well in the ICAR trials and stood the test of time with respect to various virus tolerance as well as improved yield despite weather fluctuations.

It's new launches Sanket and Jambo cotton seeds have been ranked among top 3 in most geographies and under various planting conditions. A new seed has a life cycle of 7-8years. The consistent high ranking achieved by Nath's new seeds gives reasonable confidence about its cotton seeds portfolio growing faster than the industry.

Management has been guiding for an overall 15% plus growth for next year. The company has worked on de-risking it's business by having multiple growth drivers like hybrid paddy, vegetable seeds and plant nutrient (win-chi-win) in its portfolio. The company has been able to grow itsnon-cotton non paddy portfolio to total sales to 41% of the overall revenue. Your Company has also been able to improve its working capital cycle from last year despite a challenging environment with improvement led by management of receivables. The company made provision for bad and doubtful advances given in last few years in the year 2022 for Rs 88 Cr. It is making all the necessary efforts to recover the overdue payments while ensuring that the farmers are not further aggrieved, and all possible options are being worked out with them.

Your Company strives to maintain good relations with farming community and build close contacts to work hand in hand with progressive farmers. The company has established a network of over 15,000 farmers growing seeds for the company.The Company has been awarded with the prestigious "Vasantrao Naik Prathisthan Award" for its contribution for enhancing Agricultural Productivity amongst other rewards & recognition.

NATH BIO GENES (INDIA) LIMITED

PRODUCT PORTFOLIO

Segment	Key Products	Product Pipeline	Key Geographies
Cotton	NBC 102, NBC 1022, NBC 1111, NBC 1103, NBC 10, NBHV 2205	NBC 1821, NBC 1851, NBC 1811, NBC 2020, NBC 211	North, West, Centre, and South India
Paddy	Loknath, Gorakhnath, Super Duper, Tehelka, Kabir, Gazab, Ford	Hybrid NBRH 29, Hybrid NBRH 33	Centre and East India
Vegetables	Okra- NOH05, NOH03 Tomato-NTH1831, NTH1894 Cucumber- NCH02, NCH 1061 Bitter Gourd- NBIH274 Hot Pepper-NCH811, NCH1120	In Process	PAN India
PNS	Win-chi-Win, WinGoli, WinPro	In Process	PAN India
Others	Maize, Mustard, Jowar, Bajra, Wheat, Mustard	In Process	PAN India

Cotton

This was a challenging year for the cotton industry and company also faced the headwinds. The country saw a record rise in the sale of illegal BT cotton seeds with sale of over 70 Lakh packets. WhileYour Company is working closely with Industry body and government, there is minimal impact on the ground and situation continues to remain the same. Company's marketing teams had been working closely with farmers to educate them. This helped company in maintaining cotton sales at the same level as last year. The company sold approximately 11.97 lakh packets of cotton in FY22 slightly lower that 12.24 lakh packets sold in FY21. Nath is confident on the efforts which it is making with farmers, thatwill yield results and should help company to achieve a 10-15% volume growth in FY23.

What is BT cotton-BT cotton is the only transgenic crop that has been approved by the Centre for commercial cultivation in India. It has been genetically modified to produce an insecticide to fight the cotton bollworm, a common pest.

What is HTBT cotton- The HTBT cotton variant adds another layer of modification, making the plant resistant to the herbicide glyphosate, but has not been approved by regulators.

Challenges Cotton Industry is facing- With HTBt,one round of glyphosate spraying is needed with no weeding. It saves Rs. 7,000 to Rs. 8,000 per acre for farmers. As it is not approved by the Genetic Engineering Appraisal Committee, so illegal sale takes place in Indian markets. Farmers are at risk with such illegal cotton seed sale as there is no surety of the quality of seed, it pollutes the environment, the industry is losing legitimate seed sale and the government also loses revenue.It will not only decimate small cotton seed companies but also threaten the entire legal cotton seed market in India.

NAVI BIO-GENES (INDIA) LIMITED

Products in the pipeline -NBC 1821, NBC 1851, NBC 1811, andNBHV 2205 are going under the testing under the supervision of ICAR. Government of India enhanced cotton seed prices by Rs 43 per packet this year which is helping in adding better value. Extra ordinary efforts have been put to promote unique cotton products like NBC-10, Sanket, Maharana, and Jambo. However, the treat of illegal HTBT Cotton continues to affect the industry.

In R&D, the company is developing products with:

- Medium and Large Boll
- High tolerance to sucking pests
- High tolerance to pink bollworm
- Wider adaptability
- Yield Superiority

Strategy is to provide farmers with a wide range of varieties of cotton seeds suitable for diverse climatic conditions while maintaining yield superiority. The company's two new hybrids- Sanket and Jamboare helping in boosting the growth in this segment.

Paddy

Paddy Sales is a combination of Open Pollination and Hybrid Seeds. Hybrid Paddy sells at relatively higher margins and hence paddy has the highest pie in our product portfolio. As a matter of policy, the Company changed the paddy product mix to increase the hybrid paddy sales with better margin. As a result, volume saw a decline of almost 29% in FY22, however the decline in value was much lower at 18%. Hybrid Paddy is a key focus now which is a high value low volume product. While there could be a volume decline in Paddy, the revenue and margins from this segment are expected to remain high. Paddy volume growth projected at 15-20% in FY23. The company has invested heavily in hybrid research program and has launched new products: Dhoom, Dhadak, and Dhadak Gold. The key products are Loknath, Gorkhanath, Super Duper and Tehelka.

In terms of R&D, the company is developing products with:

- Early maturity, fine grain and resistance to diseases and pests
- Tolerance to moisture stress
- Medium-Bold and Long Bold grain products, medium maturity (125-135 days), embedded with BLB and BPH resistance

NATH BIO-GENES (INDIA) LIMITED

Vegetables

Vegetables is a huge segment with varieties of product offerings. In few parts of India, it is around the year crop whereas in few it is majorly a rabi focussed crop.It is a high margin segment for the company contributing 60% plus gross margins. Your Company has its presence cross 10 products – Pan India. The company has a set a separate team for marketing and distribution. YOUR COMPANY is in the process of launching multiple new products in Tomato and Okra with high disease resistance, in Chilly and Bitter Gourd with high yield and excellent virus resistance and in cucumber with no bitterness. Vegetable growth expected to be at 25-30%.

In terms of R&D, the company is developing:

- Multiple product varieties in the existing portfolio
- New products
- Foray into fruits as well with vegetables

Plant Nutrient Supplement

Your Company has an exclusive tie-up with a Chinese company to source & market Win-Chi-Win in India. It is a Plant Nutrient Supplement, which has a proven track record of increasing the yield of the crops it is used on. Win-Chi-Win is sold round-the-year, across India &Your Company has witnessed high demand for this product for vegetables, field, plantation & horticulture crops. Two new products have been launched in the PNS vertical – both are soil conditioners and help raise a good crop by improving the soil quality.
PNS Growth is expected to be around 15%plus for FY23.

Others

Maize, Bajra, Mustard, Jowar and Wheat are majorly covered in this segment which higher concentration from Maize, Mustard and Bajra. This segment contributes about 20% to the topline of the company.

FINANCIAL REVIEW

Despite a massively challenging year, Your Company has maintained cotton sales and the long-term debt free status. This is commendable pursuant to the pandemic situation, which hampered farmer and marketing personnel movement simultaneously. However, company maintained gross contribution margin of 56% this year as well with a net profit margin of around 9% (at adjusted PAT). The company also declared adividend of 20%. Strong margins reported in the verticals of field crops, vegetable, and supplements, thus strengthening the success towards moving to a de-risked business model. Non cotton and non-paddyhave performed well and contributed to 41% of the portfolio. Maize grew by 32%, bajra by 10%, Wheatby 34%. The overall volumetric growth was 10%. Inventory is expected to normalize over the next two years. Receivable days have reduced from 130 to 115days due to better management of receivables.We maintain our guidance at a top line growth of 15-20% in FY23.

OUTLOOK AND FUTURE STRATEGIES

The company has a potential to increase the revenue multifold through introduction of new products bred by the research channel and geographies with multiplication of new territories. There is also a huge opportunity in Southeast Asia and Africa where the company has already commenced trials and licensing permissions. These would insulate your company from a single country regulatory and environmental risk

NATH BIO-GENES (INDIA) LIMITED

INFRASTRUCTURE

Your company continues to follow the path of least investment and fund blockage in infrastructure. We prefer to rent godown and processing facilities as it turns out to be more economical and efficient. We entered into a long term contractual with the one such facility provider in South India, thereby catering to all our Field Crop processing needs under one roof.

RESEARCH AND DEVELOPMENT

Using the best R&D expertise in the country, your company has successfully redefined product development & evaluation technologies, to create exceptionally high yielding hybrids with high levels of biotic & abiotic stress tolerance. One of its largest advantages over its peers comes from the company's proprietary collection of superior & world-class Trait Specific Elite Germplasm.

The company has:

- 32 Breeding and Evaluation R&D Stations in different Agro-Climatic conditions
- More than 300 acres of land dedicated to Research and Development, across the nation
- Collaboration with reputed International and National Centres of Excellence (NRCPB, CIMMYT, IRRI, ICRISAT)
- Team of handpicked plant breeders and biotechnologists, located at key R&D stations, across the country, guided by R&D veterans.

PAN INDIA OPERATIONS

YOUR COMPANY undertakes seed production in over 30,000 acres of land with about 25,000 loyal growers and 72 technically qualified organizers. Seed is produced in the states of Andhra Pradesh, Gujarat, Karnataka, Maharashtra, Rajasthan, Odisha, Uttar Pradesh, Madhya Pradesh, and Tamil Nadu which covers different agro- climatic zones of the country. The company assures that seeds of the highest quality reach its processing centres by setting rigorous field standards and quality control checks throughout the seed production process. A team of qualified production staff and quality personnel visit to monitor farms to ensure stringent controls. The foundation seed with highest genetic purity is sown in all crops. The company constantly strives to build and improve relationships on a personal level with the production growers & organizers to ensure loyalty and commitment. Understanding their constraints, providing them the necessary training, guidance and financial support have led to fruitful results.

ELABORATE SEED PROCESSING FACILITIES

The company has elaborate seed processing facilities with 3 Processing Plants located in Maharashtra, Telangana,and Andhra Pradesh. The company also has processing arrangements in Gujarat, Karnataka, Tamil Nadu, Madhya Pradesh, and Rajasthan on custom basis. The seeds received from growers are processed to achieve quality standards which surpass those prescribed by the regulatory authorities. All the plants are equipped with pre-cleaner, fine cleaner, grader, gravity separator, de-stoner, indented cylinder, treater, needle separator and packing machines. The company has independent facilities for ginning, de-linting, drying, processing, treating, packing and storage of seeds. The seed processing quality is taken to the next level by ensuring improvements in seed viability and prolonging the shelf life of seeds. All the packing material has best environmental barriers characteristics to guarantee optimal storage conditions for the seed.

NATH BIO-GENES (INDIA) LIMITED

METICULOUS QUALITY ASSURANCE

The quality policy of Your Company ensures meeting world class quality standards so that the farmers get optimal yields that maximize their profitability, keeping total quality management in view.

YOUR COMPANY has one of the most stringent and systematic Seed Testing Laboratories at Maharashtra and Andhra Pradesh. The team conducts regular field inspection in entire production area. Also, Genetic Purity tests are conducted to check germination of lots regularly. It is a consistent endeavor to ensure that the seeds are produced under best conditions and that all seed lots are of highest genetic purity. Every seed lot that comes into the Processing Plants is sampled and tested for Physical Appearance, Moisture, Other Distinguishable Varieties presence, Physical Purity, Treatment, Genetic Purity, Germination, vigor, and Soil emergence and reported. The Genetically Modified Crops undergo the ELISA test to ensure Gene Purity. Quality Assurance is also involved in Foundation Seed Production inspection and Processing Plant inspection during processing and packing. Every year more than 2 lakh quality checks are conducted throughout the supply chain process in accordance with the International Seed Testing Association (ISTA) before packing & dispatch of seeds to marketing centers.

STRONG DISTRIBUTION NETWORK

Your Company, led by Seed Marketing Veterans, has diversified to new geographies, both within & outside India, over the last 4-5 years. In India, the company has 16 business centres covering 131 territories & connecting with over 2,000 distributors, across the country. NBGL aims to improve its Direct Retailer reach to over 20,000 by the upcoming year as compared to over 7,000 currently.

With a heartened presence in India, the company has been venturing to newer geographies outside the country, possessing similar agronomical conditions as India. all set to spread its wings in other parts of Asia, Africa & the Middle East.

NATH BIO-GENES (INDIA) LIMITED

RISK MITIGATION

Uncertainties regarding government policies on GM or Hybrid seeds: Growing regulatory norms due to rising competition in the seed space, both from domestic as well as international companies could impact operations adversely.

Mitigation: Your Company has a strong compliance & R&D team, which keeps abreast of the various policy changes as well as international standards on GM and/or Hybrid seeds. The company will be able to adequately mitigate any challenges arising out of policy changes, supported by its middle-management & technology teams.

Technological Efficacy: Increased usage of the same kind of technology sometimes makes the soil or viruses and pests immune to the benefits of that technology.

Mitigation: Your Company has invested heavily in developing its R&D infrastructure, to introduce several new technologies & innovations to the Indian market and reduce its dependence on any one type of technology. The company will endeavour to continue creating seeds that remain high yielding & sufficiently resistant to several pests & viruses.

Weather Fluctuations: A large section of the world's agricultural community relies upon supportive weather conditions to produce & maintain their crops and fields. Any adverse climatic changes could impact production of foodgrains, vegetables, etc to a large degree.

Mitigation: Despite the advances in irrigation, any adverse climatic conditions continue to impact food production to a large degree. While Your Company' sales will also be impacted by such adverse weather conditions, the company is trying to reduce the impact of weather conditions by introducing seeds that can be grown in specific conditions like drought, head wave, etc. The company aims to keep the impact of such natural factors in check by proactive & prompt responses.

Cotton Business Impacted by Multiple Challenges: Uncertainty around policy approval or new technology and increasing proliferation of illegal seeds in cotton growing states. It is difficult to produce products based on consumer preferences and farmers are using illegal products which are herbicide tolerant.
Mitigation: The company has focused on creating a diversified portfolio. Company will increase focus on "All Season Products" for optimal utilisation of field force and channel partners. Company wants to target vegetable and plant nutrient segment growth at a higher rate.

HUMAN RESOURCES

As Your Company enters its growth phase, the company is investing heavily in human resources. The company has a dedicated team of researchers & scientists that form the backbone of the company & create the large variety of products that Your Company deals in. The company continues to nurture this team via various international alliances and workshops with reputed research institutes worldwide. Your Company is also focusing on increasing its sales & marketing team to widen the outreach of its products. the team undergoes constant training & motivation sessions to cultivate self-development. Your Company also endeavours to provide a supportive work environment where employees can realize their full potential. As on March 31st, 2022,the total number of employees on the company's rolls stood at 462.

INTERNAL CONTROL SYSTEMS

The Company has adequate systems of internal control and procedures covering all financial and operating functions commensurate with the size and nature of operations. The Company believes that a strong internal control framework is one of the important pillars of Corporate Governance. Continuous efforts are being made to see that the controls are designed to provide a reasonable assurance regarding maintaining of accounting controls and assets from unauthorized use or losses. The audit committee considers all aspects of internal and advises corrective action as and when required.

NATHBIO-GENES (INDIA) LIMITED

Business Responsibility Report 2021-22

==========

[As per Regulation 34 (2) (f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Nath Bio-Genes (I) Ltd, amongst the top players in the Indian seed industry, has served Indian farmers for more than two decades. The company has played a pivotal role in shaping Indigenous agriculture by developing and supplying quality hybrids seeds to farmers. The company has a presence in seventeen states which includes sixteen branches covering over 140 sales territories and markets approximately one hundred varieties of seed products to more than five million farmers across the country. It has over four hundredplus farm advisors to provide advisory services to the farming community.

Research, Reliability, and Prosperity

As farmers around the world continue to face the increasing challenges of climate change, we always continue to focus on new varieties of seed that address the dynamic changes related to climate, natural resources, and pest & diseases. Hence, we believe in Research, Reliability, and prosperity. We are creating brighter future for our farmers.

NATH BIO-GENES (INDIA) LIMITED

Nath Bio, which does transgenic research in Cotton, Paddy and brinjal, also has crop-specific alliances with global institutions. "Our research is focused, need-based and farmer-oriented. The aim is to develop sustainable agriculture that is drought, disease, and pest resistant,"

Nath Bio is also planning to enhance its presence in overseas markets. Soon, it is likely to commercialize hybrid cotton seed variety in the Philippines, Sudan, Myanmar & Uzbekistan. It is also targeting overseas markets in SAARC and East African countries.

Today Nath Bio is among the fastest and leading seed company in India offering a broad multi crop portfolio of all variety of seeds namely Cereals & Oil Seeds, Cotton, Field Crops & Vegetable Crops & Plant Nutritional Supplement.

The product innovations are backed by our strong Research & Development capabilities to meet the aspirations of the farmers & consumers. The company has developed modern infrastructure facilities, biotech lab and seed technology lab. It has a wide dealers and distribution network of PAN India marketing & Distribution network which is manned by technically and commercially skilled marketing team.

The Directors present the Business Responsibility Report of the Company for the financial year ended on 31st March2022.The Report responses to questions on our practices and performance on key principles defined by Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, covering topics across environment, governance, and stakeholder relationships.

1.	CorporateIdentityNumber(CIN)ofthe Company	**L01110MH1993PLC072842**
2.	Name of the Company	**Nath Bio Genes (India) Limited**
3.	Address of the Registered Office	**Nath House, Nath Road, Aurangabad – 431005[Maha]**
4.	Website	www.nathbiogenes.com
5.	E-mail ID	investor@nathbiogenes.com
6.	Financial Year reported	1st April 2021 To 31st March 2022
7.	Sector(s) that the Company is engaged in (industrial activity code-wise)	NIC Code:011 Description: Seed Production
8.	List three key products/services that the Company manufactures/provides (as in balance sheet)	**Products / Services**
	Cereal Seeds	Paddy, Maize, Jowar, Bajra, Wheat
	Fiber & Oil Seeds	Cotton, Mustard Seeds
	Vegetable Seeds	Chili, Coriander, Cucumber, Okra, Tomato, Water-Melon etc.
	Plant Nutritional Supplement	Win Chi Win
9.	Total number of locations where the Company undertakes business activity	
	(a) Number of International Locations	Nil
	(b) Number of National Locations	The Company hasthreemain Seed Processing, Packing and Cold storage plants and various R&D Center
10.	Markets served by the Company – Local/State/National/ International	Nath Bio's has conducted business activities in over 17 Domestic locations & in addition to serving Indian markets, we exported tovarious countries worldwide as on 31st March 2022.

NATH BIO-GENES (INDIA) LIMITED

SECTION B: FINANCIAL DETAILS OF THE COMPANY

		Rs in INR (Lacs)
1.	Paid up Capital	: 1900.40
2.	Total Turnover	:27836.23
3.	Total Profit after taxes& before Exceptional Items	:2144.39
4.	Total Spending on Corporate Social Responsibility (CSR) as percentage of profit after tax (%)	:4.64 %
5.	List the activities in which expenditure in four above has been incurred	:i] Rural Development ii] Agri–Cultivation Education

SECTION C: OTHER DETAILS

1.	Does the Company have any Subsidiary Company/ Companies	: No
2.	Do the Subsidiary Company/ Companies participate in the BR Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s)	: No
3.	Do any other entity/entities (e.g., suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/entities? [Less than 30%, 30%-60%, More than 60%]	: No

NATHBIOGENES (INDIA) LIMITED

SECTION D: BR INFORMATION

1.	Details of Director/Directors responsible for implementation of the BR Policy / Policies	: a. Details of the Director responsible for implementation of the BR policies:-
		Name : Satish Kagliwal
		Designation : Director
		DIN Number : 00119601
		b. Details of BR Head : Same as above

2. **Principle-wise (as per NVGs) BR Policy/policies (Replied inY/N)**

The National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business (NVGs) released by the Ministry of Corporate Affairs has adopted nine areas of Business Responsibility. These briefly are as follows:

No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
1.	Do you have a policy/policy for	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2.	Has the policy been formulated in consultation with the relevant stakeholders?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3.	Does the policy conform to any national /international standards?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4.	Has the Board approved the policy?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	If yes, has it been signed by MD/owner/CEO/appropriate Board Director?									
5.	Does the company have a specified committee of the Board/ Director/Official to oversee the implementation of the policy?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
6.	Indicate the link for the policy to be viewed online?	Policies can be viewed on the website of the company at http:/www.nathbiogenes.com								
7.	Has the policy been formally communicated to all relevant internal and external stakeholders?	The Policies have been communicated to Nath Bio's Key Internal Stakeholders. The BR policies are communicated through this report. Besides, the Company continues to explore other formal channels to communicate more with relevant stakeholders.								
8.	Does the company have in-house structure to implement the policy/policies?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9.	Does the Company have a grievance redressal mechanism related to the policy/policies to address stakeholders' grievances related to the policy/ policies?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
10.	Has the company conducted independent audit/evaluation of the working of this policy by an internal or external agency?	The BR Policy hasbeen evaluated internally.								

NATH BIO-GENES (INDIA) LIMITED

Principle wise Index:

- P1 – Ethics, Transparency and Accountability.
- P2 – Environment Sustainability
- P3 –Employee Well Being
- P4 – StakeholderEngagement
- P5 – Human Rights Statement
- P6 – Environment Protection and Restoration
- P7 – Business Advocacy
- P8 – Corporate Social Responsibility
- P9 – Customer Satisfaction

3. **Governance related to BR**

i.	Indicate the frequency with which the Board of Directors, Committee of the Board or CEO assesses the BR performance of the Company.	:	The Managing Director and Top Management assess the BRR performance of the Company at 3 months interval.
Ii	Does the Company publish a BR or a Sustainability Report? What is the hyperlink for viewing this report? How frequently it is published?	:	BR is published annually along with the Annual Report. The Company's BR Report can be viewed at Web link: www.nathbiogenes.com

SECTION E: PRINCIPLE-WISE PERFORMANCE

Principle No.	Description		Response
P1 – Business should conduct and govern themselves with ethics, transparency, and accountability.			
1.1	Does the policy relate to ethics, bribery, and corruption cover only the Company? Does it extend to the Group/Joint Ventures/Suppliers/Contractors/NGOs/Others?	:	The Company is committed to build a strong ethical organization. As a result, the Company has adopted the Anti Bribery Policy & Anti-Corruption Policy which is applicable to all the employees of the Company including the board members. The policy lays emphasis on the honesty, integrity and ethical conduct of the employees and has been communicated to the employeesfrom time to time, across all the locations. To ensure all employees to be well-versed with our Code of conduct, a mandatory training is provided to new recruits, and refresher workshops undertaken on anti-corruption policies and procedures which is conducted for all the employees at various levels.
1.2	How many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management? If so, provide details thereof, in about fifty words or so.	:	Nath Bio's Stakeholders include our investors, clients, employees, vendors, government. During the financial year, no complaint received from such stakeholders.
P2 – Businesses should provide goods and services that are safe and contribute to sustainability throughout their life cycle.			
2.1	List up to three of your products or services whose design has incorporated social or environmental concerns, risks and/or opportunities.	:	1. Nath Bio's plant operations team has installed two Semi-Automatic Packing Machine & one FFS Machine which would result in enhancing the quality of Packing, ensure the increase of per day output and pack field crops within time bound. Those Automatic Packing Machines, Blenders & Auto Seed Treatment Machine has installed in Cotton Plant. The Installations are environment Friendly.

NATH BIO-GENES (INDIA) LIMITED

2. A centralized & dedicated stores warehouse was created for non-seed inventory (primary, secondary packing material & seed treatment chemicals) which helps in systematic stacking of the products, proper tagging of the stacked products & correct physical verification of the inventory on periodical basis. This would result in enhancing the seed life& Productivity.

3. A huge cold storage facility has been created to store the seed, safeguard the seed from High temperature and Relative humidity and to protect the viability of the seed.

4. Nath Bio has provided Cost-Free Plant Protection Chemical **GA-3** to Cotton Seed Farmers to ward off the leaf reddening impact which is caused by physiological disorder influenced by the adverse climate condition.

5. Cyclophanes, Cyclones, Centrifugal fans and Bag Filters are used at the Seed Processing, Blending, Delinting and Packing machines to avoid dust in the workplace and their surroundings. We collect the processing dust in a bag and use it as manure in our R & D Farms.

6. Discard of used germination papers: we do not discard used germination paper. Instead, a compost pit is dug and used germination papers are decomposed and the compost used in R & D Farms.

7. Rainwater Harvesting has been implemented where we use water from constructed percolation tanks and storage tanks wherever possible. The stored rainwater after filtration is being used for plants and Laboratories.

NATH BIO-GENES (INDIA) LIMITED

2.2 For each such product, provide the following details in respect of resource use (energy, water, raw material etc.) per unit of product (optional)

a. Reduction during sourcing /production / distribution achieved since the previous year throughout the value chain? : Our strongest desire is to create brighter future for farmers through potential innovation in core crop and visualize a base that progresses us to become a market leader through our world class seed production.

Nath Bio's has rightly defined its supply chain management by placing delivery as one of the key motions for the trust of our growers and farmers. Delivery standards are highly dictated and audited, and we assure that nothing goes a miss in delivery principles.

Taking up the challenges related to seed production scenario and with meticulous planning and execution, target production volumes were realized.

Introduction of certain process and matrix changes have enhanced the production volume and quality of the product.

We assure safeguarding of seeds from unforeseen climatic conditions by organizing seed production in multiple geographies.

Focused on post-harvest operational practices by using dedicated combine harvesters during harvesting. Also, Mechanical Seeds Dryer has been used during seeds processing. As a result, there has been an increase in the viability of the seeds, along with cost

		effectiveness.
		We have reduced the workforce to over 40% by introducing mechanical grading of de-linting &processing cotton seed and sophisticated processing infrastructure which eventually saves enough time to make the seed material available for blending, treating, Labeling & packing. All these efforts so a long way towards environment protection
b.	Reduction during usage by consumer's (energy and water) has been achieved since the previous year?	: The Company regularly install waste recovery conservation measure in the fields to ensure better productivity through environmental sustainability.

2.3 Does the company have procedures in place for sustainable sourcing (including transportation)?

a.	If yes, what percentage of your inputs was sourced sustainably? Also, provide details thereof, in about fifty words or so.	: We have a Responsible Supply Chain Policy. Our suppliers are categorized in three broad categories – People, Product and Services. Our Contracts have appropriate clauses and check to prevent the employment of child labor or forced them in any form. We continuously take necessary measures for the health and safety of our employees and regularly conducts training Programs. As a seed organization we have made persistent efforts to retain our sourced seed suppliers by ensuring their continuous engagement in two seasons of seed production & by providing multiple crop seed production opportunities in multiple geographies. Resultantly, the grower base retention & loyalty, production reliability & sustainability have been ensured. We are recruiting most of the Frontline employees and daily Labor from surrounding villages and providing employment to local people. Similarly, we engage with local suppliers for sourcing both seed and non-seed products at a reasonable cost, high quality & timely supply.

2.4 Has the company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work?

NATH BIO-GENES (INDIA) LIMITED

A	If yes, what steps have been taken to improve their capacity and capability of local and small vendors?	:	The company recognizes that poverty in rural India gets accentuated by inadequate access to knowledge, information, quality agricultural inputs and markets. The company has unique model for creating bright future for farmer. We have introduced direct grower procurement model in the proximity of our seed conditioning & drying facilities to effectively engage the small land holders & the neighborhood farming societies to produce quality seed for us. This initiative of ours has yielded in complete retention of these small land holders bringing hundreds of acres under seed production & we are becoming their continued & most preferred seed company. These efforts not only support sustainable agriculture and enhance productivity, but also contribute to substantial livelihood creation.
2.5	Does the company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as <5%, 5-10%, >10%). Also, provide details thereof, in about fifty words or so.	:	As a Company being aware of the responsible use of finite natural resources, we have adopted a focused approach to manage the waste generated by our operations. Our Waste Management Strategy is framed around the three R's - Reduce, Reuse and Recycle.

Principle 3 – Business should promote the well-being of all the Employees

3.1	Please indicate the Total number of employees.	:	The company has Full Time, Permanent employees and the count standsat 462 as on 31.03.2022
3.2	Please indicate the Total number of employees hired on temporary/ contractual/casual basis.	:	The company hassixty-twocontractual employees as on 31.03.2022
3.3	Please indicate the Number of permanent women employees.	:	The number of permanent women employees isthirteenas on 31.03.2022
3.4	Please indicate the Number of permanent employees with disabilities	:	Nil
3.5	Do you have an employee association that is recognized by management?	:	Nil
3.6	What percentage of your permanent employees is members of this recognized employee association?	:	Nil
3.7	Please indicate the Number of complaints relating to child labor, forced labor, involuntary labor, sexual harassment in the last financial year and pending, as on the end of the financial year.	:	Nil

NATH BIO-GENES (INDIA) LIMITED

S. No.	Category	No of complaints filed during the financial year	No of complaints pending as on end of the financial year
1	Child labor/ forced labor/ involuntary labor	Nil	Nil
2	Sexual harassment	Nil	Nil
3	Discriminatory employment	Nil	Nil

3.8 What percentage of your under mentioned employees were given safety & skill up-gradation training in the last year? : Permanent employees: Employee training is a continuous process in the organization and all the employees are given mandatory safety training at the time of joining the Organization.

S. No.	Particulars	Safety (%)	Skill up-gradation (%)
1	Permanent Employees	100%	100%
2	Permanent Woman Employees	100%	100%
3	Casual/Temporary/Contractual Employees	100%	100%
4	Employees with Disabilities	100%	100%

100% of our employees were given safety & skill upgradation training in the last year.

NATH BIO-GENES (INDIA) LIMITED

Principle 4 - Business should respect the interests of, and be responsive towards all stakeholders, especially those who are disadvantaged, vulnerable and marginalized.

4.1 Has the company mapped its internal and external stakeholders? : Yes

4.2 Out of the above, has the company identified the disadvantaged, vulnerable & marginalized stakeholders? : There are no disadvantaged, vulnerable and marginalized stakeholders identified by the Company.

4.3	Are there any special initiatives taken by the company to engage with the disadvantaged, vulnerable and marginalized stakeholders? If so, provide details thereof, in about fifty words or so.	:	Yes, as a socially responsible organization, we are committed to work for the welfare of the communities around us. The Company believes in greater engagement with its stakeholders and being sensitive towards their needs and expectations. Stakeholders Views, Concerns, and Key Expectations have been elemental in calibrating Nath Bio's Business Strategy. The company maintains an open and constructive dialogue with all its key stakeholders, namely Investors, Shareholders, Employees, Customers, Suppliers, Government and Regulatory Authority. Nath Bio believes that engaging with stakeholders in a transparent manner helps in understanding their social needs and expectations, leading to sustainable decision making and enhanced stakeholders value creation. The Company has a whistle blower policy that provides support to employees, channel partners and vendors to report significant deviations from key management policies and report any non-compliance and wrong practices. The Company also has an investor grievance cell where the investors can raise their concerns and are resolved appropriately.

NATH BIO-GENES (INDIA) LIMITED

Principle 5 - Business should respect and promote Human Rights.

5.1	Does the policy of the company on human rights cover only the company or extend to these Group/Joint Ventures/Suppliers/ Contractors/NGOs/Others?	:	The policy covers the employees of the company
5.2	How many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management?	:	None was received

Principle 6 - Business should respect, protect, and make efforts to restore the Environment.

6.1	Does the policy relate to Principle 6 cover only the company or extends to the Group/Joint Ventures/Suppliers/Contractors/ NGOs/others?	:	Protection of the environment ranks high among our corporate goals and as a responsible corporate citizen, company is committed to operate all its plants in an environmentally friendly manner, while taking all precautionary measures and protecting the health and safety of its employees.

6.2	Does the company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc.?	:	Research initiative is regularly under-taken to combat climatic change for developing suitable hybrids.
6.3	Does the company identify and assess potential environmental risks?	:	Yes
6.4	Does the company have any project related to Clean Development Mechanism? If so, provide details thereof, in about fifty words or so. Also, if yes, whether any environmental compliance report is filed?	:	At present the company does not have any project related to clean development mechanism.
6.5	Has the company undertaken any other initiatives on – clean technology, energy efficiency, renewable energy, etc. Y/N, if yes, please give hyperlink for web page etc.	:	No
6.6	Are the Emissions/Waste generated by the company within the permissible limits given by CPCB/SPCB for the financial year being reported?	:	Yes, all the processing plants comply with the prescribed permissible limits for air emissions, effluent quality and discharge, solid and hazard waste generation, and disposal as per their regulatory authorities.
6.7	Number of show cause/legal notices received from CPCB/ SPCB which are pending (i.e., not resolved to satisfaction) as on end of financial year.	:	No pending notices as on 31.03.2022

NATH BIO-GENES (INDIA) LIMITED

Principle 7 - Businesses, when engaged in influencing public and regulatory policy, should do so in a responsible manner

7.1	Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with -	:	The Company is associated with various trade organizations, chambers etc., as follows: The Company is a member of various trade bodies and chamber associations in India such as, 1. Confederation of Indian Industry 2. The Federation Telangna Chambers of Commerce & Industry (FTCCI) 3. National Seed Association of India 4. The Asia & Pacific Seed of Association, Bangkok 5. Seed Association of Maharashtra

7.2	Have you advocated/lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes, specify the broad areas [Governance and Administrative, Economic Reforms, inclusive Development Policies, Energy Security, Water, Food Security, Sustainable Business Principles, Others].	:	Yes, we believe that it is our responsibility to help build a better business and thus a better world with opportunities for everyone. Our advocacy efforts are championed across the world by our Top Management. In an effort to drive advocacy globally and locally, we have been part of governance bodies of national and international organizations across economic, social, and environmental dimensions.

Principle 8 - Business should support inclusive growth and equitable development

8.1	Does the company have specified programs / initiatives/ projects in pursuit of the policy related to Principle 8? If yes details thereof.	:	Nath Bio's Corporate Social Responsibility supports growth of not only rural communities where we have our operations but also encompasses the overall development of societies and human capabilities. Company is committed to continuously improving its social responsibilities, environment, and economic practices to make positive impact on the society. The CSR Policy focuses on promoting Agro-Cultivation Education, promoting preventive healthcare and sanitization during the pandemic of Covid -19, Empowerment of Women, Fostering Rural Development, environmental sustainability, ecological balance etc.
8.2	Are the programs/projects undertaken through in-house team/own foundation/external NGO/government structures/ any other organization?	:	Nath Bio Genes (India) Limited has a team for the implementation and monitoring of various CSR projects namely Sustainable Development Team. The CSR Projects directly executed through Sustainable Development Team, by various Project Team in the company supported by Sustainable Development Team or through developing partnership and sharing expertise with like mined organization. Further, the Company has established a Foundation viz. Nath Research Foundation primarily for undertaking Research activities. The company has started CSR activities under the said Foundation. For, projects in villages, the Company engages persons/representatives from Villages/Gram Sabah's / Ward members. This helps in achieving the target as well as participation of the local representatives in formulating the various activities to obtain maximum benefit by community.
8.3	Have you done any impact assessment of your initiative?	:	We review our projects time to time. Each project has specific deliverables to be met. The internal teams ensure the implementation of the projects undertaken from time to time. The Company also takes feedback from the local persons/ representatives from Villages/Gram Sabah's / Ward members.
8.4	What is your company's direct contribution to community development projects- Amount in INR and the details of the projects undertaken?	:	During the year 2021-22 the company has directly spent an amount of Rs.99.45 Lacs on various CSR activities. Details of the projects undertaken are mentioned in a separate section of the annual report.

NATH BIO-GENES (INDIA) LIMITED

8.5	Have you taken steps to ensure that the community successfully adopts this community development initiative? Please explain in fifty words, or so.	:	Yes, the farming community is regularly accepting our programs for better productivity.

Principle 9 - Businesses should engage with and provide value to their customers and consumers in a responsible manner

9.1	What percentage of customer complaints/consumer cases are pending as on the end of financial year?	:	The Company has mechanism to manage customer complaints. As on March 31, 2022, less than 1% of the complaints were pending beyond the acceptable timelines as per the Standard Operating Procedures (SOP).
9.2	Does the company display product information on the product label, over and above what is mandated as per local laws?	:	The company has displayed the labels on the packing products as per regulatory requirements; comply with the Seed Act, 1966; Seed Rules, 1968; Legal Metrology Act, 2009 and Legal Metrology (Packaged Commodities) Rules, 2011 and other local laws from time to time.
9.3	Is there any case filed by any stakeholder against the company regarding unfair trade practices, irresponsible advertising and/or anti-competitive behavior during the last five years and pending as on end of financial year?	:	We have various mechanism to receive and address complaints from stakeholders related to compliance corruption or bribery. As on 31st March 2022, no stakeholders have filed any case against the Nath Bio, nor are any cases pending regarding unfair trade practices, irresponsible advertising, and /or anti-competitive behavior.
9.4	Did your company carry out any consumer survey/ consumer satisfaction trends?	:	Customer-focused excellence demands constantly sensitivity to changing and emerging customer requirements and close attention to the voice of the customer. We regularly undertake survey with farmers by internal team / independent organization to understand product satisfaction and their intention for coming season. We conduct Crop Tours/Survey by crops functional team with user farmers to understand product performance in farmer field conditions. Such a Tour/ Survey enables us to comprehensively understand the farmers expectations and needs and it serves as one of the inputs to make investment decisions. Company has provided well established system with multiple options to connect with the company such as Email, Telephone, Website, social media, Feedback Forms etc.

NATH BIO-GENES (INDIA) LIMITED

CORPORATE GOVERNANCE REPORT

==========

In accordance with Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and some of the best practices followed internationally on Corporate Governance, the report containing the details of corporate governance systems and processes at Nath Bio-Genes (India) Limited is as under:

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE.

Effective corporate governance practices constitute the strong foundation on which successful commercial enterprises are built to last. The Company's philosophy on corporate governance oversees business strategies and ensures fiscal accountability, ethical corporate behavior and fairness to all stakeholders comprising regulators, employees, customers, vendors, investors and the society at large.

The Company has a strong legacy of fair, transparent and ethical governance practices.

The Company believes that Corporate Governance is about best practices of business to be imbibed into the culture of the organization and complying with value systems, ethical business practices, laws and regulations to achieve the main objectives of the Company.

The Company is committed to optimizing long term value for its stakeholders with a strong emphasis on the transparency of its operations and instilling pride of association. The Company follows the best practices of Corporate Governance and reporting systems in accordance with SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015.

NATH BIO-GENES (INDIA) LIMITED

2. BOARD OF DIRECTORS.

As on 31st March 2022 the Company has Seven Directors comprising of two Executive Director one women director and Four Non-Executive Independent director including one women Independent Director. The composition of the Board as on 31st March 2022 is in conformity with Listing Regulations 2015 having specified combination of Executive and Non-Executive Directors.

Independent Directors are non-executive directors as defined under Regulation 16(1) (b) of the SEBI (Listing Obligations and disclosure Requirements) Regulations 2015 and Section 149(6) of the Companies Act 2013. The maximum tenure of independent directors is in compliance with the Companies Act. All the independent Directors have confirmed that they meet the criteria of independence as mentioned under Regulation 16(1) (b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Section 149(6) of the Companies Act 2013.

The Company is in compliance with the requirements stipulated under Regulations 17 to 27 read with Schedule V and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of SEBI

(Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable with regard to Corporate Governance as detailed below:

3. NUMBER OF BOARD MEETINGS.

Five meeting of the Board were held during the year. The dates on which the Board meetings were held are 24th June 2021, 10th August 2021, 01st November 2021, and 11th February 2022. And 30th March 2022 the details of attendance of Board meetings and Committee meetings held during the Financial Year 2021-22 forms part of the Corporate Governance Report.

Sr No	Date of Meeting/ Name of Director/ Attended Board Meeting YES/ NO	24/06/2021	10/08/2021	01/11/2021	11/02/2022	30/03/2022
1	Mr. Satish Kagliwal	YES	YES	YES	YES	YES
2.	Mrs. Sweta Kagliwal	YES	YES	YES	YES	YES
3.	Mr. Shrirang Agrawal (Resign on 15/02/2022)	YES	YES	YES	YES	NA
4.	Mrs. Jeevanlata Kagliwal	YES	YES	YES	YES	YES
5.	Mr. Ashu Jain	YES	YES	YES	YES	YES
6.	Mr. Vadla Nagabhushanam	YES	YES	YES	YES	YES
7.	Mr. Madhukar Deshpande	YES	YES	YES	YES	YES
8.	Mr. Hitesh Purohit (Appointed on 30/03/2022)	NA	NA	NA	NA	NA

NATH BIO-GENES (INDIA) LIMITED

4. COPOSITION AND STATUS OF BOARD OF DIRECTORS.

The composition of the Board of Directors and also the number of other Board of Directors or Board Committees of which he/she is a Member/Chairman are as under: -

Name of the Director	Category	No of Directorship as on 31-03-2022		Committee Membership/Chairmanship		No of Board Meeting Attended this year	Attendance of Last AGM on 27th August 2021.
		Listed	Public	Membership	Chairmanship		
Mr. Satish Kagliwal	Chairman Managing Director –Executive	3	3	7	1	5	Yes
Mrs. Sweta Kagliwal	Promoter, Non-Executive	3	5	0	0	5	Yes
Mrs. Jeevanlata Kagliwal	Executive Director	4	3	3	0	5	Yes
Mr Vadla Nagabhushanam	Independent, Non-Executive	3	0	5	4	5	Yes
Mr. Madhukar Deshpande	Independent, Non-Executive	3	0	5	3	5	Yes

Ms. Ashu Jain	Independent, Non-Executive	1	0	0	0	5	Yes
Mr. Hitesh Purohit	Independent, Non-Executive	4	0	7	5	NA	NA

b. Table showing details of Directors Serving Directorship in other Listed Companies As on 31st March 2022.

Sr No	Name of Director	Name of Listed Company
1.	Mr. Satish Kagliwal	1. Nath Bio-Genes (India) Limited 2. Agri-Tech (India) Limited 3. Techindia Nirman Limited
2.	Mrs. Sweta Kagliwal	1. Nath Bio-Genes (India) Limited 2. Agri-Tech (India) Limited 3. Techindia Nirman Limited
3.	Mr. Vadla Nagabhushanam	1. Nath Bio-Genes (India) Limited 2. Agri-Tech (India) Limited 3. Techindia Nirman Limited
4.	Mr. Madhukar Deshpande	1. Nath Bio-Genes (India) Limited 2. Agri-Tech (India) Limited 3. Techindia Nirman Limited
5.	Mrs. Jeevanlata Kagliwal	1. Nath Bio-Genes (India) Limited 2. Agri-Tech (India) Limited 3. Techindia Nirman Limited 4. Nath Industries Limited
6.	Ms. Ashu Jain	1. Nath Bio-Genes (India) Limited
7.	Mr. Hitesh Purohit	1. Nath Bio-Genes (India) Limited 2. Agri-Tech (India) Limited 3. Techindia Nirman Limited 4. Nath Industries Limited

NATH BIO-GENES (INDIA) LIMITED

c. DETAILS OF EQUITY SHARES HELD BY DIRECTORS.

Sr No	Name of the Director	Category	No of Shares Held	% of Number of Shares Held
1	Mr. Satish Kagliwal	Managing Director	0	0
2	Mr. Shrirang Agrawal (Resign on 15/02/2022)	Independent Director	0	0
3	Mrs. Sweta Kagliwal	Non-Executive Director	0	0
4	Mrs. Jeevanlata Kagliwal	Executive Director	293	0.001
5	Ms Ashu Jain	Independent Director	0	0
6	Mr. Vadla Nagabhushanam	Independent Director	0	0
7	Mr Madhukar Deshpande	Independent Director	0	0
8.	Mr. Hitesh Purohit (Appointed on 30/03/2022)	Independent Director	0	0

5. SEPARATE MEETING OF INDEPENDENT DIRECTOR.

Independent Directors of the Company met separately on February 10, 2022 without the presence of Non-Independent Directors and Members of Management. In accordance with Schedule IV of Companies Act, 2013, following matters were, inter-alia, reviewed and discussed in the meeting:

- Performance of Non-Independent Directors and the Board of Directors as a whole.
- Performance of the Chairman of the Company taking into consideration the views of Executive and Non-Executive Directors.
- Assess the quality, quantity and timeliness of flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

6. CODE OF CONDUCT.

The company has formulated and adopted a code of business conduct and ethics to guide our transactions with our colleagues, communities, customers, governments, investors, regulators and society. Requisite annual affirmations of compliance with the respective code have been made by the directors and the management of the company; including a declaration signed by the Director of the company regarding Compliance of the Code of Business Conduct.

7. COMMITTEE OF THE BOARD.

The board has Four Committees as on 31st March 2022 namely, Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee and Corporate Social Responsibility Committee and Risk Management Committee the board constitute additional functional committees, from time to time, depending upon business needs.

A. Audit Committee

The management is responsible for the Company's internal controls and the financial reporting process while the statutory auditors are responsible for performing independent audits of the Company's Financial Statements in accordance with generally accepted auditing practices and for issuing reports based on such audits. The Board of Directors has entrusted the Audit Committee to supervise these processes and thus ensure accurate and timely disclosures that maintain the transparency, integrity and quality of financial control and reporting. The composition, procedures, powers and role/functions of the Audit Committee constituted by the Company comply with the requirements of Regulation 18 of the SEBI (LODR) Regulations, 2015. and Section 177 of the Companies Act 2013.

1. Role of Audit Committee

- Oversight of financial reporting process.
- Reviewing with the management, the annual financial statements and auditors' report thereon before submission to the Board for approval.

NATH BIO-GENES (INDIA) LIMITED

- Evaluation of internal financial controls and risk management Systems
- Recommendation for appointment, remuneration and terms of appointment of auditors of the Company.
- Approve policies in relation to the implementation of the Insider Trading Code and to supervise implementation of the same.
- Review, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference.
- Review and monitor the auditor's independence and performance, and effectiveness of audit process.

2. Frequency of Meeting held.

Five Audit Committee meeting of the Board were held during the year 2021-2022. The dates on which the Board meetings were held are 22nd June 2021, 09th August 2021, 26th October 2021, 11th February 2022 and 30th March 2022.

3. Composition and Meetings and Attendance of Audit Committee.

Name of Director	Category	Status	No of Meetings Held and attended	
Mr. Madhukar Deshpande	Independent Director	Chairman	5	5
Mr. Satish Kagliwal	Executive Director	Member	5	5
Mr. Vadla Nagabhushanam	Independent Director	Member	5	5

NATH BIO GENES (INDIA) LIMITED

B. Nomination and Remuneration Committee.

Nomination and Remuneration Committee is constituted in line with the provisions of Regulation 19 of SEBI Listing Regulations and Section 178 of the Companies Act 2013.

1. Role of Nomination and Remuneration Committee.

- Recommend to the board to setup and composition of the Board and its committees.
- Recommend to the Board the appointment/re-appointment of Directors and Key Managerial Personnel.
- Support the Board and Independent Directors in evaluation of the performance of the Board, its Committees and individual Directors.
- Recommend to the Board the Remuneration Policy for Directors, executive team or Key Managerial Personnel as well as the rest of employees.
- Oversee familiarization programs.

2. Frequency of Meeting held.

Two Nomination and Remuneration Committee of the Board were held during the year 2021-2022. The dates on which the Board meetings were held on 26th October 2021 and 30th March 2022.

3. Composition and Meetings and Attendance of Nomination and Remuneration Committee.

Name of Director	Category	Status	No of Meetings Held and Attended	
Mr. Shrirang Agrawal (Resign on 15/02/2022)	Independent Director	Chairman	2	1
Mr. Vadla Nagabhushanam	Independent Director	Member	2	2
Mr. Madhukar Deshpande	Independent Director	Member	2	2
Mr. Hitesh Purohit (Appointed on 30/03/2022)	Independent Director	Member	2	NA

C. Stakeholders Relationship Committee

This Committee is constituted in line with the provisions of Regulation 20 of SEBI Listing Regulations and Section 178 of the Companies Act.

- Consider and resolve the grievances of security holders.
- Consider and approve issue of share certificates, transfer and transmission of Securities, Etc.

1. Role of Stakeholders Relationship Committee.

- Transfer, transmission, split and consolidation of investors holding
- Dematerialization/rematerialization of shares
- Non-receipt of dividends and other corporate benefits
- Replacement of lost/mutilated/stolen share certificates
- Non-receipt of Annual Reports and change of addresses, etc.

2. Frequency of Meeting held.

Four Stakeholders Relationship Committee meeting were held during the year 2021-22. The dates on which the Board meetings were held are 22nd June 2021, 09th August 2021, 26th October 2021, 11th February 2022.

3. Composition and Meetings and Attendance of SR Committee Meeting.

Name of Director	Category	Status	No of Meetings Held / Attended	
Mr. Madhukar Deshpande	Independent Director	Chairman	4	4
Mr. Vadla Nagabhushanam	Independent Director	Member	4	4
Mr. Satish Kagliwal	Executive Director	Member	4	4

4. Complaints Received

During the financial year 2021-22, No complaint was received and there were no complaints outstanding as on 31st March 2022. There were no share transfer requests pending as on 31st March 2022.

NATH BIO-GENES (INDIA) LIMITED

5. Name and Designation of Compliance Officer .

Mr. Dhiraj Rathi is Company Secretary and Compliance Officer of the Company.

D. Corporate Social Responsibility Committee.

This Committee is constituted in line with the provisions of Section 135 of the Act.

1. Role of the Committee.

- Formulate and recommend to the Board, a CSR Policy indicating the activities to be undertaken by the Company as specified in Schedule VII of the Act.
- Recommend the amount of expenditure to be incurred on the activities mentioned in the CSR Policy.
- Monitor the CSR Policy.

2. Frequency of Meeting held.

Two Corporate Social Responsibility Committee meeting were held during the year 2021-22. The dates on which the Board meetings were held are 26th October 2021 and 11th February 2022.

3. Composition and Meetings and Attendance of CSR Committee.

Name of Director	Category	Status	No of Meetings Held / Attended	
Mr. Vadla Nagabhushanam	Independent Director	Chairman	2	2
Mr. Madhukar Deshpande	Independent Director	Member	2	2
Mr. Satish Kagliwal	Executive Director	Member	2	2

NATH BIO-GENES (INDIA) LIMITED

E. Risk Management Committee.

This Committee is constituted in line with the provisions of Regulation 21 of SEBI Listing Regulations.

The Company has constituted a Risk Management Committee which has been entrusted with the responsibility to assist the Board in (a) approving the Company's Risk Management Framework and (b) Overseeing all the risks that the organization faces such as strategic, financial, liquidity, security, regulatory, legal, reputational and other risks that have been identified and assessed to ensure that there is a sound Risk Management Policy in place to address such concerns / risks. The Risk Management process covers risk identification, assessment, analysis and mitigation. Incorporating sustainability in the process also helps to align potential exposures with the risk appetite and highlight risks associated with chosen strategies. The Audit Committee has additional oversight in the area of financial risks and controls. Major risks identified by the business and functions are systematically addressed through

mitigating actions on a continuing basis. The Company has adopted a Risk Management Policy in accordance with the provisions of the Act and Regulation 21 of the Listing Regulations.

1. Frequency of Meeting held

Three Risk Management Committee meeting were held during the year 2021-22. The dates on which the Board meetings were held are 26th October 2021, 11th February 2022 and 30th March 2022.

2. Composition and Meetings and Attendance of RM Committee.

Name of Director	Category	Status	No of Meetings Held / Attended	
Mr. Satish Kagliwal	Executive Director	Chairman	3	3
Mr. Vadla Nagabhushanam	Independent Director	Member	3	3
Mr. Shrirang Agrawal (Resign on 15/02/2022)	Executive Director	Member	3	2

NATH BIO-GENES (INDIA) LIMITED

9. FAMILARISATION PROGRAMMES FOR INDEPENDENT DIRECTOR.

Independent Directors inducted on the Board are given a formal introduction about the Company and its operations. This is enabled through a meeting with the Managing Director and Whole Time Directors. The objective is to provide them an insight about the industry in which the Company operates and comprehensive information about Company's business and management.

Various familiarization initiative are carried out throughout the year on an on-going basis which include comprehensive update at Board and Committee meetings on Company's performance & industry scenario, and amendments in the laws and regulations applicable to the Company through presentations by Company executives.

The aim of familiarization programs is to give independent directors an update on:

i. nature of the industry in which the Company operates;
ii. the business model of the Company;
iii. the roles, rights, responsibilities of independent directors; and
iv. other relevant/ significant information pertaining to or affecting the Company to enable them take informed decisions. Independent directors on the Board of the Company have diverse background with rich experience and expertise in their respective domains. They have an aptitude to keep themselves abreast with changes in the industry and applicable regulations. The Company undertakes following initiatives to apprise them with significant and relevant information which helps in effective discharge of their duties and responsibilities as independent directors of the Company:

10. PERFORMANCE EVEALTUATION OF DIRECTORS AND FORMULATION OF THE CRITERIA FOR EVALUATION OF INDEPENDENT DIRECTOR AND THE BOARD.

Pursuant to the provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the guidance Note on Board Evaluation issued by the SEBI on 5th January 2017, the Board has carried out an annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working of its committees. The performance of the board was evaluated by the board after seeking inputs from all the directors on the basis of criteria such as the board composition and structure, effectiveness of board processes, information and functioning etc.,

The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings etc., In a separate meeting of independent directors, performance of non-independent directors, the chairman of the Company and the board as whole was evaluated, taking into account the views of executive directors and non-executive directors. The Board and the nomination and remuneration committee reviewed the performance of individual directors on the basis of criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings etc., In the board meeting that followed the meeting of the independent directors and meeting of nomination and remuneration committee, the performance of the board, its committees, and individual directors was also discussed. The performance evaluation of the Independent Directors was completed. The performance evaluation of the Chairman and the Non-Independent Directors was carried out by the Independent Directors. The Board of Directors expressed their satisfaction with the evaluation process.

MATH BIO GENIES (INDIA) LIMITED

11. DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, requires that the top 1000 listed Companies based on the market capitalization to formulate Dividend Distribution Policy. In compliance with the said requirement, the Company has formulated the Dividend Distribution Policy,

The details of which are available on the Company's website and also provided as attachment of Directors Report.

12. REMUNARATION OF DIRECTORS.

The details of Remuneration paid to Executive / Independent Directors for the year 2021-22 are as follows: -

Sr No	Name of Director	Designation	Salary In (INR Lakhs)	Perquisites and allowance	Total
1.	Mr. Satish Kagliwal	Managing Director	48.00	NIL	48.00
2.	Mrs. Jeevanlata Kagliwal	Executive Director	NIL	NIL	NIL
3.	Mrs. Sweta Kagliwal	Non-Executive Director	NIL	NIL	NIL

Sitting Fees Paid for Meetings:

Sr No	Name of Director	Designation	Remuneration	Sitting Fees
1.	Mrs. Jeevanlata Kagliwal	Executive Director	NIL	18000
2.	Mrs. Sweta Kagliwal	Non-Executive Director	NIL	18000
6.	Ms. Ashu Jain	Independent Director	NIL	18000
7.	Mr. Vadla Nagabhushanam	Independent Director	NIL	21890
8.	Mr. Madhukar Deshpande	Independent Director	NIL	21600
6.	Mr. Shrirang Agrawal (Resign on 15/02/2022)	Independent Director	NIL	18000
7.	Mr. Hitesh Purohit (Appointed on 30/03/2022)	Independent Director	NIL	0

NATH BIO-GENES (INDIA) LIMITED

13. MANAGEMENT DISCUSSION AND ANALYSIS REPORT.

A detailed report on the Management Discussion and analysis is given separately with this report.

14. DETAILS OF GENERAL BODY MEETING.

a. Annual General Meeting

The location and time where last three Annual General Meetings of the Company were held as under: -

Financial Year	Place	Date	Time
2020-21	Video Conferencing AGM	27th August 2021	11.00 AM
2019-20	Video Conferencing AGM	24th July 2020	04.00 PM
2018-19	Nath House, Nath Road, Aurangabad (MAH) 431005	10th August 2019	11.00 AM

b. Extraordinary General Meeting

No Extraordinary General Meeting of the Members was held during the year 2021-22.

c. Special Resolutions passed by Company During last three AGM.

1. Appointment of Ms. Ashu Jain as Independent Director. (2020-21)
2. Appointment of Mr. Vadla Nagabhushnam as Independent Director. (2020-21)
3. Appointment of Mr. Madhukar Deshpande as Independent Director. (2020-21)
4. Re-Appointment of Mr. Shrirang Agrawal as Independent Director. (2018-19)
5. Re-Appointment of Mr. Omprakash Sharma as Independent Director. (2018-19)
6. Re-Appointment of Mr. Kashinath Iyer as Independent Director. (2018-19)

d. Details of special resolution passed through Postal Ballot

No Special Resolution passed through the Postal Ballot.

15. OTHER DISCLOURE

a. Related party transactions-

No transaction of material nature has been entered into by the Company with its Directors/management and their relatives, etc. that may have a potential conflict with the interests of the Company. The Register of Contracts containing transactions, in which Directors are interested, is placed before the Audit Committee and Board regularly. Transactions with related parties are disclosed in the Notes to Accounts in the Annual Report. In terms of SEBI (LODR) Regulations, 2015, the Audit Committee and Board of Directors of the Company have adopted a policy to determine Related Party Transactions.

b. Details of Non-Compliance and Penalties

There were no cases of non-compliance during the last three financial years.

c. Whistle Blower Policy and Vigil Mechanism.

The Board of Directors of the Company had adopted the Whistle Blower policy. The Company has established a mechanism for employees to report to the management, concerns about unethical behavior, actual or suspected fraud or violation of the Company's code of conduct or ethics. The employees have been appropriately communicated within the organization about the mechanism and have been provided direct access to the Chairman of the Audit Committee. The mechanism also lays emphasis on making enquiry into whistle blower complaint received by the Company. The Audit Committee reviews periodically the functioning of whistle blower mechanism. No employee has been denied access to the Audit Committee.

d. Details of compliance with mandatory requirements and adoption of the non-mandatory requirements

The Company has implemented all mandatory requirements of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

e. Subsidiary Companies

Company does not have any Subsidiary Company

NATH BIO-GENES (INDIA) LIMITED

f. Policy on Determination of Materiality for Disclosures.

The Company has adopted a Policy on Determination of Materiality for Disclosures.

g. Reconciliation of Share Capital Audit Report

Regulation 76 of the Securities and Exchange Board of \India (Depositories and Participants) Regulations, 2018 and SEBI Circular No D&CC / FITTC/ Cir- 16/2002 dated December 31, 2002

A qualified practicing Company Secretary carried out a share capital audit to reconcile the total admitted equity share capital with the National Securities Depository Limited ("NSDL") and the Central Depository Services (India) Limited ("CDSL") and the total issued and listed equity share capital. The audit report confirms that the total issued / paid-up capital is in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL.

h. The Disclosures of the compliance with Corporate Governance requirements specified in Regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 are as follows:

Regulation	Particulars	Compliance Status (Yes/No)
17	Board of Directors	Yes
18	Audit Committee	Yes
19	Nomination and Remuneration Committee	Yes
20	Stakeholders Relationship Committee	Yes
21	Vigil Mechanism	Yes
23	Related Party Transaction	Yes
24	Corporate Governance requirement with respect to subsidiary of Listed entity	Yes
25	Obligation with respect to Independent Director	Yes
26	Obligation with respect to directors and Senior management	Yes
27	Other Corporate Governance requirement	Yes
46	Functional Website	Yes

NATHBIO-GENES (INDIA) LIMITED

g. Auditors Fees

Total Fees for all services paid by the Company to the Statutory Auditors and all entities in this network firm/network entity of which the statutory Auditor is part is given Below.

Sr No	Payment to Statutory Auditors	FY 2021-22
1	Audit Fees	700000
2	Others	110000
	Total	810000

16. MEANS OF COMMUNNICATION.

The quarterly and annual financial results of the Company are uploaded on NSE Electronic Application Processing System (NEAPS) and BSE Listing Centre in accordance with the requirements of Listing Regulations. The financial results are displayed on BSE and NSE websites. The quarterly, half-yearly and annual financial results of the Company are also published in leading newspapers in India which include Business Standard, and Pudhari. The results are also displayed on the Company's website www.nathbiogenes.com Financial Results, Statutory Notices, Press Releases and Presentations made to the institutional investors/ analysts after the declaration of the quarterly, half-yearly and annual results are submitted to the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) as well as uploaded on the Company's website. In terms of the Listing Regulations, the Company has a designated email ID for dealing with Investors' complaints viz., investors@nathbiogenes.com.

17. GENERAL SHAREHOLDERS INFORMATION

a. Annual General Meeting

Date & Time	Thursday 30th June 2022 .
Time	11.00 AM
Venue	The Company is conducting meeting through VC / OAVM pursuant to the MCA Circular dated May 5, 2020 and as such there is no requirement to have a venue for the AGM. For details please refer to the Notice of this AGM.

b. Book Closure

As mentioned in the notice of the AGM.

c. Financial Year

1st April 2021 to 31st March 2022

d. Listing on Stock Exchanges and stock codes / symbol.

Stock Exchange	Trade Symbol	Address
BSE Limited	537291	25th floor, P.J Towers, Dalal Street, Mumbai 400001
National Stock Exchange of (India) Limited	NATHBIOGEN	Exchange plaza, C-1 Blok-G, Bandra Kurla Complex Bandra (East) Mumbai-400001

e. CIN- L01110MH1993PLC072842

f. Market Price Data

High, Low (based on daily closing prices) and number of equity shares traded during each month in the year 2021-22 on BSE and National Stock Exchange of India Limited.

NATH BIO-GENES (INDIA) LIMITED

MONTH	BSE		NSE	
	High	Low	High	Low
Apr-21	377.60	303.40	383.70	303.10
May-21	465.95	335.00	466.25	332.95
Jun-21	448.80	378.75	474.70	379.15
Jul-21	402.00	356.50	401.65	356.00
Aug-21	400.00	307.40	396.00	307.30
Sep-21	361.85	320.95	361.00	321.00
Oct-21	332.90	324.40	343.95	283.25
Nov-21	308.00	257.90	331.30	258.10
Dec-21	297.80	237.20	297.80	233.45
Jan-22	288.50	250.55	288.60	250.00
Feb-22	263.80	191.85	264.05	192.65
Mar-22	238.4	195.25	238.00	195.00

NATH BIO-GENES (INDIA) LIMITED

g. Performance of the Share Price of the Company in Comparison to the BSE Sensex and Nifty

h. **Registry to an issue and Share Transfer Agents.**

Name-	Bigshare Services Private Limited
Address-	1st Floor, Bharat Tin Woks Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East Mumbai-400059
Telephone	022-62638200
Email-	info@bigshareonlince.com
Website	www.bigshareonline.com

i. Share Transfer System.

All share transfer and other communications regarding share certificates, change of address, dividends, etc. should be addressed to Registrar and Transfer Agents. Stakeholders Relationship Committee is authorized to approve transfer of shares in the physical segment. The Committee has delegated authority for approving transfer and transmission of shares and other related matters to the officers of the Company. Such transfers take place on weekly basis. A summary of all the transfers/ transmissions etc. so approved by officers of the Company is placed at every Committee Meeting. All share transfers are completed within statutory time limit from the date of receipt, provided the documents meet the stipulated requirement of statutory provisions in all respects. The Company obtains from a Company Secretary in practice half yearly certificate of compliance with the share transfer formalities as required under Regulation 40(9) of the Listing Regulations, and files a copy of the same with the Stock Exchanges.

j. Shareholding as on March 31, 2022.

Distribution of Share Holding as on 31st March 2022.

Shareholding of Nominal Value (Rs.)		No. of Holders	% of Total Holders	Total Shares Capital	% of Total Share Capital
1	5000	34517	95.66	23384500	**15.3**
5001	10000	801	2.21	6077611	**2.21**
10001	20000	414	1.14	6017600	**3.16**
20001	30000	129	0.35	251580	**1.71**
30001	40000	46	0.12	1643420	**0.86**
40001	50000	39	0.10	1778790	**0.93**
50001	100000	56	0.15	3910720	**2.05**
100001	9999999	81	0.22	143975780	**100**
Total		**36083**	**100.00**	**190040000**	**100**

1. **Categories of Shareholding as on 31st March 2022.**

Category	No. of Shares	% of Capital
Indian Promoters	7801783	41.05
Persons acting in Concert	0	0
Sub Total	**7801783**	**41.05**
Non-Promoter Holding		
Mutual Funds	921339	4.85
Alternate Investment fund	0	0
Banks/Financial Institutions	22	0.00
FII/FBI	13989	0.07
Sub Total	**935350**	**4.92**
Others	329572	1.73
Private Corporate Bodies	3744335	19.73
Indian Public	5674444	29.85
NRI/OCB	518516	2.72
Sub Total	**10266867**	**54.03**
Total	**19004000**	**100.00**

NATHBIO-GENES (INDIA) LIMITED

2. **Top 10 Equity Shareholders as on 31st March 2022.**

Sr. No.	Name	No of shares	% of Total Shares of the Company
1	Authum Investment and Infrastructure Limited	2623178	13.80
2	Aditya Birla Sun Life Trustee Private Limited	919139	4.83
3	Satpal Khattar	400000	2.10
4	Meghal Bakulesh Shah	308000	1.62
5	Girish Kulkarni	150000	0.78
6	Dishant Milanbhai Parikh	150000	0.78
7	Arun Kumar	115409	0.60
8	C Mackertich Private Limited	112676	0.59
9	Jaideep Sampat	100000	0.52
10	Girish Nilkanth Kulkarni	96000	0.50

3. **Dematerialization of shares and liquidity**

The Company's shares are compulsorily traded in dematerialized form on NSE and BSE. Equity shares of the Company representing 98.45 percent of the Company's equity share capital are dematerialized as on March 31, 2022. Under the Depository System, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE448G01010.

4. **Outstanding GDRs/ADRs/Warrants or any convertible instruments, conversion date and likely impact on equity:**

The Company has not issued any GDRs/ADRs/Warrants or any convertible instruments in the past and hence, as on March 31, 2022, the Company does not have any outstanding GDRs/ADRs/Warrants or any convertible instruments.

5. **Commodity price risk or foreign exchange risk and hedging activities:**

The Company does not deal in commodities and hence the disclosure pursuant to SEBI Circular date November 15, 2018 is not required to be given.

6. **Address for Correspondence**.

Nath Bio-Genes (India) Limited
Nath House, Nath road Aurangabad-431005
Email ID-investor@nathbiogenes.com.
Website-www.nathbiogenes.com
Contact No-0240-6645555

NATH BIO-GENES (INDIA) LIMITED

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT.

30th May 2022

The Members,
Nath Bio-Genes (India) Limited
Nath House, Nath road
Aurangabad-431005

Subject: Declaration regarding compliance with the Company's code of conduct for its Directors and Employees.

Ref: Regulation 34 (3) read with Part D of Schedule V to the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

I, Satish Kagliwal, Managing Director of the Company, hereby declare that as provided under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board Members and the Senior Management Personnel have confirmed compliance with the Code of Conduct and Ethics for the year ended 31st March 2022.

For Nath Bio-Genes (India) Limited

Satish Kagliwal
Managing Director
DIN-00119601

NATH BIO-GENES (INDIA) LIMITED

CEO/CFO CERTIFICATION IN RESPECT OF FINANCIAL STATEMENTS AND CASH FLOW STATEMENT.

(Pursuant to Regulation 17(8) of SEBI (LODR) Regulations, 2015 for the financial year ended March 31st 2022).

We hereby certify that:

a. We have reviewed financial statements and the cash flow statement for the Financial Year ended 31st March 2022 and that to the best of our knowledge and belief:

i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

ii. These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

b. There are, to the best of our knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or violative of the Company's code of conduct.

c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

d. We have indicated to the auditors and the Audit Committee that there are no:

i. Significant changes in internal control over financial reporting during the year;

ii. Significant changes in accounting policies during the year and that the same have been disclosing in the notes to the financial statements; and

iii. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having significant role in the company's internal control system over financial reporting.

For an on behalf of the Board of Directors

Place: Aurangabad	Chief Financial Officer	Managing Director
Dated: 30thMay 2022	Devinder Khurana	Satish Kagliwal
		DIN: 00119601

NATH BIO-GENES (INDIA) LIMITED

CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE UNDER REGULATION 34(3) READ WITH SCHEDULE V OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

To the Members of,

Nath Bio-Genes (India) Limited
Nath House, Nath Road
Aurangabad-431005

We have examined the compliance of the conditions of Corporate Governance by Nath Bio-Genes (India) Limited ('the Company') for the year ended on March 31, 2022, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub regulation (2) of Regulation 46 and para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The compliance of the conditions of Corporate Governance is the responsibility of the management of the Company. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2022.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Neha P Agrawal
FCS No. 7350, C P No: 8048

Place: Aurangabad
Date: 30th May 2022

NATH BIO GENES (INDIA) LIMITED

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS.

(*Pursuant to clause 10 of Part C of Schedule V of LODR*)

To,
The Members,
Nath Bio-Genes (India) Limited
Nath House, Nath road,
Aurangabad-431005

In pursuance of sub clause (i) of clause 10 of Part C of Schedule V of The Securities Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirement) Regulations, 2015; (LODR) in respect of NATH BIO-GENES (INDIA) LIMITED bearing CIN L01110MH1993PLC072842: (Hereinafter called "the Company"), I hereby certify that :

On the basis of the written representation/declaration received from directors and taken on record by the Board of Directors, as on March 31, 2022, none of the directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as director of the companies by the Securities Exchange Board of India (SEBI) /Ministry of Corporate Affairs or any such statutory authority.

NATH BIO-GENES (INDIA) LIMITED

For Neha P Agrawal
Practicing Company Secretary
FCS No. 7350, C P No: 8048

Place: Aurangabad
Date: 30th May 2022

ASHOK R. MAJETHIA
BCom. F.C.A.
CHARTERED ACCOUNTANT

Ashok R. Majethia & Co.
Chartered Accountants
Utsav Complex,
Office No. 7, Bazar Peth,
Dist. Raigad, Khopoli – 410 203
Tel :- (02192) 269908
Mobile: - 9404711539 / 9372169952
Email: - ashokmajethia@rediffmail.com

NATH BIO-GENES (INDIA) LIMITED

Independent Auditors' Report

To,
The Members of
Nath Bio-genes (I) Limited
Aurangabad

Report on the Audit of the Standalone Financial Statements

Opinion

1. We have audited the accompanying standalone financial statements of Nath Bio-genes (I) Limited having CIN: L01110MH1993PLC072842 ("the Company"), which comprise the Standalone Balance Sheet as at 31st March 2022, the Standalone Statement of Profit and Loss (including other comprehensive income), Standalone Statement of Cash Flows and Standalone Statement of Changes in Equity for the year then ended, and notes to the Standalone financial statements, including a summary of significant accounting policies and other explanatory information.

2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS") and the other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2022 and its loss (financial performance including other comprehensive income), the changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Emphasis of Matter

4. Attention is invited to note no 29 in respect of provisioning of certain advances granted to farmers / growers during last few years to the extent of lakhs. 8878.19 which are considered doubtful of recovery.

Key Audit Matters

5. Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current year. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key Audit Matters	Audit Procedures
Agricultural Activities	
The company is engaged in the production and processing of commercial and vegetable seeds at various pieces of lands taken on lease from various growers/farmers spread over throughout India. The company enters into seed production agreements with these farmers / growers. The company is compensating the farmers/growers for various cultivation expenses based upon the rate agreement entered in to. Thus, the company is engaged in the growing of various kinds of seeds based on the programs chalked out by the management depending on the area, climatic conditions, soil conditions, water resources, education of farmers, processing facilities etc.	We have performed the following principal audit procedures in relation to Agricultural Activities:- - Evaluation and understanding of Seed production agreements. - Verification and evaluation of the documents for existence of formers/growers on sample basis of the seeds. - Verification and evaluation of documents on sample basis for the existence of leasehold land. - Evaluation of the control / supervision over the crop. - Evaluating the appropriateness of the adequate disclosures in accordance with the applicable accounting standards.
Adoption of Ind AS 116 Leases	
As described in Note 2(AA) to the standalone financial statements, the Company has adopted Ind AS 116 Leases (Ind AS 116) in the current year. Ind AS 116 introduces a new lease accounting model, wherein lessees are required to recognize a right-of-use (ROU) asset and a lease liability arising from a lease on the balance sheet. The lease liabilities are initially measured by discounting future lease payments during the lease term as per the contract/ arrangement. Adoption of the standard involves significant judgments and estimates including, determination of the discount rates and the lease term. Additionally, the standard mandates detailed disclosures in respect of transition. The Company has leasing arrangements for operating leases for lands and premises (Agricultural lands, office, stores, go-down etc.), which are cancellable and renewable by mutual consent. The aggregate lease rentals are charged as rent in the Statement of Profit and Loss.	Our audit procedures on adoption of Ind AS 116 include: - Assessed and tested new processes and controls in respect of the lease accounting standard (Ind AS 116); - Assessed the company's evaluation on identification of leases based on the contractual agreements and our knowledge of the business; - Assessed the key terms and conditions of each lease with the under lying lease contracts and evaluation of the lease liability. - Assessed and tested the presentation and disclosures relating to Ind AS 116.

NATHBIO-GENES (INDIA) LIMITED

Information other than the Standalone Financial Statements and Auditor's Report thereon

6. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the annual report but does not include the financial statements and our auditor's report thereon.

7. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

8. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

9. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

10. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

11. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

12. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

13. As part of an audit in accordance with Standard on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

    a. Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one

NATH BIO-GENES (INDIA) LIMITED

resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

b. Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company and its subsidiary companies which are companies incorporated in India, has adequate internal financial controls system in place and the operating effectiveness of such controls.

c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

e. Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

14. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

15. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

16. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication

Report on Other Legal and Regulatory Requirements

17. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable. As required by Section 143(3) of the Act, we report that:

    (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
    (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
    (c) The Balance Sheet, the Statement of Profit and Loss, and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
    (d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

NATH BIO-GENES (INDIA) LIMITED

(e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

(g) In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements – Refer Note 32 to the financial statements;

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Ashok R Majethia & Co.
Chartered Accountants
FRN: 127769W

Ashok Majethia
Proprietor
M No: 124781
UDIN: 22124781AJVSHL3146

Place: Aurangabad
Dated: 30th May 2022

NATH BIO-GENES (INDIA) LIMITED

ANNEXURE "A" TO THE INDEPENDENT AUDITORS' REPORT

The Annexure referred to in Independent Auditors' Report to the members of the Nath Bio-genes (I) Limited on the Ind AS standalone financial statements for the year ended 31st March 2022, we report that:

1. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment. The Company has maintained proper records showing full particulars of intangible asset.

   (b) The company has regular program of physical verification of its Property, Plant and Equipment by which Property, Plant and Equipment are verified in a phased manner over a period of three years. In accordance with this program, certain Property, Plant and Equipment were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the company and nature of its business.

   (c) According to the information and explanations given to us, and on the basis of our examination of the record of the company, the title deeds of the immovable properties are held in the name of the company except in the following cases:

Description of Properties	Gross Carrying Value Rs in Lakh	Held in the name of	Whether promoter, director or their relative or employee	Period held – indicate range, where appropriate	Reason for not being held in name of company
at Village Dhangaon and Shahapur-Wahegaon, Tq. Paithan, Dist. Aurangabad admeasuring 35.97 hectares.	Rs. 2,100.00	Agri-Tech (India) Ltd	Group Company	15th March 2016	Pending approval for stamp duty exemption with State Government
at Wahegaon Tq Paithan Dist Aurangabad admeasuring 16.08 hectare	Rs. 1,350.00	Agri-Tech (India) Ltd	Group Company	15th March 2017	Pending approval for stamp duty exemption with State Government
at Village Isarwadi Tq Paithan Dist Aurangabad admeasuring 5.72 hectares.					
at Gut No 130/4, Village Dhangaon Tq Paithan Dist Aurangabad admeasuring 2.02 hectares	Rs. 2,021.00	Agri-Tech (India) Ltd	Group Company	28th December 2018	Pending approval for stamp duty exemption with State Government
at Gut No 53/1, and 53/5, Village Isarwadi Tq Paithan Dist Aurangabad admeasuring 3.95 hectares					
at Gut No 45, 53/3, 53/4 and 56 Village Wahegoan Tq Paithan Dist Aurangabad admeasuring 12.02 hectare					
at Plot No 1 admeasuring 6007.16 Sq Meter and Plot No 2 admeasuring 5183.18 Sq meter at Paithan Mega Food Park Pvt Ltd, Gut No 125, Village Dhangaon, Taluka Paithan, Dist Aurangabad.	Rs. 190.24	Paithan Mega Food Park Pvt Ltd	Group Company	10th March 2020	Pending approval for stamp duty exemption with State Government

NATH BIO GENES (INDIA) LIMITED

(d) According to the information and explanations given to us, and on the basis of our examination of the record of the company, the company has not revalued any Property, Plant & Equipment (including Right of Use assets) or intangible assets during the year.

(e) According to the information and explanations given to us, and on the basis of our examination of the record of the company, no proceedings have been initiated or are pending against the company for holding any Benami property under the "Benami Transactions (Prohibition) Act, 1988 and Rules made thereunder.

2. (a) The inventory has been physically verified during the year by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. There is no discrepancy of 10% or more noticed during verification between the physical stocks and book records. The discrepancies were not material, which have been properly dealt with in the books of account. The year-end inventory has been physically verified by the management and the same is incorporated as per inventory records and books of account maintained by the company.

(b) During the year, the Company has been sanctioned working capital limits in excess of Rs. 5 crores, in aggregate, from banks on the basis of security of current assets; the quarterly statements filed by the Company in respect of current assets held by it and offered as security with such banks or financial institutions are largely in agreement with the unaudited books of account of the Company of respective quarters and discrepancies observed have been explained in Note no 56 of the Financial Statements.

3. (a) As per the information and explanations given to us, the Company has granted loans including advances in the nature of loan to companies/ firms. The balance amount of loan outstanding at the year-end is Lakhs 1221.85. The company has provided corporate guarantee to the tune of Lakhs 4360.00 to Banks. Further, the company has made investments of Lakhs 1.52 in joint venture abroad. The company has not given any security to any party during the year.

(b) The terms and conditions for such above mentioned loan and corporate guarantee are not prejudicial to the interest of the Company except non-levy of interest on loans & non – charging of commission on corporate guarantee.

(c) In respect of loans and advances in the nature of loans the schedule of repayment of principal and payment of interest has not been stipulated; hence we are unable to comment whether the repayments or receipts are regular, overdue, renewed or extended or fresh loan granted to settle the overdue of existing loans given to the same parties;

4. The company has not provided any security to any party covered under section 185 and 186 of the Act, except that of loan, corporate guarantee and investment as mentioned in para 3 above, after complying the provisions of section 186 except non-levy of interest and non-charging of commission on corporate guarantee.

5. The Company has not accepted deposits within the meaning of sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under.

6. No maintenance of cost records has been specified by the Central Government under section 148(1) of the Act for the products of the company.

7. (a) The company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales-tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues with the appropriate authorities

NATH BIO-GENES (INDIA) LIMITED

b) There are no dues of Income tax, Sales tax, Service tax, Customs Duty, Excise Duty and Value Added Tax which have not been deposited as on 31st March, 2022 on account of disputes

8. According to the information and explanations given to us, there are no transactions recorded in the books of account as have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961, hence, clause (viii) of Order is not applicable.

9. In our opinion and according to the information and explanations given to us:-
(a) the Company has not defaulted in payment of dues to financial institution or bank or debenture holders.
(b) the company is not declared willful defaulter by any bank or financial institution or other lender.
(c) term loans were applied for the purpose for which the loans were obtained.
(d) no funds raised on short term basis have been utilised for long term purposes.
(e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures; hence the clause (ix) (e) of the Order is not applicable.
(f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies; hence the clause (ix) (f) of the Order is not applicable.

10. The company has not raised any moneys by way of initial public offer, further public offer (including debt instruments), preferential allotment or private placement of shares during the year.

11. (a) According to the information and explanations given to us, no fraud by the company or any fraud on the Company has been noticed or reported during the year.
(b) No report under sub-Section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules 2014 with the Central Government.
(c) We have not considered whistle-blower complaints, since, there is no compliant received during the year by the Company.

12. The company is not a Nidhi Company as such provisions of the clause (xii) of the Order are not applicable to the company.

13. All transactions with the related parties are in compliance with section 177 and 188 of the Act, where applicable, and the details have been disclosed in the Ind AS standalone financial statements etc., as required by the applicable accounting standards.

14. (a) In our opinion, the internal audit system is commensurate with the size of the company and nature of its business.
(b) In framing our Independent Audit Reports, we have considered Internal Auditor's Report for the period under audit.

15. The company has not entered into any non-cash transactions with directors or persons connected with him.

16. (a) The company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.
(b) In Our opinion, the Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act 1934.
(c) The Company is not a Core Investment Company (CIC) as defined under the Regulations by the Reserve Bank of India.

NATH BIO-GENES (INDIA) LIMITED

17. The Company has not incurred cash losses in the Financial Year and in the immediately preceding financial year.

18. There has been no resignation of the statutory auditors during the year.

19. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, we are of the opinion that no material uncertainty exists as on the date of the audit report which infers that the company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

20. The company does not have any unspent amount which are required to be transferred to a fund specified in schedule VII to the Act. Further, the company does not have any on-going project in hand, hence clause (xx) (b) of the Order is not applicable.

21. The company has a joint venture abroad. In view of insignificant transactions, consolidation of financial statement is not done.

For Ashok R Majethia & Co
Chartered Accountants
FRN: 127769W

Ashok Majethia
Proprietor
M No: 124781
UDIN: 22124781AJVSHL3146

Place: Aurangabad
Date: 30th May 2022

NATH BIO-GENES (INDIA) LIMITED

ANNEXURE "B" TO THE INDEPENDENT AUDITORS' REPORT

Report on the Internal Financial Controls over financial reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

1. We have audited the internal financial controls over financial reporting of **Nath Bio-genes (I) Limited** ("the Company") as of 31st March, 2022 in conjunction with our audit of the Ind AS standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the ICAI and the Standards on Auditing prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

5. We believe that the audit evidence, we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting of the company.

Meaning of Internal Financial Controls Over Financial Reporting

6. A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of

NATH BIO-GENES (INDIA) LIMITED

Ind AS standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Ind AS financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

7. Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For Ashok R Majethia & Co
Chartered Accountants
FRN: 127769W

Ashok Majethia
Proprietor
M No: 124781
UDIN: 22124781AJVSHL3146

Place: Aurangabad
Date: 30th May 2022

NATH BIO-GENES (INDIA) LIMITED

Nath Bio-Genes (India) Limited
Balance Sheet as at March 31, 2022

	Note	As at March 31, 2022 Rs. In Lakhs	As at March 31, 2021 Rs. In Lakhs
Assets			
I) Non-Current Assets			
a) Property, plant and Equipment	3	23,286.25	23,330.69
b) Intangible assets	3	1,202.62	1,361.88
c) Financial Assets			
(i) Non-current Investment	4	506.33	504.78
(ii) Other Non-current financial assets		-	-
d) Deferred Tax Assets (Net)		-	-
e) Other Non-current Assets	5	2,178.59	143.50
		27,173.79	25,340.85
II) Current Assets			
a) Inventories	6	22,034.28	22,629.99
b) Financial Assets			
(i) Trade Receivables	7	8,792.04	10,939.27
(ii) Cash and cash equivalents	8	416.80	2,921.61
(iii) Other current financial assets	9	15,019.23	16,074.11
c) Current Tax Assets (Net)	10	688.67	960.46
d) Other current assets	11	66.01	84.71
		47,017.03	53,610.15
Total Assets		**74,190.82**	**78,951.00**
Equity and Liabilities			
Equity			
a) Equity Share Capital	12	1,900.40	1,900.40
b) Other Equity	13	52,296.54	59,427.48
		54,196.94	**61,327.88**
Liabilities			
I) Non-Current Liabilities			
a) Financial Liabilities			
(i) Borrowings	14	66.48	65.28
(ii) Trade Payables		-	-
b) Provisions	15	261.06	257.46
		327.54	**322.74**
II) Current Liabilities			
a) Financial Liabilities			
(i) Borrowings	16	9,229.38	10,012.60
(ii) Trade Payables to MSME	17	51.05	62.20
(iii) Trade Payables other than MSME	17	5,457.70	3,447.32
b) Other current liabilities	18	4,731.15	3,475.81
c) Provisions	19	108.33	49.34
d) Current Tax Liabilities (Net)	20	88.74	253.11
		19,666.35	17,300.38
Total Equity and Liabilities		**74,190.82**	**78,951.00**

The accompanying Notes are an integral part of these Financial Statements.

In terms of our report of even date.

For Ashok R Majethia & Co
Firm Registration No.: 127769W
Chartered Accountants

For and on behalf of the Board of Directors

Ashok Majethia
Proprietor
Membership No.:124781
UDIN: 22124781AJVSHL3146

Satish Kagliwal
Managing Director
DIN No.: 00119601

Jeevanlata Kagliwal
Director
DIN No.: 02057451

Place: Aurangabad
Date: 30th May 2022

Devinder Khurana
Chief Financial Officer

Dhiraj Rathi
Company Secretary

NATH BIO-GENES (INDIA) LIMITED

Nath Bio-Genes (India) Limited

Statement of Profit and Loss for the year ended March 31, 2022

	Note	Year Ended March 31, 2022 Rs. In Lakhs	Year Ended March 31, 2021 Rs. In Lakhs
Revenue from Operations	21	27,836.23	30,756.11
Other Income	22	185.47	166.95
Total Income		**28,021.70**	**30,923.05**
Expenses			
Purchase of stock in trade		355.92	895.50
Production Expenses	23	9,352.61	12,286.48
Changes in Inventories of Finished Goods, Work-in-Progress and Stock in Trade	24	498.64	(2,176)
Employee Benefits Expense	25	2,478.38	2,368.86
Finance Costs	26	1,061.10	881.94
Depreciation Expense	27	308.41	281.59
Other Expenses	28	11,427.10	10,709.78
Total Expenses		**25,482.15**	**25,247.95**
Profit before exceptional item		**2,539.55**	**5,675.11**
Less: Exceptional Items	29	8,878.19	-
Profit after exceptional item before tax		**(6,339)**	**5,675**
Tax Expense			
Income Tax			
- Current Year		234.06	18.86
- Earlier Year		-	20.72
- Earlier Years written back		161.10	-
Deferred Tax Charge		-	69.37
Total Tax Expenses		395.16	108.95
Profit for the Year		**-6,733.80**	**5,566.16**
Other Comprehensive Income			
A. (i) Items that will not be reclassified to Profit and Loss		17.06	-
(ii) Income tax relating to items that will not be reclassified to Profit and Loss		-	-
B. (i) Items that will be reclassified to Profit and Loss		-	-
(ii) Income tax relating to items that will be reclassified to Profit and Loss		-	-
		17.06	**-**
Total Comprehensive Income		**(6,751)**	**5,566.16**
Earnings Per Equity Share [Nominal Value Per Share: Rs. 10 (Previous Year: Rs. 10)]			
Basic and Diluted		**(36)**	**29**

The accompanying Notes are an integral part of these Financial Statements

In terms of our report of even date.

For Ashok R Majethia & Co
Firm Registration No.: 127769W
Chartered Accountants

For and on behalf of the Board of Directors

Ashok Majethia
Proprietor
Membership No.:124781
UDIN: 22124781AJVSHL3146

Satish Kagliwal
Managing Director
DIN No.: 00119601

Jeevanlata Kagliwal
Director
DIN No.: 02057451

Place: Aurangabad
Date: 30th May 2022

Devinder Khurana
Chief Financial Officer

Dhiraj Rathi
Company Secretary

NATH BIO-GENES (INDIA) LIMITED

Statement of Changes in Equity

A. Equity

A. Equity Share Capital

(1) Current reporting period **Amount in Lakhs**

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
1,900	0	0	0	1,900

(2) Previous reporting period

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
1,900	0	0	0	1,900

Statement of Changes in Other Equity for financial year ended on March 31, 2022

B. Other Equity

Particular	Reserves and Surplus							Total
	Capital Reserve	Security Premium Reserve	Capital Redemption Reserve	Debenture Redemption Reserve	General Reserve	Other Comprehensive Income related to employees benefit	Retained Earning	
Balances at the beginning of the year 01.04.2021	1,171.76	13,350.00	62.50	29.75	297.00	-44.75	44,561.23	59,427.48
Changes in the accounting policies or prior period errors	-	-	-	-	-		-	-
Restated balance at the beginning of the year	1,171.76	13,350.00	62.50	29.75	297.00	-44.75	44,561.23	59,427.48
Additions during the Year	-	-	-	-	-	-17.06	-6,733.80	-6,750.86
Total Comprehensive Income for the year	1,171.76	13,350.00	62.50	29.75	297.00	-61.81	37,827.43	52,676.62
Dividends	-	-	-	-	-		380.08	380.08
Transfer to Retained Earnings	-	-	-	-	-		-	-
Balance at the end of the reporting period 31.03.2022	1,171.76	13,350.00	62.50	29.75	297.00	-61.81	37,447.35	52,296.54

Statement of Changes in Other Equity for financial year ended on March 31, 2021

B. Other Equity

Particular	Reserves and Surplus							Total
	Capital Reserve	Security Premium Reserve	Capital Redemption Reserve	Debenture Redemption Reserve	General Reserve	Other Comprehensive Income related to employees benefit	Retained Earning	
Balances at the beginning of the year 01.04.2020	1,171.76	13,350.00	62.50	29.75	297.00	-44.75	38,995.07	53,861.32
Changes in the accounting policies or prior period errors	-	-	-	-	-	-	-	-
Restated balance at the beginning of the year	1,171.76	13,350.00	62.50	29.75	297.00	-44.75	38,995.07	53,861.32
Additions during the Year	-	-	-	-	-	-	5,566.16	5,566.16
Total Comprehensive Income for the year	1,171.76	13,350.00	62.50	29.75	297.00	-44.75	44,561.23	59,427.48
Dividends	-	-	-	-	-		-	-
Transfer to Retained Earnings	-	-	-	-	-		-	-
Balance at the end of the reporting period 31.03.2021	1,171.76	13,350.00	62.50	29.75	297.00	-44.75	44,561.23	59,427.48

NATH BIO-GENES (INDIA) LIMITED

In terms of our report of even date.

For Ashok R Majethia & Co
Firm Registration No.: 127769W
Chartered Accountants

For and on behalf of the Board of Directors

Ashok Majethia
Proprietor
Membership No.:124781
UDIN: 22124781AJVSHL3146

Satish Kagliwal
Managing Director
DIN No.: 00119601

Jeevanlata Kagliwal
Director
DIN No.: 02057451

Place: Aurangabad
Date: 30th May 2022

Devinder Khurana
Chief Financial Officer

Dhiraj Rathi
Company Secretary

Cash Flow Statement for the year ended March 31, 2022

	Year ended March 31, 2022 Rs in Lakhs		Year ended March 31, 2021 Rs in Lakhs	
A. Cash flow from operating activities				
Net profit before tax		**-6,338.65**		**5,675.11**
Adjustments for:				
Depreciation expense	308.41		281.59	
Provision for Gratuity	30.06		-11.70	
Provision for Compansated Absenses	32.53		-17.02	
Interest Expenses / Financial Charge	1,060.70		881.94	
Provision (Reversal of Provision) for Bad Debts	-44.98		-33.67	
Provision (Reversal of Provision) for Advance	8,878.19		-	
Profit on sale/ disposal of fixed assets	-0.41		-1.79	
Loss on sale of fixed assets	0.05		1.38	
Expenses under Other Comprehensive Income	-17.06		-	
Interest income	-109.26		-121.36	
		10,138.22		979.35
Operating profit before working capital changes		**3,799.58**		**6,654.46**
Adjustments for changes in working capital:				
(Increase)/ Decrease in Trade Receivables	2,192.21		-205.81	
(Increase)/ Decrease in Inventories	595.71		-2,199.18	
(Increase)/ Decrease in Loans and Advances	-7,823.31		-2,076.67	
(Increase)/ Decrease in Other Current / Non- Current Assets	-26.39		81.08	
Increase/ (Decrease) in Trade Payables	1,999.22		-2,297.29	
Increase/ (Decrease) in Liabilities and Provisions	1,255.35	-1,807.20	185.08	-6,512.79
Operating profit after working capital changes		**1,992.37**	-	**141.67**
Income Tax paid		-287.74		-30.38
Net cash from operating activities (A)		**1,704.63**		**111.29**
B. Cash flow from investing activities				
Purchase of fixed assets	-110.36		-381.04	
Purchase of Intengible Assets	-1.30		-5.16	
Purchase of Non-Current Investments	-1.55		-5.02	
Sale of tangible assets	7.31		15.28	
Payment for capital assets purchases	-1,990.00		-773.64	
Interest income	109.26	-1,986.64	121.36	-1,028.22
Net cash used in investing activities (B)		**-1,986.64**		**-1,028.22**
C. Cash flow from financing activities				
Interest Expenses	-1,060.70		-881.94	
Dividend Paid	-380.08		-	
Increase / (Decrease) in long term secured loan	1.20		35.33	
Increase / (Decrease) in Short term secured loan	243.12		2,371.55	
Increase / (Decrease) in Short term Unsecured loan	-1,026.20	-2,222.66	115.13	1,640.07
Net cash used in financing activities (C)		**-2,222.66**		**1,640.07**
Net Decrease in Cash and Cash Equivalents (A+B+C)		**-2,504.67**		**723.14**
Cash and cash equivalents at the beginning of the year		2,921.61		2,198.48
Cash and cash equivalents at the end of the year		416.80		2,921.61
Net Decrease in Cash and Cash Equivalents (A+B+C)		**-2,504.81**		**723.13**

MATH BIO-GENES (INDIA) LIMITED

Cash Flow Statement for the year ended March 31, 2022

	Year ended March 31, 2022 Rs in Lakhs	Year ended March 31, 2021 Rs in Lakhs
Cash and cash equivalents comprise of:		
Cash on Hand	4.75	3.45
Bank Balances:		
- In Current Accounts	411.55	917.66
- In term deposit	0.50	2,000.50
Cash and cash equivalents at the end of the year	**416.80**	**2,921.61**

Notes:

1 The above Cash Flow Statement has been prepared under "Indirect Method" set out in Indian Accounting Standard - 7 on "Cash Flow Statements".

2 Figures in brackets indicate cash outgo.

3 Previous year's figures have been regrouped/ rearranged wherever necessary.

As per our report of even date.
For Ashok R Majethia & Co
Firm Registration No.: 127769W
Chartered Accountants

For and on behalf of the Board of Directors

Ashok Majethia
Proprietor
Membership No.:124781
UDIN: 22124781AJVSHL3146

Satish Kagliwal
Managing Director
DIN No.: 00119601

Jeevanlata Kagliwal
Director
DIN No.: 02057451

Place: Aurangabad
Date: 30th May 2022

Devinder Khurana
Chief Financial Officer

Dhiraj Rathi
Company Secretary

NATH BIO-GENES (INDIA) LIMITED

1 General Information

Nath Bio-Genes (India) Limited (CIN L01110MH1993PLC072842) is incorporated under the Companies Act, 1956 with its registered office at Nath House, Nath Road, Aurangabad. The company is engaged in the business of Production, Processing, and Marketing of Hybrid and GM Seeds. The Company has a product range of Field crops, Vegetable crops and Plant Nutrient Supplements. The major Processing Plants are situated at Aurangabad (MS), and Munipalli, Nizamabad (TG). The company has a Pan India presence for sales through an extensive network of distributors.

2 SIGNIFICANT ACCOUNTING POLICIES:

A Basis of Preparation and Presentation

i) The financial statements are prepared on historical cost basis in accordance with applicable Indian Accounting Standards (Ind AS) and on accounting principles of going concern except fixed assets which are measured at fair values. These financial statements have been prepared to comply with all material aspects with the Indian accounting standards notified under section 133 of the Act, (the "Act") read with Rule 7 of the Companies (Accounts) Rules, 2014, and the other relevant provisions of the Act.

ii) Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policies hitherto in use.

iii) All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Act. Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current classification of assets and liabilities.

B REVENUE RECONGNTION

i) Revenue is measured at the fair value of the consideration received or receivable where the ownership and significant risk has been transferred to the buyer.

ii) Interest on overdue debtors is accounted for as and when received, as the collection cannot be ascertained with reasonable certainty.

iii) Sales return are accounted for / provided for in the year in which they pertain to, as ascertained till finalization of the books of account.

iv) Compensation on account of crop quality discounts are accounted for as and when settled.

C PROPERTY, PLANT AND EQUIPMENTS

i) Land and buildings held for use in the production or supply of goods or services, or for administrative purposes, are stated in the balance sheet at deemed cost less and accumulated depreciation. Freehold land is not depreciated.

ii) Properties in the course of construction for production, supply or administrative purposes are carried at cost, less any recognised impairment loss. Cost includes professional fees and, for qualifying assets, borrowing costs capitalised in accordance with the Company's accounting policy. Such properties are classified to the appropriate categories of property, plant and equipment when completed and ready for intended use. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

iii) Furniture and equipment are stated at cost less accumulated depreciation and accumulated impairment losses.

iv) An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised to the standalone statement of profit and loss.

v) Seed Development know how acquired by the compnay is capitalised at the cost of acquisition.

vi) Live stock is stated at cost without any depreciation/ impairment

NATH BIO-GENES (INDIA) LIMITED

D BIOLOGICAL ASSETS

Recognition and measurement

The company recognises the biological asset (agricultural produce) when:

(a) the company controls the asset as a result of past events;

(b) it is probable that future economic benefits associated with the asset will flow to the company; and

(c) the fair value or cost of the asset can be measured reliably

The biological asset are measured at the end of each reporting period at its fair value less costs to sell.

E CAPITAL WORK-IN-PROGRESS

Expenditure related to and incurred during the implementation of the projects is included under Capital Work-in-Progress and the same are capitalized under the appropriate heads on completion of the projects.

F DEPRECIATION / AMORTIZATION

i) Depreciation on tangible Fixed Assets is provided for on basis of useful life specified in Schedule II to the Act.

ii) Intangible assets such as Gene/Seed Development Know-How are amortized in ten equal yearly instalments commencing from the year in which the tangible benefits start accruing to the Company from such assets.

iii) Depreciation is charged as per the provisions of Schedule II to the Act based upon useful life of assets. The useful life is adopted for the purpose of depreciation is as under.

Assets	Useful life year
i) Factory Building	30
ii) Plant & Machineries	15
iii) Laboratory Equipment	10
iv) Agricultural Equipment's	15
v) Office Equipment's	15
vi) EDP Equipment's	3
vii) Furniture & Fixture	10
viii) Motor Car & Light Vehicle	8

G IMPAIRMENT

Assessment is done at each Balance Sheet date as to whether there is any indication that an asset may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each Balance Sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

H RESEARCH AND DEVELOPMENT EXPENDITURE:

The research expenditure incurred is charged off to the Statement of Profit & Loss.

I INVENTORIES:

i) Inventories comprise of Unprocessed seeds, Under- Processed Seeds, Processed Seeds, Packing Material and traded goods. Inventories are valued at the lower of cost or the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost is determined on Weighted Average basis. Cost includes all charges in bringing the goods to their present location and condition and receiving charges.

ii) The cost of Under-Processed Seeds and Processed Seeds comprises of lease rental, direct labour, other direct costs and related production overheads. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

NATH BIO-GENES (INDIA) LIMITED

J FOREIGN CURRENCY TRANSACTIONS:

i) Transactions in foreign currency are recorded at the rate prevailing on the date of the transaction.

ii) Current Assets and Current Liabilities in foreign currency outstanding as at the year-end are stated at the rates of exchange prevailing at the close of the year. The resultant gains/losses of the year are recognized in the Statement of Profit and Loss.

K GOVERNMENT GRANTS

i) Grants are accounted for where it is reasonably certain that the ultimate collection will be made.

ii) Grants relating to Fixed Assets in the nature of Project Capital Subsidy are credited to Capital Reserve.

iii) Others are credited to Statement of Profit and Loss.

L EMPLOYEES BENEFITS:

Liability as at the year end in respect of retirement benefits is provided for and/ or funded and charged to Statement of Profit and Loss as follows:

i) Provident Fund / Family Pensions:

At a percentage of salary/wages for eligible employees.

ii) Retirement benefit costs and termination benefit

The Company determines the present value of the defined benefit obligation and recognizes the liability or asset in the balance sheet.

The present value of the obligation is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each year

Defined benefit costs are composed of:

(a) service cost – recognized in profit or loss; service cost comprises (i) current cost which is the increase in the present value of defined benefit obligations resulting from employee service in the current period, (ii) past service cost which is the increase in the present value of defined benefit obligations resulting from employee service in the prior periods resulting from a plan amendment, and (iii) gain or loss on settlement.

(b) remeasurements of the liability or asset - recognized in other comprehensive income.

(d) remeasurements of the liability or asset essentially comprise of actuarial gains and losses (i.e. changes in the present value of defined benefit obligations resulting from experience adjustments and effects of changes in actuarial assumptions).

Short-term benefits: A liability is recognised for benefits accruing to employees in respect of wages and salaries, annual leave and sick leave and other short term benefits in the period the related service is rendered at the undiscounted amount of the benefits expected to be paid in exchange for that service.

Other long-term benefits: Liabilities recognised in respect of other long-term employee benefits are measured at the present value of the estimated future cash outflows expected to be made by the Group in respect of services provided by employees up to the reporting date.

iii) Bonus

The company recognises a liability and expense for bonus. The company recognises a provision where contractually obliged or where there is past practice that has created a constructive obligation.

M BORROWING COST

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use. All other borrowing costs are recognised in the Statement of Profit and Loss in the period in which they are incurred. The Company determines the amount of borrowing costs eligible for capitalisation as the actual borrowing costs incurred on that borrowing during the period less any interest income earned on temporary investment of specific borrowings pending their expenditure on qualifying assets, to the extent that an entity borrows funds specifically for the purpose of obtaining a qualifying asset. In case if the Company borrows generally and uses the funds for obtaining a qualifying asset, borrowing costs eligible for capitalisation are determined by applying a capitalisation rate to the expenditures on that asset. The Company suspends capitalisation of borrowing costs during extended periods in which it suspends active development of a qualifying asset

NATH BIOGENES (INDIA) LIMITED

N AGRICULTURAL ACTVITIES

i) Income from the agricultural activities is accounted for up to the stage of dispatch of goods by the Company to the customer after processing.

ii) Expenses which are directly related to the agricultural activities have been accounted for in the books of account under the Production Expenses. Expenses which are not related to the specific activities are allocated on the basis of turnover (net of return and Schemes & Discounts) of Agricultural activities and Trading activities.

O EARNING PER SHARE

Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Earnings considered in ascertaining the Company's earnings per share is the net profit for the year attributable to equity share holders. The weighted average number of equity shares outstanding during the year and for all years presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares, that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year is adjusted for the effects of all dilutive potential equity shares.

P TAXATION

INCOME TAX

Provision for Current Tax is made and retained in the accounts on the basis of estimated tax liability as per applicable provisions of Income Tax Act 1961.

DEFERRED TAX

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered

Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet when it is highly probable that future economic benefit associated with it will flow to the Company.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Current and deferred tax for the period

Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognized in other comprehensive income or directly in equity respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.

The Company recognises interest levied and penalties related to Income Tax assessments in the tax expanse.

NATH BIO-GENES (INDIA) LIMITED

Q USE OF ESTIMATES

The preparation of Financial Statements requires estimates and assumptions to be made that affect the reported amounts of assets and liabilities on the date of Financial Statements and the reported amounts of revenues and expenses during the reporting period. Difference between the actual results and the estimates are recognised in the period in which the results are known/ materialised.

R PROVISION AND CONTINGENT LIABILITIES

Provisions: Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

Contingent Liabilities : Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

S CASH AND CASH EQUIVALENTS

In the Cash Flow Statement, cash and cash equivalents includes cash on hand, demand and short term deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

T FINANCIAL ASSETS AT AMORTISED COST

Financial assets are subsequently measured at amortised cost if these financial assets are held within a business whose objective is to hold these assets in order to collect contractual cash flows and contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

U FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

Financial assets are measured at fair value through other comprehensive income if these financial assets are held within a business whose objective is achieved by both collecting contractual cash flows and selling financial assets and a contractual terms of the financial assets give rise on the specified dates to cash flows that are solely payment of the principal and interest on the principal amount outstanding.

V FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

Financial assets are measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income on initial recognition. The transaction costs directly attributable to the acquisition of assets and liabilities at fair value through profit and loss are immediately recognised in the statement of profit and loss.

W FINANCIAL LIABILITIES

Financial liabilities are measured at amortised cost using the effective interest method, if tenure repayment of such liability exceeds one year.

X EQUITY INSTRUMENTS

An equity instrument is a contract that evidences residual interest in the assets of the company after deducting all of its liabilities. The Company recognises equity instruments at proceeds received net off direct issue cost.

NATH BIOGENES (INDIA) LIMITED

Y RECLASSIFICATION OF FINANCIAL ASSETS

The Company determines classification of the financial assets and liabilities on initial recognitions. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the company's operations. Such changes are evident to external parties. A change in the business model occurs when a company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognized gains, losses (including impairment gains and losses) or interest.

Z OFFSETTING OF FINANCIAL INSTRUMENTS

Financial assets and liabilities are offset and the net amount is reported in the Balance Sheet if there is currently enforceable legal right to offset the recognized amounts and there is on intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

AA LEASES :

Leases in which a substantial portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments and receipts under such leases are recognised to the Statement of Profit and Loss on a straight-line basis over the term of the lease unless the lease payments to the lessor are structured to increase in line with expected general inflation to compensate for the lessor's expected inflationary cost increases in which case the same are recognised as an expense in line with the contractual term.

NATH BIO-GENES (INDIA) LIMITED

NOTE No 3

PROPERTY, PLANT & EQUIPMENT FOR THE YEAR ENDED 31.03.2022

Amount in Lakhs

SR. NO.	PARTICULARS	GROSS BLOCK			AS AT 31.03.2022	DEPRECIATION / AMORTISATION				NET BLOCK	
		AS AT 01.04.2021	ADDITION DURING THE YEAR	DEDUCTION DURING THE YEAR		AS AT 01.04.2021	FOR THE YEAR	DEDUCTION	AS AT 31.03.2022	AS AT 31.03.2022	AS AT 01.04.2021
(A)	**TANGIBLE ASSETS**										
1	Freehold Land	22,210.73	-	-	22,210.73	-	-	-	-	22,210.73	22,210.73
		-	-	-							
2	Factory Building	310.22	2.61	-	312.83	190.27	5.75	-	196.02	116.81	119.95
		-	-	-							
3	Live Stock	1.08	-	-	1.08	-	-		-	1.08	1.08
		-	-	-							
4	Plant & Machineries	1,075.32	42.69	0.06	1,117.95	687.41	38.41	0.06	725.75	392.20	387.91
5	Laboratory Equipment	191.80	-	-	191.80	143.70	3.38	-	147.08	44.72	48.10
6	Agricultural Equipment's	88.85	14.80	0.02	103.63	12.90	6.11	0.02	18.99	84.64	75.95
7	Office Equipment's	52.72	10.85	-	63.57	27.34	2.96	-	30.29	33.27	25.38
		-	-	-		-	-	-			
8	EDP Equipment's	314.99	10	0.82	323.88	277.92	19.15	0.80	296.27	27.61	37.07
		-		-				-			
9	Furniture	121.36	13.54	48.25	86.66	69.89	6.19	48.25	27.83	58.83	51.48
		-						-			
10	Motor Car & Light Vehicle	759.67	16.16	61.36	714.47	386.63	65.91	54.44	398.10	316.37	373.05
	TOTAL (A)	**25,126.75**	**110.36**	**110.52**	**25,126.59**	**1,796.05**	**147.86**	**103.58**	**1,840.34**	**23,286.25**	**23,330.69**
(B)	**INTANGIBLE ASSETS**										
	Seed Development Know How	1,595.90	-	-	1,595.90	239.59	159.59	-	399.18	1,196.72	1,356.31
	Brands	0.67	-		0.67	0.13	0.07	-	0.20	0.47	0.54
	Software	5.16	1.30		6.46	0.13	0.89		1.02	5.44	5.03
	TOTAL (B)	**1,601.73**	**1.30**	**-**	**1,603.03**	**239.85**	**160.55**	**-**	**400.40**	**1,202.62**	**1,361.88**
	TOTAL (A) + (B)	**26,728.48**	**111.66**	**110.52**	**26,729.62**	**2,035.91**	**308.41**	**103.58**	**2,240.74**	**24,488.88**	**24,692.57**
	Previous Year	**26,490.16**	**386.20**	**147.88**	**26,728.48**	**1,887.33**	**281.59**	**133.01**	**2,035.91**	**24,692.57**	
											-

Notes:

1. Freehold land purchased from a related party, admeasuring 75.76 Hectares (Previous year : 57.77 Hectares) is yet to be registered in the name of Company with the Sub-Registrar of the land registry.
2. The company has purchased 2 industrial plots totally admeasuring 11190.34 Sq meter in Paithan Mega Food Park, Tal. Paithan, Dist. Aurangabad for future expansion of the processing plant for which the registry in the name of Company with the Sub-Registrar is pending.

3. The Company has not revalued its Property, Plant and Equipment (including Right-of-Use Assets) or its intengible assets during the year.

4. There is capital work in progress at the year end.

MATH BIO-GENES (INDIA) LIMITED

	As at March 31, 2022 Rs. In Lakhs	As at March 31, 2021 Rs. In Lakhs
4 NON CURRENT INVESTMENTS		
UNQUOTED; AT COST; NON-TRADE		
Nath Cooperative Society	0.40	0.38
(40,000 (Previous year : 37600) equity shares of Rs. 10 each)	-	-
	-	-
Equity Shares of Jankalyan Co-Op Bank	5.00	5.00
(50,000 equity shares of Rs. 10 each)	-	-
	-	-
UNQUOTED; AT COST; TRADE	-	-
Investment in Associate Company holding 19.98% (Previous year: 19.98%) in the paid up share capital of the investee company	-	-
Equity shares in Paithan Mega Food Parks Pvt Ltd (49,94,000 Equity shares of Rs. 10 each)	499.40	499.40
	-	-
Investment in foreign Joint Venture LLC (Refer note 4.1)	1.52	-
	506.33	**504.78**

4.1 The joint venture company in the name of Nath Bio-Genes (Central Asia) LLC with is setup at NMTP Hududi, Qurbon, Rajabov, Paxtachi District Samarkand redion, Uzbekistan with a view to carry out research & development, production, processing of agricultural seeds activities.

5 OTHER NON-CURRENT ASSETS		
[Unsecured, Considered Good]		
Security Deposits	68.59	23.50
Capital Advances	2,110.00	120.00
	2,178.59	**143.50**
6 INVENTORIES		
Stores and Packing Materials	611.83	708.91
Processed Seeds	18,972.41	20,303.37
Unprocessed Seeds	1,622.34	557.43
Seed (Traded Stock)	400.63	177.15
Plant Nutrient Supplement	427.06	883.13
	22,034.28	**22,629.99**
7 TRADE RECEIVABLES		
Secured Loan	959.32	519.76
Others	8,198.51	10,740.32
Less: Allowances bad and doubtful debts	-365.79	-320.81
	8,792.04	**10,939.27**

7.1 Trade Receivables ageing schedule

Pariculars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	more than 3 years	
i) Undisputed Trade receivables – considered good	2,977.79	5,007.61	352.88	453.76	-	8,792.04
ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	231.64	231.64
iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	134.16	134.16
Total	2,977.79	5,007.61	352.88	453.76	365.79	9,157.83

NATH BIO-GENES (INDIA) LIMITED

7.2 Movement in the allowances for doubtful debts

Particulars		
Opening provision	320.81	287.14
Add: Allowances made during the year	44.98	33.71
Less: Written off during the year	-	0.04
Closing Provision	365.79	320.81

7.3 Trade receivables from the Related parties including Directors	-	-

8 CASH AND CASH EQUIVALENTS

Cash on Hand	4.75	3.45
(includes $3273 (Previous year$ 806 and S'OM	-	-
12,64,000)	-	-
Bank Balances in Current Account	411.55	917.66
	416.30	**921.11**
Other Bank Balances		
- Fixed Deposits with original maturity more than 3 months but less than 12 months	-	2,000.00
- Fixed Deposits with original maturity less than 3 months but less than 12 months	-	-
- Lien Marked in favour of APMC, Armoor	0.50	0.50
	0.50	**2,000.50**
	416.80	**2,921.61**

9 OTHER CURRENT FINANCIAL ASSETS
[Unsecured, Considered Good]

Advances against seed production	22,122.15	14,971.78
Less: Provision for doubtful advances	-8,878.19	-
Advances to a related parties	1,221.85	538.06
Advances against purchase	376.56	507.91
Advances to Staff	176.86	56.37
	15,019.23	**16,074.11**

10 CURRENT TAX ASSETS (NET)

Income tax MAT Entitlement	411.03	682.81
Balances with Income Tax department	277.64	277.64
	688.67	**960.46**

11 OTHER CURRENT ASSETS
[Unsecured, Considered Good]

VAT Receivable	-	19.81
GST Receivable	258.44	253.12
Less: Provision for ITC on exempt goods / services	-231.91	-219.54
Prepaid Expenses	34.80	27.97
Interest and other receivable	4.67	3.36
	66.01	**84.71**

NATH BIO-GENES (INDIA) LIMITED

12 SHARE CAPITAL

Authorised Share Capital	As at March 31, 2022 No. of Shares In Lakhs	Amount	As at March 31, 2021 No. of Shares In Lakhs	Amount
Equity Shares of Rs.10 each	205.00	2,050.00	205.00	2,050.00
16% Cumulative Redeemable Preference Shares of Rs.100 eac	0.50	50.00	0.50	50.00
	205.50	2,100.00	205.50	2,100.00
Issued, Subscribed and Paid up				
Equity Shares of Rs.10 each	190.04	1,900.40	190.04	1,900.40
	190.04	**1,900.40**	**190.04**	**1,900.40**

(a) Reconciliation of Number of Shares

	As at March 31, 2022 No. of Shares In Lakhs	Amount	As at March 31, 2021 No. of Shares In Lakhs	Amount
Equity Shares:				
Balance as at the beginning of the year	190.04	1,900.40	190.04	1,900.40
Add: Shares issued during the year	-	-	-	-
Add: Bonus Shares issued during the year	-	-	-	-
Balance as at the end of the year	190.04	1,900.40	190.04	1,900.40

(b) Rights, Preferences and Restrictions attached to Shares

The Company has one class of equity shares having a par value of Rs. 10 per share. Equity shareholder is eligible for one vote per share held. They are eligible for dividend on the basis of their shareholding. In the case of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding.

(c) Details of Shares held by Shareholders holding more than 5% of the aggregate shares in the Company

	As at March 31, 2022 No. of Shares lakhs	% holding	As at March 31, 2021 No. of Shares lakhs	% holding
Equity Shares				
a) Akash Farms LLP	15.10	7.95	20.42	10.75
b) Ashu Farms LLP	20.88	10.99	20.88	10.99
c) Agri-Tech India Ltd	13.22	6.96	13.18	6.93
d) Aditya Birla Sunlife Mutual Fund	-	-	11.88	6.25
e) Authum Investment and Infrastructure Limited	27.16	14.29	28.59	15.04
			-	

d) Promoters shareholding

Shares held by promoters at the end of the year				% change during the year
Sr No	Promoter Name	No of Shares in lakhs	% of total shares	
1	Ferry Fax Farms Private Limited	3.08	1.62	0.00
2	Nath Biotechnologies Ltd	1.01	0.53	0.00
3	Barkha Farms Private Limited	3.54	1.86	0.00
4	Nath Royal Ltd	4.95	2.60	0.17
5	Tingli Finvest Pvt Ltd	5.62	2.96	0.00
6	Prabha Farms Private Limited	0.75	0.40	0.00
7	Paresh Farms Private Limited	0.00	0.00	0.00
8	Pithambar Farms Private Limited	2.50	1.32	0.00
9	Ashu Farms LLP	20.88	10.99	0.00
10	Akash Farms LLP	15.10	7.95	-2.80
11	Arati Farms Private Limited	2.03	1.07	0.00
12	Agri Tech India Limited	13.22	6.96	0.03
13	Jeevan Investment & Finance Pvt Ltd	0.00	0.00	0.00
14	Nath Industries Limited	5.32	2.80	2.80
12	Nandkishor Laxminarayan Kagliwal	0.00	0.00	0.00
13	Jeevantlata Nandkishor Kagliwal	0.00	0.00	0.00
	Total	**78.02**	**41.06**	**0.20**

NATH BIO-GENES (INDIA) LIMITED

	Year Ended March 31, 2022 Rs. In Lakhs	Year Ended March 31, 2021 Rs. In Lakhs
13 OTHER EQUITY		
Capital Reserve	1,171.76	1,171.76
Securities Premium Reserve	13,350.00	13,350.00
Capital Redemption Reserve	62.50	62.50
Debenture Redemption Reserve	29.75	29.75
General Reserve	297.00	297.00
OCI - Employee Benefit	-61.81	-44.75
Retained Earnings	37,447.35	44,561.23
	52,296.54	59,427.48
14 NON- CURRENT FINANCIAL LIABILITIES - BORROWINGS		
SECURED LOANS	-	-
Term Loan against Vehicles	66.48	65.28
14.1 Secured by hypothecation of vehicles purchased in the name of company/ directors of the company.		
14.2 The loan is repayable within a period ranging from one to five years		
	66.48	65.28
15 NON-CURRENT PROVISIONS		
PROVISIONS FOR EMPLOYEE BENEFITS		
Gratuity	183.92	200.54
Compensated Absence	77.14	56.92
	-	-
	261.06	257.46
16 CURRENT FINANCIAL LIABILITIES - BORROWINGS		
SECURED		
From Consortium of Banks	8,970.08	8,643.68
16.1 Secured by way of hypothecation of stock of seeds and trade receivables; collaterally secured by way of mortgage of land admeasuring 20503.544 Sq. meter and building thereupon situated at Gut No 64/2 (part) Itkeda, Aurangabad. Also personally guaranteed by two promoters of the Company.	-	-
	-	-
Current maturities of long term debts : Vehicle Loan	70.91	154.19
	-	-
UNSECURED	-	-
Inter-corporate loans from a related party	-	1,013.76
Loans from Others	188.39	200.97
	9,229.38	10,012.60

NATH BIO-GENES (INDIA) LIMITED

	As at March 31, 2022 Rs. In Lakhs	As at March 31, 2021 Rs. In Lakhs
17 TRADE PAYABLE		
Sundry Creditors - SME Sector	51.05	62.20
Sundry Creditors for Seeds/Supplies	4,227.12	2,257.39
Sundry Creditors for staff balances	931.49	865.25
Others Creditors	299.08	324.68
	5,508.74	3,509.52

17.1 Trade Payables ageing schedule

Pariculars	Unbilled Dues	Outstanding for following periods from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 yea	
i) MSME	0.00	51.05	0.00	0.00	0.00	51.05
ii) Others	2210.84	3092.67	34.05	97.28	22.87	5457.70
iii) Disputed dues- MSME	0.00	0.00	0.00	0.00	0.00	0.00
iv) Disputed dues - Others	0.00	0.00	0.00	0.00	0.00	0.00
Total	2210.84	3143.71	34.05	97.28	22.87	5508.74

18 OTHER CURRENT LIABILITIES		
Deposits from Dealers	636.44	592.53
Credit Balance in Debtors accounts	1,580.82	489.76
Statutory Liabilities	130.16	189.90
Advance against Sales	2,383.73	2,203.62
	4,731.15	3,475.81

19 PROVISIONS		
Provisions for Employee Benefits		
Gratuity	84.04	37.36
Compensated Absences	24.29	11.98
	108.33	49.34

20 CURRENT TAX LIABILITIES (NET)		
Income tax payable	88.74	-
Income Tax (MAT)	-	253.11
	88.74	253.11

NATH BIO-GENES (INDIA) LIMITED

	Year Ended March 31, 2022 Rs. In Lakhs	Year Ended March 31, 2021 Rs. In Lakhs
21 REVENUE FROM OPERATIONS:		
Sale of Agriculture Produce		
Commercial Seeds	25,430.41	26,606.91
	25,430.41	26,606.91
Sale of Traded Goods		
Plant Nutrient Supplements	1,536.95	3,063.03
Vegetable Seeds	747.18	896.57
	2,284.13	3,959.60
Other Operating Revenue:		
Remnant	107.23	158.22
Farm Produce Sale	14.28	9.72
Export incentives	0.18	21.66
	121.69	189.60
	27,836.23	**30,756.11**
Crop Wise sale:-	**Rs in Lakhs**	**Rs in Lakhs**
Paddy	7,884.29	9,760.21
Cotton	8,472.66	8,618.28
Maize	973.13	842.35
Bajra	1,913.34	1,739.22
Mustard	2,259.78	1,212.12
Vegetables	2,878.91	3,586.81
Plant Nutrient Supplement	1,536.95	3,063.53
	27,714.54	**30,566.51**
22 OTHER INCOME		
Interest Received	109.26	121.36
Dividend Received	0.06	-
Profit on Sale of Fixed Assets	0.41	1.79
Insurance claim received	13.68	6.77
Foreign Exchange gain	5.91	-
Excess Provision W/back	46.42	30.03
Other Miscellaneous Income	9.73	7.00
	185.47	**166.95**
23 PRODUCTION EXPENSES	-	-
Seed Production Expenses	8,511.89	11,081.85
Lease Rent for agricultural land **{Also refer note no 41(ii)}**	840.72	1,204.63
	9,352.61	**12,286.48**
24 CHANGES IN INVENTORIES		
Closing Stock		
Processed Seeds	18,972.41	20,303.37
Unprocessed Seeds	1,622.34	557.43
Seed (Traded)	400.63	177.15
Plant Nutrient Supplement	427.06	883.13
	21,422.44	**21,921.08**
Opening Stock		
Processed Seeds	20,303.37	18,295.78
Unprocessed Seeds	557.43	1,004.40
Seed (Traded)	177.15	99.15
Plant Nutrient Supplement	883.13	345.55
	21,921.08	**19,744.88**
	-498.64	**2,176.21**

NATH BIO-GENES (INDIA) LIMITED

	Year Ended March 31, 2022 Rs. In Lakhs	Year Ended March 31, 2021 Rs. In Lakhs
25 EMPLOYEE BENEFITS EXPENSE		
Salaries, Wages and Bonus	2,142.18	1,962.51
Contribution to Provident and Other Funds	108.39	102.20
Staff Welfare Expenses	28.69	23.45
Staff Incentives	199.13	280.70
	2,478.38	**2,368.86**
26 FINANCE COSTS		
Interest Expenses	1,012.52	790.24
Processing Charges	48.57	91.70
	1,061.10	**881.94**
27 DEPRECIATION EXPENSE		
Depreciation on Tangible Assets	147.86	121.80
Amortisation of Intangible Assets	160.55	159.79
	308.41	**281.59**
28 OTHER EXPENSES		
A. Seed Conditioning Expenses		
Freight Inward	147.61	190.83
Labour Wages	248.20	285.66
Stores and Processing Materials consumed	1,204.85	1,473.75
Power and Fuel	106.99	123.23
Repairs and Maintenance (Machinery)	27.01	44.53
Repairs and Maintenance (Factory Building)	9.59	8.92
Hamali & Cartage - Processing Plant	88.28	111.85
Processing Expenses	282.57	291.52
Other Seed Conditioning Expenses	74.57	73.23
	2,189.67	**2,603.52**
B. Administrative Expenses		
Rent	303.44	307.78
Rates and Taxes	23.96	26.40
Insurance	47.44	40.66
Legal & Professional Expenses	371.00	254.71
Repairs and Maintenance - Office Building	17.85	17.06
Running and maintenance - Vehicle	420.18	386.22
Repairs and Maintenance - Others	33.34	37.72
Communication	35.12	34.41
Printing & Stationery	20.93	16.50
Auditors' Remuneration:	-	-
Statutory Audit Fee	7.00	6.50
Other services	1.10	1.10
Directors' remuneration	48.00	48.00
Foreign Exchange Loss	-	12.33
Loss on sale of fixed assets	0.05	1.38
Miscellaneous Expenses	30.70	13.39
Donation	13.00	25.47
Director Sitting Fees	1.20	1.00
Bank Charges	3.28	4.68
Security Charges	34.35	35.37
Corporate Social Responsibility Expenditure (Refer Note No 48)	99.45	81.07
	1,511.39	**1,351.75**

NATHBIO-GENES (INDIA) LIMITED

	Year Ended March 31, 2022 Rs. In Lakhs	Year Ended March 31, 2021 Rs. In Lakhs
C. Selling Expenses		
Travelling and Conveyance	352.26	309.26
Advertisement and Sales Promotion	163.39	194.29
Field Days, Visits & Campaigns	549.47	710.61
Freight Outward	814.55	808.94
Commission	5.56	1.26
Other selling expenses	96.26	95.70
Provisions for Bad Debts	44.98	33.67
Bad debts written off	-	0.04
Sundry debit balances written off	0.75	8.05
	2,027.22	**2,161.81**
D. Discount, Schemes and Incentives		
Cash Discounts	399.63	367.96
Quantity Discounts	2,991.63	1,961.95
Additional Discount	1,419.04	1,347.37
	4,810.30	**3,677.29**
E. Research and Development Expenses		
Fieldwork Expenses	13.65	35.59
Laboratory Expenses	2.29	-
Salary, Wages and Other Expenses	560.72	621.27
Travel and Vehicle maintenance	44.97	33.63
Farm Lease Rent	35.16	34.27
Farming Expenses & Consumables	174.05	166.83
Membership and Meetings	57.67	23.82
	888.52	**915.41**
Total (A+B+C+D+E)	**11,427.10**	**10,709.78**

29 Exceptional Item

Provision for farmer/ grower advances	8,878.19	
	8,878.19	-

29.1 The company has provided for doubtful advances given to various farmer/ growers during the last few years against which agricultural produce was expected to be received. However due to erratic climatic conditionprevailing in some parts of the country during last few years as also due to outbreak of covid 19, the farmers/growers could neither provide agricultural produced nor could return the advances to the company. The company has been continuously following up for supply of agricultural produce or return of advances. However, being doubtful of recovery, the management thought it expedient to provide for the same.

NATH BIO-GENES (INDIA) LIMITED

30 Fair Value Measurement

Amount in Lakhs

Particular	Carrying Amount		Fair Value	
	as at 31st March 2022	as at 31st March 2021	as at 31st March 2022	as at 31st March 2021
FINANCIAL ASSETS				
Financial Assets measured at amortised cost				
a) Non-Current Investment	506.33	504.78	506.33	504.78
b) Security Deposits	68.59	23.50	68.59	23.50
c) Trade Receivable	9,157.83	11,260.09	9,157.83	11,260.09
d) Cash on hand	4.75	3.45	4.75	3.45
e) Bank Balance	412.55	2,918.16	412.55	2,918.16
f) Advances to a related parties	1,221.85	538.06	1,221.85	538.06
g) Advances against seed production	22,122.15	14,971.78	22,122.15	14,971.78
h) Advances against purchase	376.56	507.91	376.56	507.91
i) Advances to Staff	176.86	56.37	176.86	56.37
j) Balances with Income Tax department	688.67	960.46	688.67	960.46
FINANCIAL LIABILITIES				
Financial Liabilities measured at amortised cost				
a) Non- Current Borrowings	66.48	65.28	66.48	65.28
b) Current Borrowings	9,229.38	10,012.60	9,229.38	10,012.60
c) Trade Payable	5,508.74	3,509.52	5,508.74	3,509.52
d) Other Payables	4,094.72	2,883.28	4,094.72	2,883.28

NATH BIO-GENES (INDIA) LIMITED

The management assessed that the fair values of short term financial assets and liabilities significantly approximate their carrying amounts largely due to the short term maturities of these instruments. The fair value of financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction among willing parties, other than in a forced or liquidation sale

The Company determines fair values of financial assets and financial liabilities by discounting contractual cash inflows/ outflows using prevailing interest rates of financial instruments with similar terms. The fair value of investment is determined using quoted net assets value from the fund. Further, the subsequent measurement of all finance assets and liabilities (other than investment in mutual funds) is at amortized cost, using the effective interest method.

Discount rates used in determining fair value

The interest rate used to discount estimated future cash flows, where applicable, are based on the incremental borrowing rate of the borrower which in case of financial liabilities is the weighted average cost of borrowing of the Company and in case of financial assets is the average market rate of similar credits rated instrument.

The Company maintains policies and procedures to value financial assets or financial liabilities using the best and most relevant data available. In addition, the Company internally reviews valuation, including independent price validation for certain instruments.

Fair value of financial assets and liabilities is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

The following methods and assumptions were used to estimate fair value:-

a) Fair value of short term financial assets and liabilities significantly approximate their carrying amounts largely due to the short term maturities of these instruments.

b) The fair value of the Company's interest borrowing received are determined using discount rate reflects the entity's borrowing rate as at the end of the reporting period. The own non performance risk as at the end of reporting period was assessed to be insignificant.

Fair value hierarchy

All financial instruments for which fair value is recognized or disclosed are categorized within the *fair* value hierarchy described as follows, based on the lowest level input that is significant to the fair value measurement as a whole.

Level -1
Quoted (unadjusted) price is active market for identical assets or liabilities

Level 2:
Valuation technique for which the lowest level input that has a significant effect on the fair value measurement are observed, either directly or indirectly.

Level 3
Valuation technique for which the lowest level input has a significant effect on the fair value measurement is not based on observation market data.

31 Financial Instruments and Risk Review

i) Capital Management

The Company's capital management objectives are:-

The Board policy is to maintain a strong capital base so as to maintain inventor, creditors and market confidence and to future development of the business. The Board of Directors monitors return on capital employed.

The Company manages capital risk by maintaining sound/optimal capital structure through monitoring of financial ratios, such as debt-to-equity ratio and net borrowings-to-equity ratio on a monthly basis and implements capital structure improvement plan when necessary.

The Company uses debt ratio as a capital management index and calculates the ratio as Net debt divided by total equity. Net debt and total equity are based on the amounts stated in the financial statements.

Debt-to-equity ratio is as follows

Amount in Lakhs

Particular	**as at 31st March 2022**	**as at 31st March 2021**
Net Debts (A) *	8,372.73	6,651.50
Equity (B) **	54,196.94	61,327.88
Debt Ratio % (A/B)	15.45	10.85

* Net Debts includes Non-Current borrowings, Current borrowings, Current Maturities of non current borrowing net off Current Investment and cash and cash equivalent

** Equity Include Paid up Share Capital and Other Equity.

ii) Credit Risk

Credit risk is the risk of financial loss arising from counter-party failure to repay or service debt according to contractual terms or obligations. Credit risk encompasses both, the direct risk of default and the risk of deterioration of credit worthiness as well as concentration of risks. Credit risk is controlled by analysing credit limit and creditworthiness of customers on a continuous basis to whom the credit has been granted offer necessary approvals for credit.

Financial instruments that are subject to concentration of credit risk principally consists of trade receivable investments, derivative financial instruments and other financial assets. None of the financial instruments of the Company results in material concentration of credit risk

Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is as under, being the total of the carrying amount of balances with trade receivables and advances for seed production

As on	**Amount in Lakhs**
31st March, 2022	30,914.19
31st March, 2021	25,911.05

Trade receivables

Ind AS requires expected credit losses to be measured through a loss allowance. The Company assesses at each date of financial statement whether a financial asset or group of financial assets is impaired. The Company recognizes lifetime expected losses for all contract assets and / or all trade receivables that do not constitute a financing transaction. For all other financial assets, expected credit losses are measured at an amount equal to 12 months expected credit losses or at an amount equal to the life time expected credit losses, if the credit risk on the financial asset has increased significantly since initial recognition

MATH BIO-GENES (INDIA) LIMITED

Before accenting any new customer, the Company uses an external/internal credit scoring system to asses potential customer's credit quality and defines credit limits by customer. Limits and scoring attributed to customer are reviewed periodic basis

iii) Liquidity Risk

a) Liquidity risk management

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

b) Maturities of financial liabilities

The following tables detail the remaining contractual maturities for its financial liabilities with agreed repayment period. The amount disclosed in the tables have been draw up based on the undiscounted cash flow of financial liabilities based on the earliest date on which the Company can be required to pay. The table includes both interest and principal cash flows.

Amount In Lakhs

Particular	31st March 2022		31st March 2021	
	Less than 1 year	More than 1 year	More than 1 year	Less than 1 year
Financial Liabilities				
Trade Payables	5,354.55	154.19	3,503.76	5.76
Working capital demand Loan	8,970.08	-	8,643.68	-
Loan/Term Loan (at variable rate)	259.30	66.48	266.26	154.19
Total	**14,583.93**	**220.67**	**12,413.70**	**159.95**

c) Maturities of financial assets

The expected maturity for financial assets of the company are all current.

iv) Market Risk

Market risk is risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the market prices. Such changes in the value of financial instruments may result from changes in the foreign currency exchange rate, interest rate, credit, liquidity and other market changes.

NATH BIO-GENES (INDIA) LIMITED

			Current Year Lakhs	Previous Year Lakhs
32		**Contingent liabilities not provided for in respect of:-**		
	a)	Claims against the Company not acknowledged as debts in respect of legal cases including consumer cases.	166.80	142.95
	b)	Corporate Guarantee given in favour of IDBI Bank and Janakalyan Sahakari Bank towards term loan taken by Paithan Mega Food Park Pvt Ltd, (PMFPPL) a related company. The liability of the PMFPPL is Lakhs. 2160 Lakhs as on the year end. Further, promotors of PMFPPL have pledged their equity shares in favour of the company securing the above corporate guarantee.	4,360.00	4,360.00
	c)	Demand of Income tax for disallowing research and development expenses for the assessment year 2012-13, 2013-14 and 2014-15	5.79	5.79
	d)	Demand of Income tax for disallowing agricultural income for the assessment year 2017-18 and 2018-19 (Previous Year - 2017-18)	1,532.07	1,532.07
33		Estimated value of contract remaining to be executed on capital account and not provided for (Net of advances of Lakhs. 21100.00 Previous year Rs. 120.00)	765.00	200.00

34 In the opinion of the Board, Current and Non-current Assets, Loans and Advances are approximately of the value stated, if realized in the ordinary course of the business.

35 i) Certain accounts of Trade Receivable, Trade Payable, Unsecured Loans, Employees, Loans and Advances (including advances given to growers and inter party transfer & balances) are subject to confirmations and reconciliations, if any. The difference as may be noticed on reconciliation will be duly accounted for on completion thereof. In the opinion of the management, the ultimate difference will not be material.

36 In view of agriculture income earned by the company, which in exempt from Income Tax, existing brought forwarded business losses and unabsorbed depreciation, the company has not recognised deferred tax assets, as a matter of prudence.

37 **Managerial Remuneration:**

	Current Year (Lakh.)	Previous year (Lakh.)
Mr. Satish Kagliwal, Managing Director :-	48.00	48.00
Mr. Devinder Khurana, Chief Financial Officer	65.20	60.18
Mr. Dhiraj Rathi, Company Secretary	5.54	5.08

38 Disclosures as required by the Micro, Small and Medium Enterprises Development Act, 2006 are as under:-

Particulars	**Amount (In Lakhs) Year Ended March 31, 2022**	**Amount (In Lakhs) Year Ended March 31, 2021**
Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	51.05	62.20
Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	1.86	1.82
Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	107.78	164.00
The amount of interest due and payable for the period of making delay payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act	-	-
Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	1.82	8.70
Interest due and payable towards suppliers registered under MSMED Act, for payment already made	1.86	1.82
Further interest remaining due and payable for earlier years	-	-

Note:- This information has been given in respect of such vendors to the extent they could be identified as Micro and Small enterprises on the basis of information available with the Company.

39 The Information related to Segmental Reporting as required to be disclosed in accordance with the Indian accounting standard: '108-operating Segment' are as under:-

(A) Broadly the activity of the company falls within Two segments

Criteria	**Segments**
Product Base	1. Agricultural Activities (Seed Production)
	2. Trading Activities

NATH BIO-GENES (INDIA) LIMITED

(B) The financial data of both segments are as follows

Amount in Lakhs

Sr No	Particulars		Agriculture Activities	Trading Activity	Total
a	Segment Revenue (Net of trade discount, Scheme and discounts)				
i	External Sales/income	CY	21,182.55	1,843.38	23,025.93
		PY	24,065.04	3,013.78	27,078.82
ii	Inter-segment Sale		-	-	-
			-	-	-
iii	Other Income	CY	-	185.47	185.47
		PY	-	136.92	136.92
	Change in inventory	CY	266.05	232.59	498.64
		PY	-1,560.62	-615.58	-2,176.21
iv	Total Revenue	CY	20,916.50	1,796.26	22,712.76
		PY	25,625.67	3,766.28	29,391.95
b	Total Revenue of each segment as a percentage of total revenue of all segment	CY	92.09	7.91	100.00
		PY	87.19	12.81	100.00
	Less: Production Expenses /Purchases	CY	10,350.38	562.99	10,913.38
		PY	13,338.67	1,317.07	14,655.74
	Less: Other Expenses	CY	8,518.53	741.31	9,259.84
		PY	8,079.32	1,011.81	9,091.13
c	Segment Result [Profit/(loss)]	CY	2,047.59	491.96	2,539.55
		PY	4,207.68	1,437.41	5,645.08
d	Segment Result as a percentage of segmental result to the Profit	CY	80.63	19.37	100.00
		PY	74.54	25.46	100.00

(c) CY denotes current year and PY denotes previous year.
(d) The allocation of other expenses as mentioned in (B) (b) above, which are not directly relating to specific activity of production or trading, have been made by the management in the ratio of turnover and relied upon by the auditors.

Geographical Segment:

(Lakhs)

Particulars	Year Ended March 31, 2022			Year Ended March 31, 2021		
	India	Outside India	Total	India	Outside India	Total
Revenue						
External Segment Revenue	27,643.93	192.30	27,836.23	30,611.50	144.61	30,756.11
Total Segment Revenue	**27,643.93**	**192.30**	**27,836.23**	**30,611.50**	**144.61**	**30,756.11**
Other Information						
Carrying Amount of Segment Assets	74,031.29	159.54	74,190.82	78,745.83	205.16	78,951.00
Carrying Amount of Segment Liabilities	19,910.36	83.52	19,993.89	17,423.58	199.54	17,623.12

40 In the opinion of the Board, fixed assets have been stated at cost, which is at least equal to or less than the realizable value if sold in the ordinary course of business. Consequently, the management is of the opinion that there is no impairment of assets.

41 i The company is engaged in agricultural activities of production of seeds on lease hold land situated at various part of India.

ii The company has entered into agreements with various farmers/growers for cultivation and production of agricultural produce in view of the fact that the company itself is unable to carry on such activities which are spread over various parts of India. The company has compensated the production expenses (Refer Note No .23) based upon the agreements entered into with the farmers/ growers.

42 Employee Benefits

The company has classified the various benefits provided to employees as under

Defined Contribution Plans :

During the year, the Company has recognized the following amounts in the Profit & Loss Account

(Lakhs)

		Current Year	Previous Year
-	Employers Contribution to Provident Fund	-5,79,000	96,58,808
-	Employers Contribution to ESI	2,88,942	2,78,481
-	Employers Contribution to Labour Welfare Fund	1,224	3,996

Defined Benefit Plans

The company has neither created fund nor contributed to Scheme framed by the Insurance Company for the defined benefit plans for the qualifying employees. The present value of the defined benefit obligation and the related current service cost were measured using the Projected Unit credit method with actuarial valuations being carried out at each balance sheet date.

In accordance with Indian Accounting Standard 19, actuarial valuation was done in respect of the aforesaid defined benefit plan of gratuity based on the following assumptions: -

Particulars	Current Year	Previous Year
Discount Rate	6.95%	6.95%
Salary escalation rate	6%	6%
Expected rate of return on Plan Assets	-	-
Expected average remaining service of employee in the number of years	-	-

Disclosures for defined benefit plans based on Actuarial Reports as at 31st March 2022

NATHI BIO-GENES (INDIA) LIMITED

a) Change in Present Value of Defined Benefit Obligation

(Lakhs)

Particulars	Current Year	Previous Year
Present value of obligations at the beginning of the year	237.90	249.59
Current Service Cost	30.87	28.62
Liability Transferred in / acquisition	-	-
Past Current Service Cost	-	-
Interest Cost	16.53	17.02
Actuarial (Gain) / Loss due to Change in Demographic Assumptions	3.54	-
Actuarial (Gain) / Loss due to change in financial assumption	1.19	-2.72
Actuarial (Gain) / Loss due to experience	12.33	-46.43
Benefit paid	-34.40	-8.19
Present value of obligations at the end of the year	**267.96**	**237.90**

b) Change in Fair value of plan assets

Particular	Current Year	Previous Year
Fair Value of plan assets at the beginning of the year	-	-
Expected return on plan assets	-	-
Employer's contributions	0	0
Actuarial gain / (loss) on plan assets	-	-
Benefit paid	0	0
Fair value of plan assets at the end of the year	-	-

c) Percentage of each category of plan assets to total fair value of plan assets as at 31st March 2022

Particulars	Current Year	Previous Year
Obligation on the part of the Company	100%	100%

d) Reconciliation of the present value of defined benefit obligations and the fair value of plan assets

Particulars	Current Year	Previous Year
Present value of funded obligations as at the end of the year	267.96	237.90
Fair value of plan assets as at the end of the year	-	-
Funded (Assets)/liability recognized in the Balance Sheet as at the end of the year	-	-
Present value of unfunded (assets) / obligations as at the end of the year	267.96	237.90
Unrecognized past service cost	-	-
Unrecognized actuarial (gain)/loss	-	
Unfunded net (Assets)/liability recognized in the Balance Sheet as at the end of the	**267.96**	**237.90**

e) Net employee benefit expense (Recognized in employment cost) for the year ended on 31st March 2022

Particulars	Current Year	Previous Year
Current Service Cost	30.87	28.62
Interest Cost	16.53	17.02
Expected return on plan assets	-	-
Net Actuarial (Gain) / Loss recognized in the year	13.52	-49.15
Past Service cost	-	-
Net Gratuity (income) / expense	**60.93**	**-3.51**

f) Detail of Present value of obligation, Plan Assets and Experience Adjustments

Particulars	Current Year	Previous Year
Present value of obligation	267.96	237.90
Fair value of plan assets	-	-
(Surplus) / Deficit	267.96	237.90
Experience Adjustment	-	-
(Gain)/ Loss on plan liabilities	-	-
(Gain)/ Loss on plan assets	-	-

g) Expected contributions to Gratuity Fund next year Lakhs. NIL (Previous Year Lakhs. NIL)

h) The liability for leave encashment and compensated absences as at year end is Lakhs. 101.42 (Previous year liability Lakhs. 68.90)

43 Related parties disclosure

List of related parties

a) Associates: -

i) Global Transgenes Ltd.
ii) Agri Tech (India) Ltd.
iii) Paithan Mega Food Parks Pvt Ltd
v) Arati Farms Pvt Ltd

b) Key Management Personnel:-

i) Mr. Satish Kagliwal (Managing Director)
ii) Mr. Devinder Khurana (Chief Financial Officer)
iii) Mr Dhiraj Rathi (Company Secretary)

NATH BIO-GENES (INDIA) LIMITED

d) Transactions carried out with related parties as referred to in (a) to (d) above, in the ordinary course of the business:

Amount in Lakhs

Sr no	Name of party	Nature of transactions	Current year	Previous year
1	Nath Bio-Genes (Central Asia) LLC	Investment made in Capital	1.52	-
		Reimbursement of expenses paid	4.67	-
2	Agri Tech (India) Ltd.	Loan recovered	992.96	892.71
		Transfer (credit to account)	499.28	626.92
		Loan repaid	720.96	401.79
		Transfer (debit to account)	35.59	576.25
		Loan taken	879.73	802.59
		Interest paid	121.91	6.75
		Advance given against purchase of land	1,950.00	-
3	Arati Farms Pvt Ltd	Amount Received	782.01	1,323.96
		Amount Paid	1,334.86	792.56
		Transfer (debit to account)	12.18	6.65
		Transfer (credit to account)	51.01	-
4	Paithan Mega Food Park Pvt Ltd	Warehouse Rent	114.28	114.28
		Advance given against purchase of land	40.00	40.00
		Reimbursement of expenses paid	27.84	29.01
5	Satish Kagliwal	Remuneration	48.00	48.00
7	Devinder Khurana	Remuneration	65.20	60.18
8	Dhiraj Rathi	Remuneration	5.54	5.08

e) Out standing balances at the year end

		as on 31.03.2022 Lakhs	as on 31.03.2021 Lakhs
1	Global Transgenes Ltd.	136.13 Cr	156.09 Cr
2	Agri Tech (India) Ltd. (Loan taken)	0	1013.76 Cr
3	Agri Tech (India) Ltd. (Loan granted)	2303.61 Dr	538.06 Dr
4	Arti Farm Pvt Ltd	868.24 Dr	354.21 Dr
5	Paithan Mega Food Parks Pvt Ltd (advance for purhcase of land)	160.00 Dr	120.. Dr
6	Paithan Mega Food Parks Pvt Ltd (for expenses)	42,309 Cr	2.45 Cr
7	Nath Bio-Genes (Central Asia) LLC	4.67 Dr	0

Notes:

1 Related party relationship is as identified by the Company and relied upon by the Auditors.
2 No amounts in respect of related parties have been written off/back during the year, nor have been provided for as doubtful debts.

44	FOREIGN CURRENCY TRANSACTIONS	Current Year Lakhs	Previous Year Lakhs
	CIF value of Imports: Purchase of Win Chi Win & Vegetable Seeds	-	434.07
		-	-
	Expenditure in Foreign Currency: -	-	-
	Travelling Expenses	12.86	7.72
	Software License Fee	7.56	11.37
	Membership Fee	39.37	5.16
		-	-
		-	-
	Earning in Foreign Currency: F O B value of Exports	192.30	144.61
45	Difference in Foreign Exchange Gain (Loss) included in other income	5.91	-

46 Details related to Investments made, Loans and Advances given and security provided as per section 186 of the Companies Act 2013.

(Lakhs)

Name of the Party	Resolution Passed on	Limit prescribed in resolution	Investment made	Amount outstanding as on 31st March, 2022
Investment	08.08.2016	25,000.00		
Paithan Mega Food Park Pvt. Ltd.			499.40	499.40
Nath Bio-Genes (Central Asia) LLC			1.52	1.52

NATH BIO-GENES (INDIA) LIMITED

(Lakhs)

Name of the Party	Resolution Passed on	Limit prescribed in resolution	Loan granted during the year	Amount outstanding as on 31st March, 2022	Maximum outstanding during the year
Loans and Advances					
	08.08.2016	25,000.00			
Arti Farms Pvt Ltd			1,334.86	868.24	1,168.24
Agritech (India) Ltd.			1,297.67	353.61	353.61
			2,632.54	**1,221.85**	**1,521.85**

(i) In respect of above parties, rate of interest is Nil.

(Lakhs)

Name of the Party	Resolution Passed on	Limit prescribed in resolution	Additional Guarantee granted during the year	Amount outstanding as on 31st March, 2022	Maximum outstanding during the year
Guarantee Given					
	08.08.2016	25,000.00			
IDBI Bank (in favour of Paithan Mega Food Parks Limited)			-	3,000.00	3,000.00
Janakalyan Sahakari Bank (in favour of Paithan Mega Food Parks Limited)			-	1,360.00	1,360.00
				4,360	**4,360**

47 OPERATING LEASE

The Company's significant leasing arrangements are in respect of operating leases for lands and premises (Agricultural lands, office, stores, godown etc.). These leasing arrangements which are cancellable range and are usually renewable by mutual consent on mutually agreeable terms. The aggregate lease rentals payable are charged as rent in the Statement of Profit and Loss.

48 Expenditure on Corporate Social Responsibility Activities

Particulars	Amount in Rs
(a) amount required to be spent by the company during the year,	97.50
(b) amount of expenditure incurred,	99.45
(c) shortfall at the end of the year,	-
(d) total of previous years shortfall,	0
(e) reason for shortfall,	None
(f) nature of CSR activities,	Rural Transformation
(g) details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,	None
(h) where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown separately	None

The company has been engaged in farmers education for imparting farming training in technology, use of upgraded seeds and methodology of seed production etc. In view of this some of such programme undertaken by the Company are classified as CSR activities.

49 The net profit (loss) for the purpose of measurement of basic and diluted earnings per share in terms of Indian Accounting Standard - 33 on Earnings Per Share has been calculated as under:

	Current Year Lakhs	Previous Year Lakhs
Net Profit (loss) as per Profit & Loss Account	-6,750.86	5,566.16
Less :- Dividend on Preference Shares	-	-
Numerator: Profit Available for equity share holders	-6,750.86	5,566.16
Denominator: Weighted Average Number of Equity shares outstanding (no's)	190.04	190.04
Denominator for Diluted equity share holder	190.04	190.04
Basic Earnings per share is arrived at by dividing Numerator by Denominator	-35.52	29.29
Diluted Earnings per share is arrived at by dividing Numerator for diluted equity share holder by Denominator	-35.52	29.29
The nominal value per equity shares is Rupees	10.00	10.00

50 Disclosure of Derivatives:

Particulars	Foreign Currency Denomination	Foreign Currency Amount In USD	Amount (In Lakhs)	Foreign Currency Amount In USD	Amount (In Lakhs)
		March 31, 2022		March 31, 2021	
Assets (Trade Receivables)	USD	2,04,409.00	155.21	2,74,580.00	200.99
Assets (Advance for purchase)	USD	5,700.00	4.33	5,700.00	4.17
					-
Liabilities (Trade Payable)	USD	-	-	1,28,882.00	94.34
Liabilities (Advance against sales)	USD	1,10,000.00	83.52	1,43,716.60	105.20

The foreign currency outstanding has been translated at the rates of exchange prevailing on the Balance Sheet date in accordance with Indian Accounting Standard 21 - "The Effects of Changes in Foreign Exchange".

51 The company has used the borrowings from banks and financial institutions for the purpose for which it was taken at the balance sheet date.

52 The Company does not have any investment property, hence related disclosure is not required.

53 Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person, that are:

Type of Borrower	Amount of loan or advance in the nature of loan outstanding	Loan Given Lakhs	Percentage to the total Loans and Advances in the nature of loans
Related Parties: -			
Arti Farms Pvt Ltd	repayable on demand	868.24	71.06
Agritech (India) Ltd.	repayable on demand	353.61	28.94

54 Details of Benami Property held - No proceeding has been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.

55 Willful Defaulter - The company is not declared wilful defaulter by any bank or financial Institution or other lender during the year.

NATHBIO-GENES (INDIA) LIMITED

56 The Company has made borrowings from banks on the basis of security of current assets. At times, there are certain differences in the statement of security filed with bank and books of account of the company. The reason being timing difference on accounting of sales return and thereby resulting in more assets in the books of account than what has been given to bank. Further, the company maintained adequately drawing power.

57 **Registration of charges or satisfaction with Registrar of Companies** - During the year, the company has registered charges on the assets of the Company with the Registrar of Companies, where applicable and also satisfied the charges within the time specified under the Companies Act, 2013.

58 **Relationship with Struck off Companies -** During the year, the company has not carried out any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.

59 **Various Ratios**

Name of Ratio	Numerator	Denominator	Current Year	Previous Year	Variation in %	Reasons for variation
			Ratio			
Current Ratio (Times)	Current Assets	Current Liabilities	2.39	3.10	-22.85	Due to provisioning of doubtful advance granted to Farmer/Grower
Debt-Equity Ratio (Times)	Debts (Long and Short Term)	Equity and Others Equity	0.17	0.16	4.38	No explaination required
Debts Service Ratio (Times)	Profit before Interest and Tax	Term Liabilities	54.16	100.44	-46.08	Due to reduction turnover resulted into lowering of profit
Return on Equity Ratio (%)	Profit After Exceptional Item and Tax	Equity Capital	134%	299%	-55.25	Due to reduction turnover resulted into lowering of profit
Inventory Turnover Ratio (Days)	Inventories	Turnover	288.92	268.56	7.58	No explaination required
Trade Receivables Turnover Ratio, (Days	Trade Receivable	Turnover	115	130	-11.20	No explaination required
Trade Payables Turnover Ratio, (Days)	Trade Payable	Turnover	72	42	73.43	Extended credit received from the market
Net Capital Turnover Ratio (times)	Net Working Capital	Turnover	98.26%	118.06%	-16.77	No explaination required
Net Profit Ratio (%)	Net Profit after tax	Turnover	9.12%	18.45%	-50.56	Due to reduction turnover resulted into lowering of profit
Return on Capital Employed (%)	Net Profit after tax	Capital Employed	4.69%	9.25%	-49.36	Due to reduction turnover resulted into lowering of profit
Return on Investment (%)	Net Profit after tax	Investment	4.69%	9.25%	-49.36	Due to reduction turnover resulted into lowering of profit

60 **Utilisation of Borrowed funds and share premium:** The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

61 **Undisclosed income** - There is no case of search or survey of any other cases related to income surrendered or disclosed in any tax assessments under the Income Tax Act, 1961.

62 The company has not invested in Crypto Currency or Virtual Currency, hence related details are not provided

63 Previous year's figures have been regrouped / rearranged wherever necessary to conform to the current year's presentation.

Jeevanlata Kagliwal Director DIN No.: 02057451	Satish Kagliwal Managing Director DIN: 00119601	Devinder Khurana Chief Finance Officer	Dhiraj Rathi Company Secretary

Place: Aurangabad
Date: 30th May 2022

NATH BIO-GENES (INDIA) LIMITED

NATH SEEDS®

Nath Bio-Genes (I) Ltd.

Nath House, Nath Road, Aurangabad-431005 (MS)
Tel. : 0240-2376314/5/6/7, 6645555 Fax : 0240-2376188
www.nathbiogenes.com